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CHAPTER ONE
INTRODUCTION TO SUPRAMOLECULAR AND MEDICINAL CHEMISTRY
When referring to medicinal chemistry, one often does not typically
think about supramolecular chemistry as a related field. However, medicinal
chemists are often tasked to synthesize biologically active compounds with
the objective of targeting a specific cell receptor, anti-body, or an enzyme.
One should remember that these targets, such enzymes or receptors, are
host-guest complexes. In a very real sense, these enzymes are
supramolecular entities that function as hosts that have affinity to specific
guests that encompass the correct electronic and structural properties to
complement the macrocyclic host. In supramolecular chemistry, chemists
build supramolecular complexes to study host-guest chemistry effects,
attempting to mimic biological systems, drug delivery systems, molecular
self-assembly techniques to construct lipophilic micelles or vesicles, and
build macrocyclic tweezers to function as either artificial cell receptors or
part of a cavity of an enzyme. It is these concepts of host-guest interactions
that essentially tie medicinal and supramolecular chemistry together, and
each field truly complements the other. Supramolecular chemistry is a field
that will continue to grow, and researchers will continue to develop and
1
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revolutionize macrocyclic systems that mimic and improve our
understanding of biological systems, or to develop new methods to safely
and efficiently deliver drugs minimizing undesired drug side-effects and
efficiently eliciting the proper biological response or termination of cancer
cells.
Supramolecular chemistry involves the formation of complex molecular
entities that have the capacity to participate in specific molecular recognition
of guest molecules. Supramolecular structures are often pursued due to their
intrinsic ability to be chiral and to mimic biological systems and dynamics. A
commonly employed scaffold in supramolecular chemistry is the trimeric
crown-shaped molecule cyclotriveratrylene (CTV). CTV has been studied
extensively for its capability of binding a number of smaller organic and
organometallic guests within its bowl-shaped cleft and has been used as a
building block enabling the construction of more complex cryptophanes. The
goal of this research is the synthesis and characterization of novel chiral
macrocyclic derivatives. These new cyclophanes should have greater
versatility than the parent CTV hydrocarbon macrocycle including greatly
enhanced water solubility, the ability to coordinate to metal ligands, the
potential for use in drug delivery, and unique optical and liquid crystal
properties. Enantiopurity assessment of a chiral macrocyclic lactam was
addressed and accomplished using a chiral shift reagent (Chirabite-AR)—

3
itself a chiral macrocycle, which has been used for the enantiopurity
determination of small molecules that can fit into its macrocyclic cleft, but
not previously for other supramolecular scaffolds.
Globally, cancer has affected many people and families and there are
many types of cancer. The challenge with cancer is to design active
pharmaceutical compounds to selectively target cancer cells without
affecting normal healthy cells. It is the ultimate goal for medicinal chemists
to design such compounds that have high specificity for cancer cells as
opposed to healthy cells. Normal treatments of cancer involve chemotherapy
and radiation, however these methods are typically hard on the body
because they affect normal cells. Often times, cancer patients with weak
immune systems cannot tolerate radiation or chemotherapy because their
immune system would severely be affected making them susceptible to
infections, thus losing the battle against cancer. On the other hand, localized
delivery of radiation is a targeted therapy that has been gaining much
attention in the medical community. One of the methods of in situ generated
of radiation is boron neutron capture therapy (BNCT). Coupling medicinal
chemistry and BNCT is a powerful tool in delivering boron-based compounds
to cancer cells, which in combination with a neutron source generate an
internal source of localized radiation within the cancer cell and ultimately
destroys cancer cells without affecting normal cells. Within this dissertation,

4
the objective of this anticancer work was to utilize a potent pharmacophore
that has the potential to target multiple forms of cancer (brain, prostate,
ovarian, breast, liver, colon, pancreatic, lung, head/neck, mouth, bone), and
even rheumatoid arthritis which also involves upregulated matrix
metalloprotease (MMP) enzymes. Toward accomplishing the generation of
localized radiation within cancer cells, the essential pharmacophore (missile)
was coupled with a carborane moiety which is the ultimate source (warhead)
of the radiation once exposed to neutrons. Targeting cancer cells can be
accomplished by identifying a cellular receptor or enzyme that is upregulated
in cancer cells. In this dissertation, the host enzymes that are of interest are
MMP enzymes since these enzymes are upregulated and are highly overexpressed in cancer cells. Establishing host-guest relationships of inhibitors
bound to MMPs is of interest since it is these interactions that allow an active
compound to be bound to an enzyme. Establishing bioavailability for oral
dosing is not as important since the boron-containing drug will be
administered i.v. Within this dissertation is described the synthesis of two
novel MMP inhibitors that contain a carborane moiety. The key chemistry
involved installation of the carborane group using Click chemistry. These
Click carborane products were evaluated by in vitro MMP inhibition testing
against MMP-1, MMP-2, MMP-9 and showed nanomolar potency against
MMP-2 and MMP-9 and also sparing MMP-1.
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Understanding host-guest interactions is an essential key for medicinal
and supramolecular chemists. It is these interactions that allows researchers
to evaluate how specific enzymes functions. From these lessons, the
researchers generally prepare new substrate analogs to target a specific
enzyme with the aim that these new analogs will bind more strongly than
the native substrate. Based on this, molecular modeling also provides
another powerful tool to assess whether designed guest molecules would
serve as proper substrates for a given enzyme. Within this research,
molecular modeling and docking illustrated key structural differences
between methylated L,L-SDAP ligands inside the active site of succinyldiaminopimelate desuccinylase (DapE) that allowed the focus to synthesize
the best analog (monomethyl L,L-SDAP) for a novel ninhydrin-based assay
developed within our research group. During route selection of the
monomethyl substrate, an asymmetric synthesis was accomplished providing
the alternate L,L-SDAP substrate in high enantiomeric purity.

CHAPTER TWO
FORMATION AND ENANTIOMERIC PURITY DETERMINATION OF BECKMANNDERIVED CTV LACTAM WITH CHIRABITE-AR AND ATTEMPTED RESOLUTION
Section 1: Introduction
There are four characteristics1 to be expected in cyclophanes2 and
supramolecular3 scaffolds. The first is the electronic interaction between
aromatic rings positioned in a “face-to-face” manner. Second, the
substitution on one aromatic ring influences reactivity on adjacent rings
within the cyclophane influencing intramolecular/intermolecular substitution
reactions of the aromatic rings. Third, intramolecular charge-transfer
complexes are possible. Lastly, the ring strain, steric strain, and
transannular strain present in a macrocyclic molecule will dramatically
impact the chemistry of the entire system.
Section 2: Introduction to Supramolecular Chemistry with
Particular Emphasis on Cyclotriveratrylene (CTV)
Supramolecular chemistry involves the formation of complex molecular
entities that have the capacity to participate in specific molecular recognition
of guest molecules.3 Cyclophanes are supramolecular structures comprised
of aromatic units with bridging chains forming cage-like structures2 and have
6
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found applications in molecular recognition as synthetic receptors, as models
for intercalation, as building blocks for organic catalysts, and in the
preparation of crown ethers and cryptands.1 Cyclophanes have been utilized
as molecular scaffolds in the design of new pharmaceuticals4-7including use
as cholesterol shuttles to modulate cholesterol metabolism, 8 as potent
human choline kinase (ChoK) inhibitors,9 and as inhibitors of HIV protease.10
Recently, CTV analogs that have been constructed to be water-soluble motifs
have been designed to function as drug delivery agents and successfully
tested against HepG2 (human liver hepatocellular carcinoma) cell lines.11
Supramolecular entities have received much attention such that they are
being employed to improve therapeutics by utilizing the macrocycle's ability
to target and host drugs as guests and provide subsequent delivery of the
drug based on physiological indicators.12
The crown-shaped cyclophane cyclotriveratrylene (CTV, 1,
hexamethoxy tribenzocyclononene)13 has been employed extensively as a
scaffold in supramolecular chemistry. This [1.1.1]orthocyclophane is readily
prepared from the trimerization of veratryl alcohol in acid and has been
extensively studied for its capability of binding a variety of smaller organic
and organometallic guests within its bow-shaped cleft.14-16 Many clathrates
of CTV and of CTV derivatives17-20have been structurally characterized
including clathrates with anionic C70 dimers.21 Thioether derivatives of CTV
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have recently been employed to immobilize C60 onto gold surfaces,22, 23and
water soluble CTV derivatives have been developed for biomedical
applications including the biological delivery of fullerenes24 and selective
anion sensing.25 Other clathrates of CTV have been structurally
characterized, including DMSO and ethanol,26 chlorinated organics,18
xenon,19 lanthanides,20 organometallic complexes,17 C60,27 and anionic C70
dimers.21CTV has been employed as a supramolecular building block to
construct more complex cage-like cryptophanes,28 and as a crystal
engineering tecton giving network structures of unusual topology.29CTV
derivatives have also been studied for their mesomorphic properties30 and
are capable of forming liquid crystals by themselves31 and as complexes with
C60.31CTV is a natural product and was isolated from the bark of
Zanthoxylum conspersipunctatum found in New Guinea.32
Section 3: Background Including Previously-Published
Work on the Synthesis of Selected CTV Derivatives
Our work in supramolecular chemistry is based on the supramolecular
scaffold cyclotriveratrylene (CTV, 1), which has enjoyed much attention in
the literature, but almost no focus on functionalization of the apex of the
structure (see Figure 1). We have focused both on functionalization of the
apex via oxidation reactions, as well as on a scaffold wherein the three
apical methylenes are replaced by nitrogen atoms33 (“N3-CTV”).
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Figure 1. Classic Preparation of CTV13 and designation of apical and
peripheral regions
The bowl-shaped crown conformer is essential for host-guest
chemistry with CTV and its derivatives. CTV itself exists almost exclusively
in the crown conformer. Oxidation of CTV to the monoketone 2 afforded the
crystalline product, which was shown by X-ray crystallography to crystallize
in an enantiomerically pure crystal. Formation of the oxime of the ketone
afforded two products, surprisingly, which we demonstrated were the crown
(15) and saddle (16) conformers of the CTV oxime.34 Given the importance
of the kinetics and thermodynamics for host-guest chemistry, we pursued a
study of the interconversion of the oxime conformers (see Figure 2),
followed by proton NMR. The oxime saddle conformers of 16 are favored in
CDCl3 (Keq = [saddle]/[crown] = 1.4), whereas the CTV oxime crown
conformer 15 is favored in three more polar solvents studied (DMSO-d6,
acetonitrile-d3, acetone-d6). The t1/2 of the saddle 16 was determined to be
2.45 ± 0.15 h in CDCl3 at 25 °C, and 3.71 ± 0.07 h in DMSO-d6.35
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Figure 2. X-Ray crystal structure of CTV monoketone 2, and the two
atropisomers of CTV oxime (15 and 16)
To expand the macrocycle from a 9-membered ring macrocycle to a
10-membered ring we employed the Beckmann rearrangement of the oxime
15, which proceeded in high yield with thionyl chloride to generate the 10membered lactam 19 (see Figure 3).36

Figure 3. Beckmann rearrangement of CTV-oxime to the ring-expanded
lactam
We found that the 10-membered N-acetyl macrocyclic imide 21
crystallizes as a solid solution of racemic columnar assemblies comprised of
alternating enantiomers in a stacked-cup array, each as a chloroform
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monosolvate, but with a random distribution of the columns within the
crystal leading to whole molecule disorder within the crystal, comprising a
2-D solid solution (see Figure 4).37

Figure 4. Columns of N-acetyl CTV imide 21 comprising the 2D solid solution
observed in the X-ray crystal structure
Interestingly, under certain conditions for the Beckmann
rearrangement for making the 10-membered lactam 19, a helical pentacycle
20 was obtained, which arose via an unexpected tandem BeckmannElectrophilic Addition cascade sequence (see Figure 5).36

Figure 5. Observation of a Tandem-Beckmann/electrophilic aromatic addition
cascade
The observation of the tandem-Beckmann cascade drew our attention
to the possibility of a synthetically useful intermolecular metal-free tandem
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Beckmann-electrophilic aromatic substitution cascade affording diaryl
imines, ketones, amines and quinazolines, which was realized (Figure 6).38

Figure 6. Intermolecular Tandem-Beckmann rearrangement
Oxidation of cyclotriveratrylene (CTV, 1) to the corresponding diketone
3 and subsequent bromination resulted in an unexpected rearrangement to
a highly functionalized 9-aryl-10-bromoanthracene derivative 11 and 12.
Electroluminescent 9,10-diaryl anthracenes have been shown to be
promising host and hole-transporting materials in organic
electroluminescence due to their high thermal stability, electrochemical
reversibility, and wide band gap useful for organic light-emitting diodes
(OLEDs), especially blue OLEDs, so we employed Suzuki couplings to
synthesize a series of 9,10-diaryl compounds (13a-c and 14a-c) that are
structural analogues of anthracene derivatives used in the preparation of
OLEDs but are more highly functionalized, including electron-donating
methoxy groups in addition to substitution by a carboxylic acid moiety (see
Figure 7).39
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Figure 7. Electroluminescent 9,10-diaryl anthracenes (13a-c, 14a-c)
derived from diketone 3
Furthering the apical functionalization of CTV 1, we also explored the
apical functionalization of the veratrylene tetramer, cyclotetraveratrylene
(CTTV, 7), obtaining the CTTV tetraketone 8 (see Figure 8). Curiously, the
tetraketone 8 undergoes two distinct trans-annular cyclization reactions,
depending upon the conditions, either to a bis-spiro lactone 9 reminiscent of
the closed, lactone form of fluorescein or to 10. When tetraketone 8 is
heated with acid, the CTTV tetraketone 8 produces a highly symmetric
diketone 10 in high yield (see Figure 8).40
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Figure 8. Preparation of CTTV tetraketone 8 and two different rearrangement
products 9 and 10. X-ray crystal structures of CTTV tetraketone 8
Further, as a complementary avenue for apical functionalized analogs
of CTV 1, we targeted the tris-N derivative (N3-CTV), which conceptually is
the combination of CTV and the well-known ligand TACN
(triazacyclononane). The nitrogen atoms should provide both a handle for
functionalization on the apex through alkylation, as well as the possibility of
metal complexation (see Figure 9).41

Figure 9. Design of “N3-CTV” as a conceptual combination of CTV and TACN
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Section 4: Discussion of Current Work Including
Improvement in the Synthesis of CTV Analogs
This section summarizes advances in the synthesis of cyclotriveratrylene
(CTV) derivatives that have not already been published. These novel macrocyclic
molecules have unique and intriguing properties including pseudorotation, rapid
nitrogen umbrella inversions, elegant intramolecular transannular cyclizations, the
ability to crystallize in random columnar assemblies, the ability to undergo ring
expansions through both traditional and tandem Beckmann rearrangements,
formation of helical like bonds, oxidative rearrangements, and the possibility of the
electroluminescent properties which are enhanced by the highly functionalized
moieties present on the molecules synthesized within this section.
Cyclotriveratrylene (CTV, 1) was the starting material for the synthesis of various
CTV derivatives. The synthetic process improvements for CTV analogs of interest
were monoketone 2, oxime conformers 15 and 16, lactam 19, and
menthyloxyacetic acid imide 23.

One of the oxidized products of CTV, monoketone 2, was previous
synthesized utilizing either acidic conditions adopted by Cookson and
Stevens42 or slightly basic conditions. We found that using slightly alkaline
conditions increased the rate of reaction, made isolation of the desired
oxidized products easier, and eliminated the formation of spirolactone5.
Within this work, the process of preparing monoketone was further
improved using neutral conditions that employed ethyl acetate as the
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solvent which avoided the use of pyridine. Furthermore, the process
implemented a simple trituration step for purification of monoketone 2
rather than resorting to normal phase chromatography.
Another intermediate compound prepared in this work was the oxime
of CTV which exists as the individual crown (15) and saddle (16) conformers
that were previously isolated and characterized.34 Previous isolation of CTV
oximes consisted of concentration from pyridine, aqueous workup, and a
tedious chromatography. Within the present work, the process was improved
to isolate the CTV oximes as a mixture of atropisomers directly from the
crude reaction mixture such that both saddle and crown oxime conformers
were isolated together as a filterable solid.
The Beckmann rearrangement of CTV oximes to prepare racemic CTV
lactam 19 has been modified to avoid the use of corrosive thionyl chloride,
prevent the formation of helical pentacycle (6) and simplify for the
purification process. Furthermore, previous methods required the use of
pure crown CTV oxime conformer to achieve high yields of CTV lactam,
however this work employs a newly-modified procedure where a mixture of
oxime conforms can be used and still achieve high isolated yields of desired
CTV lactam 19.
CTV lactam 19 exists as a mixture of enantiomers (racemate) and
these supramolecular enantiomers were observed spectroscopically via1H
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NMR using commercially-available Chirabite-AR chiral shift reagent.
Furthermore, the CTV lactam racemate (19a + 19b) was derivatized using a
chiral auxiliary, (-)-menthoxyacetyl chloride, generating an enriched
diastereomeric imide 23 (87:13) confirmed by 1H NMR and X-ray analysis.
The use of Chirabite-AR was employed to monitor the chiral purity of CTV
lactam after hydrolytic removal of the chiral auxiliary.
Section 5: Oxidations of Cyclotriveratrylene (CTV)
We are interested in the preparation of novel apex-functionalized
derivatives of CTV and have reported the isolation and the kinetics and
thermodynamics of the interconversion of the saddle and crown conformers
of CTV oxime ,34 and reported the discovery of a new tandem Beckmannaromatic addition reaction sequence affording a helical pentacycle 20 from
the CTV oxime 15.38, 46 We then turned our attention to the preparation of
the elusive CTV triketone 4 due to the potential applications of this highly
symmetric molecule as a new supramolecular host molecule as well as its
potential utility as a synthetic intermediate.
Cookson and Stevens had reported the isolation of CTV monoketone 2
and CTV diketone 3 by the direct oxidation of CTV 1 with sodium dichromate
in acetic acid under reflux.42 Cookson and Stevens additionally reported42
the isolation of another CTV derivative from this oxidation that they
indicated was CTV triketone 4. The correct structure was given shortly
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thereafter by Baldwin43 as spirocyclic compound 5,44 an isomer of the CTV
triketone thus giving rise to misleading combustion and mass spectrometry
analyses. We believe that the triketone may be produced under the sodium
dichromate oxidation conditions, but also that the spirocycle 5 results from
rapid acid-catalyzed electrophilic addition and rearrangement of the
intermediate diketone 3 or triketone 4.
Furthermore, it is very well possible and seems more reasonable that
CTV diketone 3 is the intermediate for the formation of spirocycle 5. Below
are two schemes which illustrate two different mechanisms for the formation
of spirocycle 5. Another rationale that diketone 3 may be the precursor to 5
is that after intramolecular transannular cyclization, the corresponding
benzylic carbon is even more activated for oxidation to the ketone. CTV
diketone 3 is difficult to oxidize to the triketone 4 due to the incorrect
dihedral angles of the benzylic carbon making it an unactivated methylene,
as discussed below.
From Schemes 1 and 2, with respect to the formation of spirolactone
5, the diketone route (see Scheme 2) actually seems more reasonable than
the triketone route, because when the aryl π-electrons of the diketone
undergo intramolecular nucleophilic attack on the protonated carbonyl, the
ortho methylene is electron donating (ortho activated) thus creating a more
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reactive nucleophilic, in contrast to the triketone which has an electron
withdrawing group ortho to the aryl π-system.
Scheme 1. Mechanistic Hypothesis of the possible conversion of CTV
Diketone 3 to Spirocycle 5
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Spirolactone 5 was formed via a transannular electrophilic addition of
a putative intermediate cyclotriveratrylene triketone 4 and is made up of
both an anthrone and an isobenzofuranone ring that are connected via one C
atom to form a spiro compound. The anthracene and isobenzofuranone ring
systems of the spiro compound are both essentially planar and are
perpendicular to each other, with a dihedral angle of 89.90° between them.
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Scheme 2. Mechanistic Hypothesis of the Possible Conversion of
CTVTriketone 4 to Spirocycle 5
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Cookson et al.42 described the first synthesis of the spirolactone
molecule 5. Baldwin & Kelly43 subsequently reported its correct identification
as the spiro compound by UV and NMR methods.
Cookson et al.42 reported the isolation of a CTV derivative from
oxidation of CTV 1 with sodium dichromate in acetic acid that they thought
was the CTV triketone 4. The triketone 4, however, has in fact never been
isolated, and the compound isolated by Cookson and was shortly thereafter
identified using UV–Vis and NMR-spectroscopic methods43 to have a spiro
structure (structure 5), produced via acid-catalyzed electrophilic addition
and rearrangement of the putative triketone under the acidic conditions.
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Both this spirolactone 5 and the tandem Beckman/electrophilic addition
products36, 44, 45 are formed via transannular electrophilic addition to
somehow-related cationic intermediates. Interestingly, the spiro derivative is
a structural analogue of the cyclized lactone form of the exceedingly useful
fluorescent spirolactone fluorescein. The spirolactone 5 contains a diaryl
ketone rather than the diaryl ether of fluorescein.

Figure 10.Structure of Spirolactone (Cmpd 5)
We initially suspected the presence of triketone 4 in the Cookson
oxidation42 method and isolated a small amount (1.5-3.5%) of high-melting
yellow solid (mp 338-340ºC) which we thought had C3V symmetry, thus
displaying only two singlets in the 1H NMR in a ratio of 1:3 at 7.68 and 4.07
ppm respectively, and only five signals total in the

13

C NMR corresponding to

the carbonyl, the methoxy, and three aryl carbons. High resolution mass
spectrometry demonstrated the presence of the appropriate ion for the
trimeric triketone, although this must have been detection of a minor
component in the material which was subsequently confirmed to be the
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known dimeric 2,3,7,8-tetramethoxyanthraquinonone (structure 6). The
main component was certainly unexpected given the presumed integrity of
the trimeric CTV system, but we hypothesize that it was formed via a
reverse electrophilic aromatic substitution under the acidic conditions and
expulsion of one of the three 3,4-dimethoxybenzyl moieties and re-closure
to the dimeric anthraquinone 6 (see Scheme 3).
Scheme 3. Dimeric Anthraquinone 6 via Oxidation of CTV

Based on the fact that oxidation of CTV 1 itself, or oxidation of the
mono/diketone analogs (3/4) under acidic conditions afforded the undesired
spirolactone 5, other means of carrying out the oxidation was investigated.
Previously, alternative oxidative conditions of CTV 1 (Scheme 4) were
developed using an excess of KMnO4(36 eq) supported on activated MnO2
(72 eq) in refluxing pyridine. After 3 h at reflux, the reaction was complete
and isolation afforded a 35% yield of CTV monoketone 2 and 16% CTV
diketone 3. These basic conditions were convenient due to the fact that
spirolactone 5 does not form and chromatography is much easier in terms of
separating CTV monoketone 2 from diketone 3 after normal phase
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chromatography. The isolated monoketone 2 and diketone 3 were analyzed
via X-ray analysis (Figure 11). Interestingly, the monoketone 2 crystallizes
as a single chiral conformer.35 The X-ray crystal structure of the diketone 3
has not been published.

Figure 11.X-Ray structure of CTV monoketone (2) and CTV diketone (3).
Hydrogens were omitted for clarity
Scheme 4. KMnO4 supported on MnO2 oxidation of CTV
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One drawback of the KMnO4/MnO2 conditions is that when the reaction
is deemed complete by HPLC and TLC analysis, the crude material after
filtration is concentrated and the resulting mass balance is always only 5060% of the theoretical amount. The low mass balance may be due to that
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some of the starting material or desired products are decomposing by
permanganate over-oxidation side reactions, or the desired products exist as
manganese complex salts, perhaps even as a triketone manganese complex,
and if true, then the lost mass may represent material that was successively
oxidized to the triketone.
Unfortunately, CTV triketone 4 has not yet been isolated from these
conditions. To investigate the robustness of the KMnO4/MnO2 conditions, CTV
diketone 3 was treated with 36 eq KMnO4 on activated MnO2 in refluxing
pyridine or quinoline to determine if CTV triketone 4 can be prepared, but
only starting material 3 was observed even after seven days of heating. This
result indicates that perhaps the dihedral angle of hydrogen abstraction on
the methylene carbon of CTV diketone 3 is not ideal for proper radical
stabilization. However, Synder et al.46 is the only report to-date of
successful preparation of a CTV triketone derivative, and in that report, the
methoxy moieties were ortho to the benzylic carbon. Synder performed DFT
calculations of their triketone derivative compared to CTV-derived triketone
4 (both in protonated form) and showed that the adjacent methoxy groups
provided better stabilization of the protonated ketone thus discouraging
unproductive intramolecular transannular cyclization. Based on his findings,
it is likely that under basic conditions the mechanism may involve radical
intermediates. If the process is operating under radical type pathway, then
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the ortho-methoxy groups should also provide proper radical stabilization
that generates significant twisting allowing the methylene and phenyl ring to
be perpendicular and in turn this creating the correct dihedral angle for
oxidation to occur.
Based on Synder's findings, the synthesis of triketone 4 was no longer
pursued. However, during screening reaction conditions for triketone 4, it
was found that some of the results showed high conversion to
monoketone/diketone and thus the preparation of CTV monoketone can be
carried out efficiently in a more suitable and more green solvent, ethyl
acetate. Details about this will be discussed below.
Section 6: Process Developments for Improving the
Synthesis and Isolation of CTV Monoketone
Based on previous methods for the preparation of CTV monoketone,
there was a need to develop a more suitable process for CTV monoketone 3,
since that the monoketone is key starting material in subsequent research
described below, that did not involve the use of sodium dichromate or
pyridine as the solvent. As mentioned above, during the search for preparing
CTV triketone, many conditions were investigated which evaluated the effect
of various solvents, temperatures, and ratio of potassium permanganate and
manganese dioxide. Each experiment was monitored by TLC and/or HPLC
analysis to determine the progress of oxidizing CTV 1 to CTV monoketone
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2and diketone 3. Table 1 summarizes the results from the solvent screening
at specified temperatures.
Table 1. Solvent screening for CTV oxidation to monoketone at various
temperatures
Experiment*

Solvent

Temp
(oC)

TLC Analysis
Monoketone 2
Present?
Yes
Yes
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes (faint spot)
Yes (faint spot)
No
No
Yes (faint spot)
Yes (faint spot)

Comments

1
pyridine
100 oC
2
pyridine
65 oC
3
NMP
100 oC
Only SM.
o
4
NMP
65 C
5
MeOH
65 oC
Only SM.
6
MeOH
25 oC
Only SM.
o
7
t-BuOH
65 C
Only SM.
o
8
sulfolane
100 C
9
sulfolane
65 oC
10
MeCN
65 oC
11
EtOAc
65 oC
12
EtOAc
80 oC
13
THF
65 oC
14
chloroform 65 oC
15
MeNO2
100 oC
Only SM.
o
16
MeNO2
65 C
Only SM.
o
17
dioxane
65 C
18
dioxane
100 oC
*All experiments used KMnO4/MnO2 (34 eq/52 eq) and 15 mL of solvent. Each experiment
was heated for 18 h then analyzed by TLC analysis using EtOAc/DCM (20/80).

Based on the solvent screening and using TLC analysis to judge the
presence of monoketone 2, selected solvents that contained monoketone
were further evaluated and analyzed by HPLC to quantitatively assess how
much monoketone 2 and diketone 3 formed along with how much unreacted
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starting material (CTV, 1) remained. Table 2 illustrates the HPLC results
from this study.
Table 2. Selected solvents studied for the oxidation of CTV and monitoring
conversion to monoketone by HPLC analysis
Entry

Solvent

Temp
(oC)

Time

HPLC Analysis
%CTV
%MK
1
2
62
25
43
45
22
58
72
15
50
31
30
56
30
56
75
17
75
17
74
19
42
51
16
70
15
72

1
pyridine
65 oC
3h
o
2
pyridine
65 C
17 h
3
pyridine
100 oC
3h
o
4
sulfolane
65 C
3h
o
5
sulfolane
65 C
17 h
o
6
sulfolane
100 C
10 h
7
sulfolane
100 oC
28 h
o
8
MeCN
65 C
3h
o
9
MeCN
65 C
17 h
o
10
EtOAc
65 C
3h
11
EtOAc
65 oC
17 h
o
12
EtOAc
80 C
18 h
o
13
EtOAc
80 C
37 h
*All experiments used KMnO4/MnO2 (34 eq/52 eq) and 15 mL of solvent.

%DK
3
1
3
6
3
10
7
7
1
1
1
4
9
9

Based on the results in Table 2, performing the oxidation in ethyl
acetate was superior compared to the other solvents employed in the study.
The use of ethyl acetate also presents the opportunity to eliminate the use
of pyridine which is toxic, has a strong disagreeable odor, and can cause
impotence. Following these results, the next step was to optimize the
amount of KMnO4/MnO2 in the oxidation of CTV in ethyl acetate. Table 3
illustrates the results of varying the amounts of KMnO4/MnO2 at specific
temperatures.
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Table 3. Optimization of KMnO4/MnO2 in the oxidation of CTV in ethyl acetate
and subsequent scale up
Entry
1
2
3
4
5
6
7
8
9
10
11
12

CTV
Qty.

KMnO4

MnO2

Temp
(oC)

0.25 g

11
11
20
20
30
30
11
11
20
20
30
30

20
20
20
20
20
20
20
20
20
20
20
20

65
80
65
80
65
80
65
80
65
80
65
80

eq
eq
eq
eq
eq
eq
eq
eq
eq
eq
eq
eq

eq
eq
eq
eq
eq
eq
eq
eq
eq
eq
eq
eq

2h
5h
19 h
2h
5h
19 h

HPLC Analysis
%CTV %MK
1
2
9.9
76.4
0.5
86.4
9.3
74.3
0
81.3
9.6
75.9
0
79.4
2.4
83.9
0.4
86.9
1.1
80.9
0
77.3
1.2
78.7
0
63.5
41.3
56.6
21.6
72.8
0
91.7
61.3
36.7
43.4
52.3
9.2
83.9

%DK
3
13.7
13.2
16.4
18.7
14.5
20.6
13.6
12.7
18.0
22.7
20.1
36.5
2.1
5.6
8.3
2.1
4.3
6.9

18 h

0

8.0

Time

o

C
C
o
C
o
C
o
C
o
C
o
C
o
C
o
C
o
C
o
C
o
C
o

o

13

5.00 g

10 eq

20 eq

80 C

14

0.25 g

7 eq

14 eq

80 oC

15

76.2 g

9 eq

18 eq

80 oC

18 h

37 h

92.0

Table 3 illustrates that performing the oxidation at 65 oC for 18 h did
not achieve full consumption of CTV 1 even with higher loadings of KMnO4.
However, when the reactions were carried out at 80 oC for 18 h (entries 2, 4,
6), HPLC analysis revealed that CTV 1 was completely consumed and higher
conversion of monoketone 2 and diketone 3 were observed. Increasing the
reaction time did not show any benefit for enhancing the conversion to
monoketone, however when increasing the amount of KMnO4 to >11 eq,
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diketone conversion was enhanced especially at 80 oC. Interestingly, entry
13 employed slightly lower loadings of oxidizing mixture (10 eq KMnO4/20
eq MnO2) and after 19 h generated 91.7% of monoketone 2 and 8.3%
diketone 3. Scaling the oxidation (per entry 15) using 76 g of CTV and
employing even lower loadings of KMnO4 (9 eq)/MnO2 (18 eq) in ethyl
acetate at 80 oC generated the same conversions of monoketone/diketone
as entry 13.
The next step was to identify purification conditions for monoketone 2
without resorting to column chromatography and subsequent
recrystallization. Fourteen solvents were evaluated using crude monoketone
(starting purity: 85% pure by HPLC that contained 11% diketone 3) and the
solvents that showed promise were acetonitrile, n-butanol, toluene, ethyl
acetate, and xylenes. Ultimately, acetonitrile showed the best results for
purifying CTV monoketone 2. Recrystallization from acetonitrile provided
96% purity but with only 46% recovery of monoketone. Performing a
trituration in acetonitrile (3 volumes) at 70 oC overnight (~16 h), cooling to
room temperature, and isolating by filtration provided 98% pure
monoketone with 70% recovery. Scaling the trituration of the crude
monoketone (51.0 g) in acetonitrile (3 volumes) at 70 oC overnight provided
the first crop of monoketone (32.5 g, 65% recovery, 98% pure by HPLC).
The mother liquors were partially concentrated removing about half of the
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solvent to generate a slurry which was filtered to yield a second crop of
monoketone (15.8 g, 31% recovery, 95% pure). The overall recovery of
monoketone was determined to be 96%.
It is evident that the process for preparing monoketone has been
substantially improved compared to previous reported methods. The benefits
of the improved oxidation method include that the process does not use
toxic and pungent smelling pyridine but rather the process uses a friendlier
and less harmful solvent such as ethyl acetate, allows one to use
considerably less KMnO4/MnO2, allows for higher conversion to monoketone,
and lastly purification via a trituration in acetonitrile which proved to be very
efficient and eliminated the need to employ a tedious and time-consuming
column chromatography purification.
Section 7: Improved Synthesis for the Beckmann
Rearrangement of cyclotriveratrylene (CTV) Oxime
The preparation of novel apex-functionalized derivatives of CTV (1) is
of great interest in our research group. Toward this end, we have previously
synthesized the oxime derivatives of CTV 15/16via the CTV monoketone
(2) (see Scheme 5). Monoketone (2) was originally prepared utilizing a
modification47 of Steven’s method42 for oxidation of CTV with sodium
dichromate in acetic acid under reflux, however this process was improved
as described above using KMnO4/MnO2 in ethyl acetate and avoiding
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chromatography. The conversion of 2 to the corresponding oximes 15/16
was quite sluggish and required an excess of hydroxylamine and overnight
heating in pyridine to push the reaction to completion. The indolent nature of
the monoketone in forming the oxime was presumably due to the aryl
hydrogens ortho to the ketone hindering the approach of the nucleophilic
hydroxylamine. The ortho hydrogen atoms are almost at contact distance,
with 2.5 Å between their centers.13Furthermore, the conformational
flexibility of monoketone may suggest that the pseudorotation also allows
the phenyl rings to block the electrophilic carbonyl and prevent attack from
the incoming hydroxylamine.
Scheme 5. Synthesis of Crown (15) and Saddle CTV-Oximes (16)
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Our former procedure for preparation of CTV oximes 15/16 involved
concentration of pyridine under reduced pressure, performing aqueous
workup in ethyl acetate, and chromatographic purification over silica gel to
isolate pure crown CTV oxime conformer 15 in 45-50% yield and pure
saddle CTV oxime conformer 16 in 45-50% yield. However, since water and
pyridine are miscible, we found that that CTV oximes 15/16 can be isolated
as a filterable solid directly from diluting the partially concentrated reaction
mixture with water and the isolated oxime product can be used in the
Beckmann rearrangement. HPLC analysis of the filtered oxime solid
indicated that the mixture was comprised of an 89:11 ratio (normalized) of
crown to saddle conformers as illustrated in Figure 12. The 11.7 min
component in the HPLC chromatogram is not the tandem product 20, but
rather an unidentified impurity that was not characterized.
We previously found that the Beckmann rearrangement performed on
pure CTV oxime crown conformer 15 promoted with thionyl chloride in
dilute solution at 0 oC proceeds in essentially quantitative yield (99%) to
afford the 10-membered lactam 19. Modified conditions afforded a helical
pentacycle 20 derived from an unusual tandem Beckmann rearrangement
and electrophilic aromatic addition followed by demethylation and
tautomerization as illustrated in Scheme 6.36
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Figure 12. HPLC chromatogram of isolated CTV oximes 15/16 from
pyridine/water
The ring-expanded lactam exists at room temperature exclusively as
the crown conformer 15 based on the geminal coupling observed in the
proton NMR [4.67 (1H, d, J = 15.0 Hz), 4.44 (1H, d, J = 15.3 Hz), 3.70 (1H,
d, J = 15.0 Hz), 3.56 (1H, d, J = 15.3 Hz)], as pseudorotation of the flexible
saddle conformation 16 is known to lead to magnetic equivalence of the
geminal benzylic methylene protons. Furthermore, the N-acetyl CTV imide
21 showed that the 10-membered macrocycle exists in a crown
conformation.37 Interestingly, the lactam crown conformer 19 is a
structurally chiral molecule, although lacking chiral tetrahedral carbon atoms
(Schemes 6 and 7, structure 19).
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Scheme 6.Beckmann rearrangements of cyclotriveratrylene (CTV) oxime 15

Based on our previous reported work, it is known that the Beckmann
rearrangement of oxime 15 under certain conditions produces lactam 19
and helical pentacycle 20 resulting from a tandem Beckmann rearrangement
and intramolecular electrophilic aromatic addition (see Scheme 7).
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Scheme 7.Beckmann rearrangement of CTV oxime crown conformer to
Beckmann lactam 19 and tandem Beckmann/electrophilic aromatic addition
product 20.

As reported previously, the product distribution in the Beckmann
rearrangement was dependent upon the reaction conditions36 when
employing thionyl chloride in a diethyl ether/DCM mixture. Further efforts to
develop conditions for preparing CTV lactam were evaluated in hope to
minimize or eliminate the formation of the helical byproduct 20. In addition,
the previous procedure that used thionyl chloride in large excess required
the use of pure crown form of CTV oxime 15, plus it was preferred to
eliminate the use of noxious thionyl chloride from the process.
Evaluation of other Beckmann reaction conditions were screened to
determine if the formation of the tandem product 20 could be prevented.
Thus, treatment of the oxime 15 with acetic anhydride in xylenes with
microwave heating to 200–210 oC for 1.5 h under conditions employed by
Savarin40 to produce isoindoles from oximes gave only 26% of lactam 19
and none of the tandem product 20. Heating the oxime 15 to 75 oC for 4 h
with p-toluenesulfonyl chloride and DMAP in pyridine gave a 56% isolated
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yield of lactam 19, and none of tandem-derived product 20. On the other
hand, heating the oxime directly in polyphosphoric acid at 140 oC for 7 min
gave pentacycle 20 in 22% yield with none of the Beckmann lactam 19.
Subjecting oxime 15 to iodine and triphenylphosphine in acetonitrile at 60 oC
provided 14.1% conversion by HPLC to lactam 19, and formation of 20 was
not observed. Reaction of oxime 15 with catalytic ruthenium chloride
hydrate in MeCN at 80 oC for 20 h resulted in only 17% conversion to CTV
lactam 19 and unreacted starting material.
Ultimately, it was found that reacting CTV oxime 15 with
carbonyldimidazole (CDI) generated a stable oximo-carbamate intermediate
22 which was subsequently treated with aqueous trifluoroacetic acid at 70oC
to generate clean conversion to CTV lactam 19 without formation of the
tandem-derived product 20 as illustrated in Scheme 8. The 10-membered
lactam 19 was isolated directly from the reaction mixture in 82-85% yield
with 95% purity according to HPLC analysis.
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Scheme 8. Modified Beckmann rearrangement using CDI/TFA/water to
cleanly access CTV lactam 19

In conclusion, the Beckmann rearrangement process for preparing
lactam 15 has been simplified and has been improved mainly by eliminating
the use of thionyl chloride which required careful quenching of excess
unreacted thionyl chloride followed by neutralization of hydrochloric acid
waste streams. The improved procedure does not require the neutralization
since the resulting waste stream is a mixture of imidazole and trifluoroacetic
acid and the pH is within allowable disposal limits. Furthermore, the use of
the improved method also allows one to use mixtures of oxime conformers
15 and 16 and easily access CTV-lactam 19 rather than using solely crown
oxime 15 which was required when using thionyl chloride. Note also that the
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oximes used for this work were isolated directly from the hydroxylamine
reaction in pyridine by addition of water and the mixture was triturated,
filtered, and dried to afford oximes as an isolatable solid which is another
process improvement in its own right. Previous isolation of CTV oximes
required extractive workup after removing pyridine and subsequent
chromatography over silica gel which afforded foams or glass solids post
concentration. Furthermore, the Beckmann rearrangement process can now
be implemented into our research lab and allow undergraduates to easily
carry out the preparation of racemic CTV lactam 19 using less hazardous
conditions. With an improved procedure for CTV lactam, further studies were
evaluated to determine if resolution of the chiral lactam enantiomers (19a
and 19b) could be achieved as mention in the next section.
Reduction of the crown shaped lactam 19 with lithium aluminum
hydride in THF under reflux gave the corresponded racemic amine 24 in
quantitative yield (see Scheme 9). The amine could potentially be applied as
a linker to stationary phases or peptides which lead to the capability of
allowing host-guest chemistry reactions to occur. In addition, amine 24 is
envisioned to increase water solubility of the CTV-like scaffold allowing 24 to
be a potential precursor for drug-delivery systems.
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Scheme 9. Reduction of 19 with Lithium Aluminum Hydride to afford water
soluble CTV derivative 24

Section 8: Attempted Resolution and Observed Racemization of the
Beckmann-Derived CTV-Lactam and the Use of Chirabite to
Determine Optical Purity of the Supramolecular Scaffold
Chiral cyclophanes have applications in enantiodiscrimination
processes including catalysis, recognition and sensing, determination of
enantiomeric excess, and signaling chiral information of guests,48, 49 as with
chiral molecular tweezers that exhibit selective binding and chiral recognition
of specific guests.50 CTV and its [1.1.1]cyclophane congeners in their rigid
crown conformation are unique bowl-shaped molecules have applications in
sensors, self-organized materials, liquid crystals, and metallosupramolecular
chemistry.51 CTV and its cryptophane derivatives are of great interest in
molecular recognition.52 CTV derivatives are members of a larger family of
inherently chiral concave molecules that have applications in chiral
recognition and asymmetric synthesis.49 A chiral CTV derivative bearing
Kemp’s triacid was shown to induce triple helix formation of collagen
peptides.53 Chiral CTV derivatives have been used for the dynamic covalent
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synthesis of chiral nanocubes with potential utility as vessels for
biomacromolecules,54 and a similar dynamic thermodynamic resolution
strategy was recently reported of racemic CTV units by remote stereogenic
centers.55 Helically chiral CTV units have been employed to construct
enantiopure molecular cages,56 along with a host of elegant CTV-derived
coordination cages.57 Some of the fascinating supramolecular structures of
self-assembled cages derived from CTV-type scaffolds have recently been
reviewed,58 such as a racemic C3-symmetric bipyridyl-bearing CTV ligand
with zinc shown to self-assemble into triply interlocked chiral catenanes
within an overall chiral crystal.59 CTV-based host compounds bearing three
binaphthol moieties have been reported as chiral sensors with recognition of
sugar derivatives.60
The crown form of the cyclotriveratrylene can undergo umbrella
inversion which inverts chiral derivatives to their enantiomeric structure, as
Collet demonstrated by observing the slow racemization of structurally chiral
cyclotriveratrylene derivatives.61 Resolution and NMR studies have been
performed on the crown and saddle conformers of a CTV derivative toward
chiral liquid crystals.62 We have studied the kinetics and thermodynamics of
the crown-saddle equilibria in CTV derivatives.35 Indeed, while most work
with CTV has focused on peripheral functionalization, we selected to focus on
apical functionalization, enabling attachment of CTV “bowl-out” receptors on
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surfaces.63 We observed that CTV-derived oxime 1534 undergoes facile
Beckman rearrangement to afford the macrocyclic lactam 19 which is chiral
as the crown conformer and thus potentially resolvable.
The great interest in synthetic macrocyclic receptors includes
applications in chiral analysis and separation,64 and Ema has developed
chiral selectors with multiple H-bonding sites in macrocyclic cavities65-67
including the commercially available Chirabite-AR.
While the macrocycle of lactam 19 contains a larger 10-membered
ring, lactam amide resonance68 reduces flexibility through restricting rotation
around the carbonyl C-N bond. We were interested if Chirabite-AR, which is
designed for determining the e.e. of small molecules that can ideally be
contained within its macrocycle, might be used to determine the e.e. of a
larger supramolecular scaffold including the CTV-derived lactam 19, and if
lactam 19 might be resolvable via attachment of a chiral auxiliary through
N-functionalization of the lactam as in derivative 21.

Figure 13. Synthesis of the 10-membered CTV-derived Lactam 19 and Nacetyl imide derivative 21
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Results and Discussion
The Beckmann rearrangement of CTV-oxime generates CTV-lactam19
as a racemic mixture of CTV-lactam enantiomers (19a and 19b). As shown
in Scheme 10, either of two phenyl rings can migrate (as denoted by either
a red or green arrow) to form the chiral nitrilium ions (18a-b) which are
trapped by water leading to a 50:50 mixture of enantiomers19a-b as a
racemate.
Scheme 10. Formation and Mechanism for Racemic Cyclotriveratrylene (CTV)
Lactam19

Assessment of the relative energies of the crown and saddle
conformers of lactam 19were assessed through calculations on model
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structures lacking the six methoxy groups. Density functional theory (DFT)
calculations (EDF2/6-31G*) were performed using Spartan ’16
(Wavefunction, Inc., Irvine, CA). It was found that the crown conformer is
9.22 kcal/mol more stable than saddle conformer of lactam 19. AM1
calculations that we reported earlier for the 9-membered ring CTV
monoketone2 revealed the saddle conformer as (3.15 to 5.23 kcal/mol, i.e.
13.2 to 21.9 kJ/mol) higher in energy than the more stable crown
conformer.35

a)

b)

Figure 14. DFT energy minimized structures for a) crown conformer, b)
saddle conformer
Given that lactam 19 exists as a racemate in the crown form,
attempting to observe the two enantiomeric lactam components was
evaluated using 1H NMR and Chirabite-AR as illustrated in Scheme
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11.Chirabite-AR is a macrocyclic compound that structurally has a unique
cavity where the hydrogen-bond donor and acceptor sites are well organized
to facilitate the binding of a wide range of smaller compounds as guest
molecules. Once the guest molecules interact with Chirabite-AR, the guest
molecule will experience a strong anisotropic ring-current effect arising from
the BINOL moiety, which is a chiral source, and which allows the chemicalshift nonequivalence between the two diastereomeric complexes to be
distinguished.
Scheme 11. Resolution of racemic macrocyclic lactam 19 using macrocycle
chiral shift reagent Chirabite-AR

The racemic macrocyclic lactam 19 was treated with increasing
amounts Chirabite in CDCl3 solution and examined by 1H NMR spectroscopy,
demonstrating that the individual enantiomers could be baseline separated
in the NMR for ultimate optical purity determination. The ratio of Chirabite
was increased from 0.01 equivalent to 0.3 equivalents, and separation was
already evident with only 0.01 equivalent of Chirabite, but 0.05 equivalent
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was optimal to provide baseline separation for the proton resonances in the
aromatic region of the two enantiomers, while only 0.025 equivalent was
sufficient for baseline separation of some methoxy resonances. Additional
quantities of Chirabite (> 0.30 eq) were counterproductive, leading to large
chemical shift displacements and compromising the ability to assign the
peaks. We surmise that Chirabite is interacting most strongly with the
lactam carbonyl oxygen, which bears a calculated Mulliken charge of -0.489
au which is the greatest point electron density on the molecule, as expected,
and should H-bond accept strongly from an H-bond donor of Chirabite.
Toward resolution of the chiral lactam, analogs of the macrocyclic Nacetyl imide should be resolvable when utilizing chiral acyl substituent in
place of the acetyl moiety of 3, since resolving the macrocyclic lactam 2 into
its enantiomers may provide a new and potentially useful chiral scaffold,
although admittedly, the cavity of the macrocyclic CTV-lactam or macrocyclic
N-acetyl imide is modest in size and the asymmetry of the lactam moiety is
on the apical side of the molecule.
Several different chiral auxiliaries were explored for reaction with
lactam 2, including (1S)-(-)-camphanic chloride, (S)-(+)-ɑ-methoxy-ɑtrifluoromethylphenylacetyl chloride, diacetyl-L-tartaric anhydride and
ketopinic acid chloride, which did not provide N-acylated adducts under a
number of conditions explored, including heating in pyridine as solvent.
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However, (-)-menthyloxyacetic acid chloride was successful in providing
diastereomeric imide adducts in good yield using an excess of
menthyloxyacetic acid chloride in pyridine at reflux providing a 69% yield of
the desired imide 23 (see Scheme 12).
Scheme 12. Preparation of the diastereomeric menthyloxyacetic acid adduct
23

After purification, the 1H NMR revealed a mixture of diastereomers in
an 87:13 ratio. Attempts to separate the diastereomers and improve the
diastereomeric purity using recrystallization and achiral column
chromatography techniques were unsuccessful. Recrystallization from
DCM/hexane provided X-ray quality crystals. In fact, the crystal structure
obtained through X-ray crystallography also confirmed the diastereomeric
ratio through relative densities and the overall molecular structure including
the absolute configuration of the chiral bowl-shaped CTV-imide 23.
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Figure 15. X-ray crystal structure of the menthyloxyacetic acid-CTV imide
adduct 23
Cleaving the chiral auxiliary of the 87:13 mix of diastereomers was
accomplished using aqueous LiOH in THF. Optical rotation of the lactam
proved to be unsuccessful to determine the rate of racemization from 87:13
to 50:50. We also used Eu(fod)3, a chiral lanthanide shift reagent, to try to
show the mix of enantiomers of the chiral CTV lactam in 1H NMR , but, while
the Eu(fod)3 did complex with the lactam, the peaks were too broad to
obtain any conclusions. An alternative chiral shift reagent, Chirabite AR,
functioned significantly better giving better resolution and complexation with
the chiral CTV lactam entities.

48
Shown below in Figures 16-20 are the overlap of 1H NMR spectra
showing resolution of racemic CTV-lactam into two enantiomeric components
at different loading equivalents of Chirabite-AR reagent.

Figure 16. Overlap of the 6-10 ppm region for the 1H NMR Spectrum of CTVLactam and different loadings of Chirabite
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Figure 17. Overlap of the 6.5-7.3 ppm region for the 1H NMR Spectrum of
CTV-Lactam and different loadings of Chirabite

Figure 18. Overlap of the 3.35-4.05 ppm region for the 1H NMR Spectrum of
CTV-Lactam and different loading of Chirabite
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Figure 19. Overlap of the 4.2-4.7 ppm region for the 1H NMR Spectrum of
CTV-Lactam and different loading of Chirabite
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Figure 20. Overlap of the 3.2-3.6 ppm region for the 1H NMR Spectrum of
CTV-Lactam and different loading of Chirabite
There are multiple regions of the 1H NMR spectra that provide target
peaks to track and integrate the enantiomeric CTV-lactam components.
Within the aromatic region (6.5-7.3 ppm) shown in Figures 16 and 17, the
six aromatic CH peaks all resolved fairly adequately where each of the six
peaks resolved into 12 separate resonances when 0.125 equiv of ChirabiteAR was employed. It is even discernible that the lactam NH resonances can
be differentiated when 0.30 equiv of Chirabite was utilized. Furthermore, the
aromatic CH peak at 6.7 ppm was resolved quite beautifully giving near
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baseline separation using very low loading of Chirabite-AR (0.05 equiv). In
the methoxy region (3.7-4.05 ppm), nearly all the methoxy moieties from
each enantiomeric lactam component were separated into nearly 12
separate peaks especially when 0.175-0.20 equivalents of Chirabite-AR was
used as illustrated in Figure 18. Interestingly when focusing on the apex
portion of CTV-lactam in Figure 19, the methylene C-H signals can be also
distinguished into separate enantiomeric peaks when using 0.05 equivalents
of Chirabite. Furthermore, the remaining methylene C-H peaks that resonate
at 3.54 and 3.58 ppm also exhibited nearly baseline separation when 0.150.20 equivalents of Chirabite-AR was employed (see Figure 20).
Furthermore, the NMR resonances for Chirabite-AR did not overlap with any
of the peaks for CTV-lactam due to the fact that most of the Chirabite
resonances occurred downfield of 7.27 ppm where there are no peaks
relating to CTV-lactam 19a-b.
Another potential analysis tool to determine chiral purity is the ability
to do chiral separation by supercritical fluid chromatography (SFC) or chiral
HPLC. Chiral screening on SFC and HPLC chiral stationary phases were
evaluated but unfortunately there was not any success in resolving the
enantiomers of CTV-lactam 19. Based on the fact that 1H NMR spectroscopy
provided excellent results in distinguishing enantiomeric peaks of racemic
CTV lactam 19, the next objective was to determine if the enriched CTV
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menthoxyacetic imide 23 can be hydrolyzed to release the chiral auxiliary
(menthyloxyacetyl) and in parallel use Chirabite-AR to observe a 87:13
enantiomeric ratio of the resolved CTV lactam.
Before performing the hydrolysis, the time required for complete
hydrolysis was determined by HPLC and it was confirmed that the hydrolysis
reaction is completed (> 95% conversion) within 15 min and verified that
the cleaving the chiral auxiliary group from 23 (retention time at 25.4 min)
was accomplished giving CTV lactam 19 (retention time at 12.8 min). See
below the HPLC chromatogram in Figure 21.

Figure 21 - HPLC Chromatogram illustrating the hydrolysis of Chiral Auxiliary
Group on 23 with LiOH in aq THF
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As illustrated in Scheme 13, the hydrolysis of chiral auxiliary was
carried out on enriched CTV menthyloxyacetic imide 23 in aqueous THF
using lithium hydroxide (3.5 eq) at < 5

o

C for 15 min, then the reaction

mixture was sampled, quickly concentrated, redissolved in CDCl3 containing
Chirabite-AR (0.30 equiv), and finally analyzed by 1H NMR.
Scheme 13. Hydrolysis of the enriched diastereomeric menthyloxyacetic
imide and subsequent enantiomeric purity assessment using Chirabite-AR

Shown below in Figure 22 and 23 is the data from 1H NMR analysis
post cleavage of the menthyloxyacetic group (shown in green), and the data
showed that the CTV lactam product 19 had racemized to a 50:50 mixture
based on the two sets of peaks (6.51/6.53 and 6.63/6.69 ppm) that
integrated with the same area under the curve. In regards to Figure 23, it is
evident that the set of peaks of interest to monitor enantiomeric purity are
at 6.63/6.69 ppm and 6.51/6.53 ppm as indicated by the black circles.
These black circles also illustrate which peaks corresponds to the singlet
peaks in racemic CTV lactam as denoted in (A). These results suggest that
once the chiral auxiliary is cleaved that the nitrogen umbrella inversion is
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quite rapid furnishing a racemate. In more detail regarding Figure 23, there
are two explanations of why the chemical shifts were different for (B) and
(D). First explanation is there was an excess of hydroxide used in (B) that
likely reduced the potency of Chirabite used (0.30 eq), therefore the actual
amount of Chirabite used in the experiment is < 0.30 eq. Therefore,
referring to Figure 17 where different loading equivalents of Chirabite was
studied, the 1H NMR spectrum profile that best fit to (B) was when 0.175 eq
Chirabite was employed thus indicating that there was about 0.175 eq of
Chirabite present in (B). The second explanation is that hydroxide is
competing with CTV lactam and the lactam moieties of the Chirabite scaffold,
since lactams are an H-bond acceptor, and hydroxide is an H-bond acceptor
as well.
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Figure 22.1H NMR spectrum of hydrolyzed 23 in the presence of Chirabite
showing the integrated peaks that indicate racemization
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Note. A (purple) shows racemic lactam without Chirabite showing singlets. B (green) shows
the 1H NMR spectrum of crude reaction mixture (post cleavage of chiral auxiliary group,
menthyloxyacetate) containing Chirabite (0.30 eq) and excess hydroxide that shows a 1:1
ratio of singlets revealing sadly racemization of lactam. C (red) illustrates the enantiomeric
separation of peaks for Racemic CTV Lactam in the presence of 0.175 eq Chirabite which the
profile closely resembles B likely due to that excess hydroxide is reducing the potency of
Chirabite. D (blue) illustrates the enantiomeric separation of peaks for racemic lactam using
Chirabite (0.30 eq) affording two separated singlets at 6.51 and 6.53 ppm.

Figure 23. Post hydrolysis of 23 and using Chirabite-AR to determine
enantiomeric purity of resolved lactam 19
In addition to 1H NMR spectroscopy, optical rotation was attempted to
study if the enriched diastereomeric CTV mentholoxyacetic imide 23 could
be cleaved such that the chiral purity of the resolved CTV lactam could be
determined. However, the data generated provided inconclusive results since
the byproduct of the reaction (mentholoxyacetic acid) is chiral. Attempts to
run a standard sample of (-)-menthyloxyacetic acid in the same solvent
medium did not provide satisfactory results and this analytical approach was
no longer pursued.
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Section 9: Conclusion
Within this work, the previously-reported processes to prepare and
isolate specific CTV analogs (monoketone 2, oxime 15/16, lactam 19) were
improved, which allowed the sequential steps to be carried out more
efficiently. We have shown that racemic CTV lactam 19 can be kinetically
driven to an enriched diastereomer 23 by reaction of lactam racemate with
(-)-menthyloxyacetyl chloride affording an 87:13 mixture of diastereomers
that was confirmed by 1H NMR and X-ray analysis. Furthermore, for the first
time, we report that Chirabite-AR can be utilized employing
substoichiometric amounts on a racemic macrocycle providing successful
observation of the two macrocylic lactam enantiomers 19a-b with nearly
baseline separation and resolution. Basic hydrolysis of the 87:13
diastereomeric imide 23, however, proceeded with rapid bowl inversion to
yield only racemic lactam 19 as confirmed by 1H NMR in the presence of
Chirabite-AR.
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Section 10: Experimental
Cyclotriveratrylene (CTV, 1, hexamethoxy-tribenzocyclononene)

To a 5-liter glass reactor (3-necked), equipped with an overhead
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser,
and nitrogen inlet, was added 3,4-dimethoxybenzyl alcohol (201.7 g, 1.20
moles). The mixture was heated to 60°C followed by addition of formic acid
(99%, 3 liters) using a dropping funnel over a period of 15 min which the
temperature had decreased 40°C. The resulting mixture was a white slurry.
The slurry was reheated to 60oC and held at 60oC for an additional 3 h to
give a light blue slurry. The slurry was cooled to room temperature and USP
purified water (2 liters) was added. The slurry was cooled to < 10oC and
held at < 10oC overnight. The following day (17 h later), the cold slurry was
filtered over a fritted funnel and the wetcake was washed with USP purified
water (4 x 1 liter), pulled dry, and further dried in vacuo at 75oC to provide
crude CTV (133.51 g, white solids).
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Recrystallization of crude CTV
To a 5-liter glass reactor (3-necked), equipped with an overhead
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser,
and nitrogen inlet, was charged crude CTV (132.7 g) and toluene (2.9 L).
The slurry was heated to reflux (102.8°C) to give a slight hazy solution.
While at reflux, chloroform (100 mL) and methanol (50 mL) was added
slowly over 10 min to provide a homogeneous pale yellow solution. The
solution was allowed to gradually cool to room temperature. After 3.5 h later
the temperature was 25°C. The white slurry was filtered over a fritted funnel
and the wetcake was washed with ice cold toluene (2 x 100 mL), pulled dry,
and further dried in vacuo at 40 °C to provide purified CTV 1 (82.57 g,
46.2% yield, white solids). HPLC (220 nm): 98.3%. The 1H NMR data is in
accordance with that reported in the literature.69, 70
Improved Procedure for the Synthesis of CTV monoketone (10,15dihydro-2,3,7,8,12,13-hexamethoxy-5H Tribenzo[a,d,g]cyclononen5-one, 2)
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To a 5-liter glass reactor (3-necked), equipped with an overhead
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser,
and nitrogen inlet was charged in the following order: CTV 1 (76.22 g, 0.17
moles, 18 eq), ethyl acetate (2 L), activated manganese dioxide (264.7 g,
3.05 moles), ground potassium permanganate (241.1 g, 1.53 moles, 9 eq)
and lastly ethyl acetate (0.29 L) as a rinse. The reaction was allowed to stir
at room temperature to ensure that there was no exotherm. The mixture
was then heated to reflux and stirred overnight. After 18 h, TLC and HPLC
analysis indicated that the reaction was deemed complete. Note: the
reaction solution was colorless (once solids settled) indicating that all KMnO4
had reacted. The reaction mixture was cooled to 50°C, filtered over a pad of
Celite (70.6 g), and Celite Cake was rinsed with ethyl acetate (3 x 500 mL)
and DCM (2 x 500 mL). The filtrate was concentrated under reduced
pressure at 40-50°C to give crude monoketone (61.91 g, pale yellow solids).
Purification of crude CTV Monoketone
Crude monoketone (51.00 g) was placed into a 250-mL glass reactor
(2-necked), equipped with a large magnetic stir bar, J-Kem thermocouple,
heating mantle, and reflux condenser. To the reactor was added acetonitrile
(150 mL, HPLC grade). Heated mixture to 70 °C and allowed slurry to stir
(250-300 rpm) at 70°C for 18 h. The slurry mixture was allowed to gradually
cool to room temperature over 4 h, then continued to stir at room
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temperature for approximately 3 h. The slurry was filtered over a fitted
funnel, the wetcake was washed with acetonitrile (60 mL), pulled dry, and
further dried in vacuo at 60°C overnight to give purified CTV monoketone 2
(32.54 g white solids, 65% yield).
The mother liquor was partially concentrated to remove about 75% of
the solvent to provide a slurry. The slurry was filtered and the wetcake was
washed with ethyl acetate/heptane (50/50, 10 mL) and dried to give a
second crop (15.8 g, 31% yield, white solids) of purified CTV-monoketone 2.
Total recovery = 96%. Total yield: 74% yield (corrected). The 1H NMR data
is in accordance with that reported in the literature.35
10,15-Dihydro-2,3,7,8,12,13-hexamethoxy-5Htribenzo[a,d,g]cyclononen-5-oxime,CTV Oxime Crown (15) and CTV
Oxime Saddle (16)

To a 500-mL glass reactor (3-necked), equipped with a magnetic stir
bar, reflux condenser, J-Kem thermocouple, and nitrogen inlet, was charged
CTV monoketone 2 (19.00 g, 40.91 mmol), hydroxylamine hydrochloride
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(42.64 g, 613.6 mmol, 15.0 eq), and pyridine (190 mL). The mixture was
heated to reflux (110 °C) under a nitrogen atmosphere. After 16.5 h, the
heat was turned off and the reactor was sampled for TLC analysis
(EtOAc/DCM, 20/80) and showed that the reaction was deemed complete.
The reaction mixture was transferred to a 500 mL flask (1 neck) and
partially concentrated at 60°C under reduced pressure to provide a crude
residue. To the crude residue was added USP purified water (275 mL) and
the mixture was allowed to triturate at room temperature for about 30 min.
The slurry was filtered, and the wetcake was washed with USP purified water
(2 x 50 mL), pulled dry, and further dried in vacuo at 50 °C overnight to
provide a pure mixture of CTV-oximes (saddle/crown, 17.63 g, white solids,
90% yield). The filtrate was extracted with ethyl acetate (3 x 75 mL). The
combined organic extracts were washed with 1N HCl (1 x 50 mL), brine (75
mL), dried with sodium sulfate, filtered, and concentrated under reduced
pressure to provide an additional quantity of CTV-oximes (2.29 g). HPLC
analysis showed a total purity of 96% for both oxime conformers which were
a ratio of 89:11 (crown:saddle). The 1H NMR data is in accordance with that
reported in the literature.35
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Improved Procedure for the Synthesis of CTV-lactam (19)
(2,3,8,9,13,14-hexamethoxy-11,16-dihydrotribenzo[b,e,h]azecin6(5H)-one)

Based on a similar procedure,36 this process was modified and
improved. To a 1-liter round bottom flask (3-necked), equipped with an
overhead mechanical stirrer, nitrogen inlet, and J-Kem thermocouple, was
added CTV oxime (10.00 g) and acetonitrile (200 mL). The mixture was
allowed to stir at ambient temperature for 20 min, then carbonyldiimidazole
(CDI, 7.18 g) was added. Additional acetonitrile (20 mL) was used to rinse
contents off the reactor flask walls. After 1 hour at room temperature, TLC
analysis (EtOAc/DCM, 80/20) revealed that the oxime starting material was
completely consumed and a new spot appeared (oxime O-acyl imidazole
intermediate 22, Rf = 0.10). The reaction mixture was cooled to < 5oC and
de-ionized water (50 mL) was added followed by drop-wise addition of
trifluoroacetic acid (TFA, 50 mL) over 20 min using a dropping funnel. After
20 h at room temperature, TLC analysis (EtOAc/DCM, 80/20) showed
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complete conversion of acyl imidazole intermediate to CTV-lactam 19 (Rf =
0.18). To the reaction mixture was added de-ionized water (600 mL) dropwise over 30 min providing an opaque pink slurry. The slurry was allowed to
stir for 20 h and filtered. The wetcake was washed with water (50 mL),
pulled dry, and further dried in vacuo at 50 oC to provide CTV-lactam (8.13
g, 82% yield). HPLC purity (220 nm): 95.2%. The 1H NMR data is in
accordance with that reported in the literature.36
5-[1,2,3,4-Tetrahydro-1-[[[(1R,2S,5R)-5-methyl-2-(1methylethyl)cyclohexyl]oxy]acetyl]-]acetyl-11,16-dihydro2,3,8,9,13,14-hexamethoxy-tribenz[b,e,h]azecin-6(5H)-one (23)

Preparation Method 1:
To a solution of CTV lactam 19(175 mg, 0.36 mmol) in pyridine (1.8
mL) was added (-)-menthyloxyacetic acid chloride (913 mg, 3.92 mmol) at
room temperature and the solution was heated to reflux for 2 h. The
mixture was then concentrated under reduced pressure, and the resulting
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residue was diluted in dichloromethane and poured onto ice. The layers
were separated, and the aqueous layer was extracted two additional times
with dichloromethane. The combined organic layers were washed
successively with 1N hydrochloric acid (2x), saturated aqueous sodium
bicarbonate, distilled water, brine, dried over sodium sulfate and
concentrated to afford the crude product as a solid (999 mg). The mixture
was passed through neutral alumina (17 g) eluting with ethyl
acetate/dichloromethane (20/80) to remove excess menthyloxyacetic acid,
followed by elution of the cyclotriveratrylene lactam starting material that
was recovered (40 mg, 25% recovered). The remaining material (477 mg)
eluted from the alumina was chromatographed on silica gel (24 g) eluting
with a gradient from pure dichloromethane to ethyl acetate/dichloromethane
(50/50) to afford the desired imide 23 (167 mg, 69%) as a pale yellow solid.
The product was crystallized using DCM and hexane yielding an 87:13
mixture of diastereomers: mp 200-203 oC; [α]D = -218

o

(c = 2.4 g/100

mL); IR 2998.6, 2953.5, 2927.6, 2868.3, 1723.0, 1696.3, 1608.0 ,
1517.9, 1463.1 cm-1. 1H NMR (400 MHz, CDCl3): δ 6.87 (bs, 2H), 6.71 (bs,
0.12H), 6.69 (bs, 0.11H), 6.68 (bs, 0.11H), 6.67 (bs, 0.13H), 6.60 (bs,
0.22H), 6.59-6.52 (complex, 3.2H), 6.47 (bs, 0.13H), 6.46 (bs, 0.13H), 6.39
(bs, 0.45H), 6.38 (bs, 0.55H), 5.07 (bs, 0.19H), 5.03 (bs, 0.26H), 4.98-4.84
(m, 0.87H), 4.80 (bs, 0.27H), 4.76 (0.20H), 4.47 (bs, 0.03H), 4.42 (bs,
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0.04H), 4.37 (bs, 0.04H), 4.32 (bs, 0.31H), 4.29 (bs, 0.28H), 4.26 (bs,
0.24H), 4.23 (0.26H), 4.16 (bs, 0.04H), 4.13-4.11 (complex, 0.27H), 4.104.05 (complex, 0.45H), 4.04-4.02 (complex, 0.52H), 4.01-3.97 (complex,
0.43H), 3.95-3.91 (complex, 6.2H), 3.90 (bd, 1H), 3.87 (bd, 1H), 3.83 (bs,
1H), 3.81 (bs, 0.43H), 3.80-3.78 (complex, 1.2H), 3.74 (bd, 3.2H), 3.73
(bs, 3.2H), 3.71-3.60 (complex, 6.4H), 3.62-3.58 (complex, 1H), 3.55 (bd,
1H), 3.49 (bs, 0.30H), 3.45 (bd, 0.54H), 3.42 (bs, 0.28H), 3.33-3.27 (td,
1.1H), 3.20-3.07 (complex, 0.32H), 2.41-2.24 (complex, 1.35H), 2.25-2.19
(complex, 1.23H), 2.12-2.00 (complex, 0.55H), 1.68-1.58 (complex, 5.4H),
1.46-1.18 (complex, 8H), 1.08-0.71 (complex, 22.2H).

13

C-NMR (75 MHz,

CDCl3): δ 16.1, 16.2, 16.3, 20.9, 21.0, 21.1, 21.9, 22.1, 22.3, 23.2, 23.3,
25.4, 25.5, 25.6, 29.6, 31.5, 33.8, 33.9, 34.2, 34.4, 34.5, 35.7, 35.8, 40.0,
40.2, 48.2, 48.3, 55.5, 55.6, 55.7, 55.8, 55.9, 56.0, 56.1, 56.2, 70.9, 71.2,
76.6, 77.0, 77.2, 77.4, 80.1, 80.5, 80.6, 109.2, 109.4, 111.2, 111.3,
111.5, 111.6, 111.7, 111.9, 112.1, 112.2, 112.5, 113.6, 114.2, 114.3,
115.4, 127.5, 128.1, 128.8, 129.9, 130.0, 130.5, 130.8, 131.0, 131.1,
131.3, 146.8, 147.4, 147.7, 147.8, 148.3, 148.8, 149.6, 173.4, 174.4 MS:
Calculated for C39H50NO9+ [M+H]: m/z 676.3, found 676.3.
Preparation Method 2:
To a solution of CTV lactam 19 (400 mg, 0.83 mmol) in pyridine (4.1
mL) was added commercially available (-)-menthyloxyacetic acid chloride
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(0.75 mL, 0.78 g, 3.35 mmol) at room temperature and the solution was
heated to 80 oC for 2 h. The mixture was then concentrated under reduced
pressure to give a crude residue. The residue was diluted in ethyl acetate
(30 mL), washed with 1N HCl (20 mL), 5% aqueous NaHCO3 (2 x 20 mL),
saturated brine solution (20 mL), dried with sodium sulfate, filtered, and
concentrated under reduced pressure to give crude product (1.20 g) as a
dark yellow glass solid. The crude product was dissolved in DCM (20
mL)/triethylamine (0.5 mL) and silica gel (2.1 g, 60-200 micron) was added
and the resulting mixture was concentrated to dryness to provide crude
product adsorbed onto silica gel which was loaded into a solid loading
cartridge (60 g). Purification was accomplished on a Teledyne Isco Rf200
unit using a 40 g RediSep Rf Gold silica gel cartridge column and an ethyl
acetate/n-heptane gradient containing 0.5% triethylamine to afford the
desired imide 23 (205 mg, 36% yield). The product was recrystallized using
DCM/heptane or ethyl acetate affording an 87:13 ratio of diastereomers.
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Hydrolysis of Imide 23 and the use of Optical Rotation to determine
resolution of CTV-Lactam:

CTV Lactam 19 from hydrolysis of the imide23
To enriched CTV-menthyloxyacetic imide 23 (24 mg, 0.037 mmol), at
0 °C in THF/water (3:1, v/v, 0.75 mL), was added lithium hydroxide (3 mg,
0.911 mmol) and stirred for 15 min. The mixture was extracted with
dichloromethane (3 x 20 mL). The combined organic layers were washed
with distilled water (10 mL), brine (10 mL), filtered over sodium sulfate, and
concentrated under reduced pressure to afford a solid (24 mg). The product
was filtered through alumina eluting with ethyl acetate/dichloromethane
(20/80) to isolate CTV lactam 19 (17 mg); [α]D = 0o (3.4g/100mL).
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Hydrolysis of Imide and the use of Chirabite-AR to determine
resolution of CTV-Lactam:

CTV Lactam 19 from hydrolysis of the imide23
To enriched CTV-menthyloxyacetic imide 23 (13.2 mg, 0.019 mmoles)
was dissolved in THF (0.75 mL) and then cooled to 0-5 °C using an ice-water
bath. A solution of 0.24 M lithium hydroxide monohydrate (0.275 mL, 0.068
mmol, 3.5 eq) was added. The mixture was allowed to stir at 0-5 °C for 15
min, then the reaction mixture was transferred to a 20 mL scintillation vial
and concentrated under high vacuum for 5 min. The residue was dissolved in
CDCl3 (0.75 mL) followed by addition of 0.10 M Chirabite-AR solution in
CDCl3 (60 µL, 0.006 mmol, 0.3 equiv.) and this mixture was placed in a NMR
tube. Two min later, NMR analysis started. 1H NMR analysis showed that the
resolution was lost and the mixture was a racemate based on that the two
peaks at 6.51 and 6.53 ppm were 1:1 by integration and peak height.
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Chirabite-AR Study with Racemic CTV-Lactam

To racemic CTV-lactam 19 (20 mg, 0.042 mmoles) was added CDCl3
(1.0 mL) to provide a solution and this solution was transferred to a 400
MHz tube. A solution of 0.10 M Chirabite-AR in CDCl3 was prepared by
mixing Chirabite-AR (38 mg, 0.05 mmoles) in CDCl3 (0.5 mL).
Below in Table 4 denotes the following equivalents of Chirabite-AR
solution added to the NMR tube. The equivalents of Chirabite-AR that were
evaluated were 0.01, 0.025, 0.050, 0.075, 0.10, 0.125, 0.150, 0.175, 0.20,
and 0.30 equiv. After addition of the specified amount of Chirabite solution
into the NMR sample containing racemic CTV-lactam, the sample was placed
into the NMR spectrometer, analyzed, then proceeded to the next charge of
Chirabite solution.
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Table 4. Loading of Chirabite-AR Solution
Loading of
Chirabite-AR
Solution
(0.10 M in CDCl3)
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3
Chirabite-AR
Solution in CDCl3

MW

Loading
equiv.

Total
Volume
uL

Vol to be
added
portion-wise
to NMR
Sample

759.72

0.010

4.2

4.2

0.0004

759.72

0.025

10.4

6.3

0.0010

759.72

0.050

20.9

10.4

0.0021

759.72

0.075

31.3

10.4

0.0031

759.72

0.100

41.7

10.4

0.0042

759.72

0.125

52.1

10.4

0.0052

759.72

0.150

62.6

10.4

0.0063

759.72

0.175

73.0

10.4

0.0073

759.72

0.200

83.4

10.4

0.0083

759.72

0.300

125.1

41.7

0.0125

mmole

CHAPTER THREE
CARBORANE HYDROXAMATE MMP INHIBITORS FOR TREATMENT OF
CANCER AND RHEUMATOID ARTHRITIS EMPLOYING BNCT
Section 1: Introduction
Antimicrobial therapy has saved millions of lives over the past 80
years, yet our arsenal of effective antibiotics is increasingly diminished by
the alarming rise of bacteria that are resistant to all currently available
antibiotics.1 Over two million people annually in the United States acquire
infections that are resistant to antibiotics, and at least 23,000 people die as
a result, according to are port issued by the Centers for Disease Control and
Prevention.2 In the U.S., antibiotic resistance adds $20 billion in additional
direct health care costs, with lost productivity as high as an additional $35
billion annually.2
There is an urgent need for antibacterial agents with new cellular
mechanisms of action, yet the pharmaceutical industry shows little interest
in antibiotic R&D due to the high cost of development and the typically
short-term treatment regimen of antibiotics which is considered to be less
profitable than the treatment of chronic diseases.3
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The sharp increase in mortality and morbidity due to rising bacterial
infections caused by antibiotic-resistant bacteria4 underlines the need to
discover and identify previously-unexplored enzymes as novel antibiotic
targets with the goal of developing new molecular leads. For example,
invasive methicillin-resistant Staphylococcus aureus (MRSA) is a serious and
growing health problem.5 Several newly discovered strains of MRSA show
antibiotic resistance even to vancomycin, which has been considered for
decades as the last line of defense for the treatment of systemic infections.6
An attractive bacterial target is the dapE-encoded N-succinyl-L,Ldiaminopimelic acid desuccinylase (DapE, E.C. 3.5.1.18),7 which is a
member of the lysine biosynthetic pathway in bacteria (see Figure 24) that
provides lysine and meso-diaminopimelate (m-DAP),8 both of which are
essential for peptidoglycan cell-wall synthesis.
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Figure 24. Biosynthetic pathways producing mDAP and lysine in bacteria
As illustrated in Figure 25, DapE catalyzes the hydrolysis of N-succinylL,L-diaminopimelic acid (L,L-SDAP) to succinate and L,L-diaminopimelic acid
(L,L-DAP), and is ultimately responsible for synthesizing lysine for bacterial
peptide synthesis, and for providing both mDAP and lysine for peptidoglycan
cell wall formation in both Gram-negative and most Gram-positive bacteria.8
Deletion of the DapE gene is lethal to Helicobacter pylori and Mycobacterium
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smegmatis, demonstrating the indispensable role of this bacterial enzyme in
pathogens.9,10 Furthermore, lack of a similar pathway in humans suggests
that inhibition of DapE may be selectively toxic to bacteria but not to human
hosts, eliminating the concern of mechanism-based toxicity and making
DapE a very promising target for the development of antibiotics with a new
mechanism of action.7

Note. L,L-SDAP (1a) and analogs N6-methyl SDAP (1b), and N6-acetyl-SDAP (1c) with
formation of hydrolysis products succinate (2) and L,L-diaminopimelic acid derivatives (3ac). Hydrolysis was not observed for N-acetyl analog 1c

Figure 25. Hydrolysis of L,L-SDAP and analogs by HiDapE
Previously, it was shown that DapE isozymes exhibit >60% of their
maximal activity towards L,L-SDAP when only one Zn(II) ion is present in its
active site,11 with the tighter binding site confirmed by high-resolution X-ray
crystallography. These structures obtained from X-ray crystallography have
enabled further refinement of a mechanistic hypothesis of amide bond
cleavage by DapE enzymes, which have facilitated inhibitor identification.12A
small, focused screen of compounds containing zinc-binding groups
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identified the thiol-containing ACE inhibitor captopril as a low micromolar
competitive inhibitor (IC50 = 3.3 µM) of the DapE from Haemophilus
influenza (HiDapE) along with several other small molecule inhibitors
including 3-mercaptobenzoic acid (IC50 = 35 µM), phenylboronic acid (IC50 =
107 µM), and 2-thiopheneboronic acid (IC50 = 92 μM).13 A high-resolution
(1.8 Å) X-ray crystal structure of captopril bound to the DapE from Neisseria
meningitidis (NmDapE) revealed a thiolate-bridged dinuclear Zn(II) active
site providing a model for in silico approaches to identifying potential
inhibitors of DapEs.14
The most widely used DapE assay monitors amide bond cleavage of
L,L-SDAP spectrophotometrically at 225 nm.13

While this assay is simple

and reliable for simple molecules, it cannot be used to test potential
inhibitors that absorb strongly in the UV region, precluding its use in testing
many of the preferred medicinal chemistry leads and analogs. While several
assays have been developed for evaluating inhibitors of DapEs, these assays
are technically troublesome and/or difficult to reproduce.15 For example,
Gelb et al.16 exploited the fact that L,L-DAP reacts somewhat faster with
ninhydrin than L,L-SDAP; however, this assay suffers from poor
reproducibility.

Two alternative assays were also reported, the first of

which employed14C-labeled L,L-SDAP while the second was a coupled assay
that utilizes porcine succinate thiokinase and inositol triphosphate to convert

78
liberated succinate to succinyl-CoA (CoA = coenzyme A) and inositol
diphosphate. The inositol diphosphate was then detected by its reaction
with phosphoenolpyruvate to yield liberated pyruvate, itself being detected
spectrophotometrically using lactate dehydrogenase. The

14

C-labeled

substrate assay requires working with radioactivity, necessitating extra
safety protocols and waste disposal issues, while the coupled assay is
cumbersome and expensive while also being technically difficult and
therefore challenging to reproduce. Moreover, none of these assays is
amenable to high-throughput screening studies, a necessity for the
discovery of new lead compounds with antibacterial properties.
Recognizing the ease and reliability of ninhydrin-based assays to
detect primary amino groups, such as that formed upon the hydrolysis of
L,L-SDAP, and the importance of the N6-amino group of L,L-SDAP,17 we
synthesized L,L-SDAP derivatives with partially blocked free amino groups to
prevent ninhydrin side reactions. N6-Acetylated, N6-methylated, and N6,N6dimethyl derivatives of L,L-SDAP were investigated and prioritized using
molecular docking and modeling. Based on these data, a new enzymatic
assay for HiDapE is described using N6-methylated L,L-SDAP, which we have
shown is simple, robust, and amenable to high-throughput screening. These
data open the door to medicinal chemistry efforts toward the discovery of
HiDapE inhibitors that can function as a new class of antibiotics.
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Section 2: Existing Synthetic Preparations of
2,6-Diaminopimelic Acid (DAP)
The 2,6-diaminopimelic acid (DAP) analogs are relatively difficult to
synthesize by conventional routes, due to the fact that the spacing of the
groups on synthetic intermediates tends to favor intramolecular ring closure
to form a piperidine system. For instance, one can envision the possible
synthesis of 2,6-diaminopimelic acid from either 2,6-dibromopimelic acid or
2,6-dibromopimelate ester in the presence of ammonia or some other
amine, however once one molecule of ammonia attacks one of the carbons
bearing the bromo group, the resulting primary amine has the opportunity to
undergo an intramolecular ring closure attacking the other carbon bearing
the bromo substituent which generates a 2,6-disubstituted piperidine
derivative rather than the seven-carbon linear chain structure that bears the
equally spaced amino groups.18-23
In 1964, a patent was awarded to Dow Chemical24 for a synthesis of
racemic DAP starting with either glutaraldehyde or 2,6dihydroxypimelonitrile to furnish trimethylene-1,3-bis(5-hydratoin). The
process of forming the bis-hydantoin starting from glutaraldehyde requires
the use of sodium sulfite (2.1 eq) and sodium cyanide (2.04 eq) in water
which, after extractions with diethyl ether, provides 2,6dihydroxypimelonitrile in 90% yield, which is then converted to a bis-
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hydantoin using a pressure bomb reactor at 85 oC in the presence of
ammonium carbonate and 14N ammonium hydroxide. Subsequent reaction
of the intermediate hydantoin under high temperature acidic or alkaline
hydrolytic conditions (48% HBr or 50% NaOH at 175-185 oC in a stainless
steel bomb) hydrolyzed the hydantoin intermediate to a mixture of
diastereomers of 2,6-diaminopimelic acid which then required purification on
ion-exchange resin and recrystallization from ethanol/water to access the
DAP as the bis-ammonium salt in 37% yield. This procedure is most likely
the commercial route for preparing racemic DAP; however, this route in an
academic setting is not ideal due to the use of cyanide, pressure bombs, and
elevated temperature of volatile mixtures (acidic/alkaline) which are serious
safety concerns leaving many researchers little choice except to purchase
synthetic DAP. However, it still raises concerns for individual working in
manufacturing who are assigned to carry out this process.
Developing a method to synthesize sufficient quantities of DAP and
SDAP materials for the ninhydrin-based assay developed by Dr. Tahirah
Heath at Loyola University Chicago was a challenging process that would
have required the use of synthetic processes that were generally low yielding
and inefficient if only making use of the known methodology. Alternatively,
L,L-DAP can be purchased at significantly higher costs and associated lead
times. We needed the synthetic flexibility to produce specific derivatives of
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L,L-DAP and L,L-SDAP that were not possible from the commercial material.
Thus, there was an urgent need to develop a safer, scalable and more
flexible process for the asymmetric synthesis of DAP, SDAP, and related
analogues.
Section 3: SDAP Route Comparisons and Improvements
Previous synthetic routes of L,L-N-succinyl-diaminopimelic acid (L,LSDAP) were generally tedious and non-stereoselective involving multiple
purifications that ultimately made the synthesis a very low throughput
process. Typically, one needed to start with D,L-diaminopimelic acid (DAP)
isoforms and perform multiple recrystallizations using naphthalene- β sulfonic acid25to produce a 1:1 mixture of L,L and D,D-DAP isoforms. The
general approach for preparation of diastereomerically pure L,L-SDAP
consisted of a laborious and time consuming process as illustrated in
Scheme 14 below.
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Scheme 14. General Preparation of L,L-SDAP

This process of preparing L,L-SDAP required separation of D,D and L,Lisoforms from the D,L/L,D isoforms through a classical recrystallization
method using naphthalene-β-sulfonic acid25,26 to form sparingly-soluble
ammonium salts in 1N HCl. To ensure that the D,L/L,D-DAP isoforms are
removed, in excess of six recrystallizations from 1N HCl were required, with
no indication in the literature of percent recovery after each
recrystallization.26 The subsequent step required conversion to the free base
of the resolved D,D/L,L-isoforms using 15% pyridine in ethanol for 2 days at
room temperature releasing naphthalene-β-sulfonic acid. Installation of the
succinyl group on D,D/L,L-DAP then required the method of Lin et al15 which
involved treatment of D,D/L,L-DAP with potassium bicarbonate (2.2 eq) in
water in the presence of succinic anhydride (1.01 equiv) and, after overnight
at room temperature, the reaction mixture was adjusted to pH 2 with dilute
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hydrochloric acid, concentrated, and loaded onto a purification column
packed with microcrystalline cellulose that was eluted with a quaternary
solvent system (methanol/water/concentrated HCl/pyridine). After
purification over cellulose, the corresponding fractions were analyzed using
TLC on cellulose plates, and pure D,D/L,L-SDAP fractions were then pooled
and concentrated. The resulting concentrate was further purified by ionexchange chromatography using H+ form resin to eliminate residual
succinate as well as pyridinum hydrochloride. After ion-exchange
purification, a yield of 41% was reported which provided 1.1 g of DL-SDAP
ammonium salt. The ion-exchange purification required about 1 liter of
water and 3M ammonium hydroxide to flush the product from the resin.
After this step, the final step still required reverse-phase chiral HPLC on an
expensive chiral HPLC column (Chirobiotic T column, Alltec) to separate the
D,D and L,L-SDAP isomers. It is evident that this process for achieving
diastereomerically pure L,L-SDAP is highly inefficient and exhaustive due to
issues involving multiple recrystallizations of nosylate salts (naphthalenesulfonic/DAP salts), purification over cellulose, low-throughput purification
over ion-exchange resin, and finally extremely low throughput and a timeconsuming separation to isolate the L,L-isoform followed by concentration of
aqueous streams to isolate desired L,L-SDAP isoform via chiral reverse
phase HPLC.
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Section 4: Development of Routes to Access L,L-DAP, L,L-SDAP,
N6-Monomethyl-SDAP, and N6,N6-Dimethyl-SDAP
as Potential DapE Substrates
Previous attempts in our lab to prepare monomethyl and dimethylSDAP involved the direct methylation of racemic SDAP or L,L-SDAP, which
produced an inseparable mixture of unreacted starting material,
monomethyl, dimethyl, and quaternary ammonium salt as illustrated below
in Scheme 15. Depending on the conditions, methylation of the carboxyl
moieties was also of concern since formation of methyl ester(s) are possible.
Reductive amination of racemic SDAP was difficult since isolation of the
monomethyl or dimethyl products was troublesome due to high water
solubility of the products, combined with the need for isolation from
inorganic salts. Based on these synthetic difficulties for preparing
monomethyl SDAP, alternative routes were outlined to develop a scalable
process.
Scheme 15. Attempts to form Monomethyl and Dimethyl SDAP
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During literature searching, it was observed that many syntheses
focused on the synthetic preparation of diaminopimelic acid (DAP) or
acylated derivatives.27 Hlavácek demonstrated that racemic DAP (R,S)-2,6diaminopimelic acid) can be selectively protected which required the free
amino group to be protected with a Boc group and the carboxyl groups
protected as benzyl esters using N,N´-diisopropyl-O-benzylisourea (Scheme
16). This fully protected material is much more soluble in many organic
solvents compared to its parent, unprotected structure (diaminopimelic acid)
which has poor organic solubility and requires polar solvents (such as water,
methanol, DMF, or DMSO) to ensure material is dissolved and allow chemical
transformations to occur more readily in a homogeneous manner. The Boc
moieties were removed under acidic conditions followed by mono-protection
of one of the free amino groups using Cbz-Cl giving a 37% yield over the
two steps of Boc deprotection and carbamate formation after extensive
purification. At this point, the mono-acylated free amino component was
then acylated with an anhydride, hydrogenated to cleave the benzyl groups,
and then purified by achiral reverse-phase HPLC followed by chiral reverse
phase HPLC to afford limited quantities of pure L,L-SDAP with high
diastereomeric purity. This method offered some advantages, however the
use of racemic DAP did not seem appealing since reverse-phase
chromatography is typically a low-throughput method, and higher quantities
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were required for the ninhydrin assay. Furthermore, the mono-protection
step using Cbz-Cl is low yielding, and based on the expense of purchasing
DAP, this route would not be useful in preparing sufficient quantities of
monomethylated SDAP.
Scheme 16. Hlavácek synthesis of SDAP and its analogs

One of the methods of producing orthogonally-protected S,S-DAP was
accomplished via olefin cross-metathesis which was reported by Blicher.28
Drawbacks of this method included a challenging selective hydrogenation of
the alkene in the presence of the Cbz groups, and also the need to minimize
the self-crossed metathesis byproducts which depends on the generation of
Grubb's catalysts used. In relation to Blicher's route, a similar synthesis
reported by Takahata29 which demonstrated that protected meso-DAP can
be prepared by cross metathesis of the Garner aldehyde-derived vinyl
glycine with protected allyl glycine in the presence of Grubb’s secondgeneration catalyst. Based on this Blicher's method, the proposed route

87
shown below in Scheme 17 (Route A) illustrates how Blicher's method could
be employed to prepare monomethylated SDAP. The proposed route was
modified such that the Cbz group could be exchanged for a Boc group. This
would simplify the hydrogenation because the alkene and Cbz groups could
be selectively reduced in the presence of succinic anhydride to generate the
succinate amide. However, in order to perform the cross metathesis
reaction, the requisite starting materials would need to be prepared,
specifically the N-methylated Boc protected vinyl glycine and N-Cbz vinyl
glycine. It was decided not to pursue this route since formation of self-cross
metathesis products is a significant drawback that would give rise to a 3040% yield loss of desired product as reported by Blicher28 and Takahata.29
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Scheme 17. Proposed Route A for the Preparation of Monomethyl L,L-SDAP
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Another interesting approach to preparing diastereomerically pure
monomethyl SDAP is illustrated in Scheme 18 (Route B). The synthesis
starts with the commercially-available and inexpensive starting material,
methyl L-methioninate hydrochloride, which reacts with methyl succinyl
chloride to form the succinate amide methyl ester. The subsequent step
involves the oxidation of the sulfide using sodium periodate to form the
sulfoxide component. Under high temperatures and/or high
temperature/high pressure conditions either in a microwave reactor or
continuous flow, the sulfoxide is eliminated to afford the corresponding
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alkene. The generated alkene after elimination of the sulfoxide would couple
with the N-methyl-N-Boc allyl glycine in a cross-metathesis reaction using a
Grubb’s II generation catalyst. Upon formation of the desired alkene, this
product would undergo hydrogenation to reduce the alkene to the saturated
form, then global deprotection of the trimethyl ester to the corresponding
carboxylic acid and removal of the Boc group to afford the monomethyl
SDAP ammonium salt. This proposed route was conceptually attractive,
however the generation of the alkene via sulfoxide elimination might be a
problematic step since these reactions require high temperatures and it is
not known whether the succinate amide would epimerize through alkene
isomerization of the double bond, which would prefer to be conjugated to the
carbonyl ester system with generation of an enamide. Based on these
concerns, this route was not pursued.
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Scheme 18. Proposed Route B for the Preparation of Monomethyl L,L-SDAP
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The next proposed route illustrated in Scheme 19 (Route C) for
preparation of diastereomerically pure monomethyl SDAP was designed
around the preparation of an aldehyde through the use of commerciallyavailable N-Boc-L-allylglycine. This route is very similar to the route
ultimately selected for preparation of monomethyl SDAP (refer to Route D),
however this route primarily is designed around an alternative preparation of
the aldehyde. The first step requires the formation of the methyl ester
followed by installation of the methyl group onto the N-Boc moiety. Next,
the hydration of the allyl group then proceeds via hydroboration followed by

91
oxidation of the primary alcohol to aldehyde using either PCC/PDC or Swern
conditions. This route relies on the fact that aldehydes and
phosphonoglycine esters can couple efficiently to form enamides through the
use of the Horner-Emmons-Wadsworth olefination reaction. The subsequent
step involving hydrogenation of the Cbz group followed by succinylation
yields the succinate amide. Lastly, aqueous acid to perform global
deprotection via hydroylsis is expected to furnish the monomethyl-SDAP
salt, however the hydrolysis of the trimethyl ester may require lower
temperature/lower acid concentration to prevent hydrolysis of the amide
group. This route does seem promising for the preparation of monomethyl
SDAP, however there are a few concerns regarding the initial two steps such
as installation of methyl group onto the Boc-amide group. Installation of the
methyl group using silver(I) oxide could be problematic since silver(I)
species interact with olefins which could complicate the desired methylation
of Boc-amide. Alternatively, methylation under alkaline conditions using
DMAP/MeI or NaTMDS/MeI could be employed but there is the risk that
alkene isomerization will occur, which would affect the hydroboration
reaction leading to incorrect functionalization of the hydroxyl moiety and
thus leading to formation of ketone rather than desired aldehyde.
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Scheme 19. Proposed Route C for the Preparation of Monomethyl L,L-SDAP
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A synthesis of diaminosuberic acid (DAS) was developed by Nájera et
al30using a palladium-catalyzed allylic double substitution which could be
applied to the synthesis of DAP. This approach generates a 1:1 mixture of
diastereomers and thus is not appropriate for the preparation of
diastereomerically pure diaminopimelic acid (DAP). Other known
preparations of diaminopimelic acid (DAP) have been cited, however these
preparations generally give a mixture of diastereomers.31-33
An orthogonally synthetic method for producing a protected meso-DAP
derivative was reported by Fukase.34 Fukase's synthetic methodology
focused on the use of a Kocienski-modified Julia olefination that effectively
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coupled a homologated-serine based Garner aldehyde, itself derived from
Boc-protected D-serine35 and a modified Julia sulfone (also derived from Cbz
protected D-serine)36 to yield a key seven-carbon backbone intermediate
that leads to the formation of a protected meso-DAP derivative after 5
additional chemical steps. Thus, Fukase reported an elegant synthesis in
which no epimerization was observed, however this route is not amenable
toward the synthesis of monomethyl L,L-SDAP since the homologated
Garner aldehyde starting material (L or D-serine) requires 7 chemical
steps35, 37 to access the homologated Boc-protected Garner aldehyde and
attempting to install a methyl group during the first three steps route will
prohibit the formation of Garner aldehyde. Thus, the only means to form the
N-methyl would be at a time before reducing the methyl ester to the
aldehyde/alcohol. The installation of a methyl group for the sulfone
precursor is also not attractive due the requirement of a multi-step approach
to furnish a monomethyl starting material. Granted that Fukase's method
proved successful for his objectives, the synthesis is not practical for
preparation of monomethyl L,L-SDAP at larger scale due to the high cost and
time-demanding multi-step synthesis to furnish a monomethyl adduct.
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Scheme 20. Proposed and Selected Route D for the Preparation of
Monomethyl L,L-SDAP
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Proposed route D (see Scheme 20) was partly based on the previous
work by Hruby38 which demonstrates that DAP can be enantiomerically
synthesized through asymmetric hydrogenation of an enamide precursor. In
this route, the starting material, Boc-L-Glu-OtBu, was selected due to its
commercially availability and low cost. The methyl ester could have been
purchased, however this was not as commercially available, and the cost
was higher compared to the free acid. The preparation of the methyl ester
can be accomplished by a variety of methods, however the simplest
approach was using methyl iodide or dimethyl sulfate. Methyl iodide and
potassium carbonate in DMF was selected for the formation of the methyl
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ester for the work described herein. The next step to install a methyl group
on the N-Boc moiety was planned to be carried out in the same pot to avoid
aqueous workup of the methyl ester. Following Hruby's method of reducing
the methyl ester to the aldehyde using DIBAL at cryogenic conditions, it was
found that this method was not applicable for the N-methyl-Boc substrate
due to the formation of mixtures, thus alternative methods for a highyielding reduction/reoxidation protocol were investigated. The next step
incorporated the Horner-Emmons-Wadsworth olefination by treating the
prepared aldehyde with Cbz-α-phosphonoglycine ester and DBU. The
Horner-Emmons reaction using Cbz-α-phosphonoglycine dimethyl ester free
carboxylic acid was also attempted but this approach was unsuccessful with
no conversion of starting materials observed. The asymmetric reduction
seemed very promising for the monomethyl-SDAP since it was determined
that Rh-DUPHOS is an effective chiral catalyst to access the enantiomerically
pure L,L-DAP scaffold. The subsequent step requires removal of the Cbz
group using hydrogenation followed by succinylation using succinic
anhydride and triethylamine in DCM. Lastly, based on literature precedent,
the concurrent hydrolysis of the methyl ester, Boc group, and t-butyl ester
can be accomplished using aqueous hydrochloric acid or aqueous
hydrobromic acid, which Hruby employed for hydrolysis of the methyl ester
and Cbz groups to access diaminopimelic acid (DAP).
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Executing the proposed route for preparation of monomethyl L,L-SDAP
followed a similar approach of Hruby38 but the route was modified and
significantly improved as needed for subsequent scale-up for preparation of
intermediates, finally yielding enantiomerically pure monomethyl L,L-SDAP.
Scheme 21 depicts the modified synthetic routes utilized for preparation of
monomethyl L,L-SDAP denoted as 1b.HCl and 1b.TFA for the hydrochloride
and trifluoroacetate salts, respectively.
Scheme 21. Asymmetric synthesis of N6-Methyl-L,L-SDAP 1b. Synthetic
route for preparation of monomethyl substrate analog as the hydrochloride
salt (1b.HCl) via the methyl ester or the trifluoroacetate salt (1b.TFA) via
the benzyl ester
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N2-Succinyl-N6-methyl-L,L-DAP 1b was prepared enantioselectively
with the key olefination and asymmetric hydrogenation steps38 modeling the
synthesis of diaminopimelic acid, which lacks the N6-methyl as well as the
succinate. In addition, the present route avoids any use of ion exchange
chromatography that was used in previous smaller-scale work.38 The first
step involves the one-pot methylation of the BOC-L-glutamic acid t-butyl
ester 4 with potassium carbonate and methyl iodide, in the presence of
silver oxide, to afford the N-methylated ester 5. Reduction of the methyl
ester with sodium borohydride afforded the primary alcohol 6, which was
oxidized to the aldehyde 7 with PCC or PDC, or under Swern conditions. The
oxidation using PCC or PDC was more convenient than Swern conditions
which typically formed an impurity (believed to be a mixed thioacetal) that
was difficult to remove by normal-phase chromatography and resulted in
lower yields of the desired aldehyde. Furthermore, the use of PDC appeared
to be more facile and typically produced less baseline material as determined
by TLC analysis. Attempts to access the aldehyde directly from the methyl
ester using DIBAL were unsuccessful and typically gave mixtures of starting
material, aldehyde, and alcohol. Oxidation of alcohol to aldehyde with
activated manganese dioxide was also not successful. Horner-WadsworthEmmons olefination with Cbz-α-phosphonoglycine ester (Cbz =
carboxybenzyl) gave the enamide in excellent yield. Alternatively, the
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Horner-Emmons reaction using Cbz-α-phosphonoglycine dimethyl ester free
carboxylic acid was attempted but this approach was unsuccessful with no
conversion of starting materials. The enamide product was enantioselectively
hydrogenated in the presence of catalytic amounts of 1,2-bis[(2S,5S)-2,5diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I)
trifluoromethanesulfonate affording the L,L-Cbz-protected amino acid 9a in
93% yield. This asymmetric hydrogenation and catalyst selection follows
previous work that established an asymmetric synthesis of diaminopimelic
acid.38 The asymmetric hydrogenation of the enamide described within this
work was accomplished using lower hydrogen pressure (50 psi) compared to
Hruby's method which employed 70 psi of hydrogen using a Parr Shaker.
Furthermore, the asymmetric hydrogenation process described within this
work was executed safely using lower hydrogen pressure and the process
was carried out in a more controlled manner where the pressure vessel was
equipped with mechanical agitation and better thermal control throughout
the duration of the reaction. Removal of the Cbz protecting group by
hydrogenolysis followed by reaction with succinic anhydride afforded the
succinamide derivative in 99% yield, which was subjected to hydrolysis with
aqueous HCl to afford N6-methyl L,L-SDAP as the hydrochloride salt
(1a.HCl) in 97% yield. The hydrochloride salt was very hygroscopic, and
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eventually the material became an un-weighable solid and the quality of the
product declined presumably due to desuccinylation.
In more detail, the overall route to monomethyl SDAP was modified
and improved based on Hruby's method, since that installation of the methyl
group on the N-Boc moiety was required. Hruby's method of accessing the
aldehyde strictly depended on the bis-Boc-amide which under reductive
conditions using DIBAL gave primarily the aldehyde. It was found that once
the methyl ester-N-methyl-Boc 5 was prepared, the reduction of methyl
ester to aldehyde using DIBAL was problematic producing a mixture of
aldehyde, alcohol, and unreacted starting material methyl ester which could
be oxidized to primarily aldehyde using PDC/PCC but made isolation of
aldehyde very difficult. Furthermore, carrying forward the methyl ester
starting material as an impurity would lead to its hydrolysis if carried to the
final step, which would create problems downstream during the synthetic
sequence. Therefore, conditions for accessing the aldehyde were modified
and then accomplished by reducing the methyl ester cleanly to the alcohol
using sodium borohydride followed by an efficient oxidation to aldehyde
using either PDC/PCC or Swern conditions. Furthermore, the use of sodium
borohydride left the tert-butyl ester unaffected due to the bulky nature of
the t-butyl group.
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The use of hydrobromic acid in acetic acid, based on literature
method,38 to hydrolyze the methyl ester and Cbz group was not amenable
for the hydrolysis of monomethyl SDAP due to the fact that the succinyl
group was also hydrolyzed affording monomethyl-diaminopimpelic acid as an
impurity which proved to be an inhibitor in the ninhydrin assay. Given that
the combination of acid and heat does increase the risk of epimerization of
the amino substituent(s), two alternative methods were developed to control
epimerization and prevent hydrolysis of the succinyl group. The two methods
evaluated were the use of 6M HCl at ambient temperature to control the
epimerization but this method also eventually produced small amounts of
desuccinylated by-product giving a primary amine. The second method is
based on the benzyl ester analog (discussed below) that consisted of nonaqueous conditions using trifluoroacetic acid to cleave both the t-butyl and
Boc groups that generated the mono-methyl SDAP analog cleanly without
any desuccinylated impurity and with better control in avoiding
epimerization.
The Horner-Emmons-Wadsworth monomethyl product did show
evidence of cis-trans alkene isomers based on 1H NMR analysis, although the
ultimate enantioselectivity was not compromised. During the asymmetric
hydrogenation of the monomethyl enamide intermediate, 1H NMR was
employed to monitor the progress of the reaction. Isomerization of the
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alkene was not observed, and both E/Z enamides were hydrogenated to
achieve high e.e. as described and supported by Burk's study.39, 40
The use of the benzyl ester route proved to be more amenable to
large-scale reactions as the benzyl moiety can easily be deprotected after
the asymmetric hydrogenation. Conversely, the intrinsic substrate selectivity
for asymmetric hydrogenation of the methyl ester was actually better than
for the benzyl ester enamide scaffold, as determined by HPLC analysis; the
methyl ester chiral purity was 97.4% e.e. whereas 92.0% e.e. was achieved
for the benzyl ester. The benzyl ester still remained the most attractive
procedure since hydrolysis of the methyl ester is often accompanied by
desuccinylation generating a primary amino moiety which dramatically
affects the ninhydrin assay, therefore the benzyl ester enamide route proved
to be superior in generating cleaner, mono-methyl SDAP, combined with the
fact that a final crystallization in the benzyl ester route afforded material
over very high e.e., as detailed below.
A second route was also developed that was an improvement, based
on yield, over the initial methyl ester route by utilizing a benzyl ester. In
this synthetic scheme, the Wadsworth-Emmons reaction of the aldehyde 7
with benzyl 2-{[(benzyloxy)carbonyl]amino}-2-(dimethoxyphosphoryl)
acetate (R = Bn) afforded enamide 8b, which was enantioselectively
hydrogenated in the presence of catalytic 1,2-bis[(2S,5S)-2,5-
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diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I)
trifluoromethanesulfonate to afford the L,L-Cbz-protected amino acid benzyl
ester 9b in 97% yield. Hydrogenolytic removal of both Cbz and benzyl
groups followed by reaction with succinic anhydride gave the succinate
amide (92-97% for 10b). Removal of the tert-butyl ester with
trifluoroacetic acid in methylene chloride gave the trifluoroacetate salt of 1b
in nearly quantitative yield. Overall, the benzyl ester route proved to be
more amenable for large scale reactions, although the intrinsic substrate
diastereoselectivity for asymmetric reduction of the methyl ester yielded
material of 97.4% e.e. for methyl ester 9a, compared to 92.0% e.e. for the
benzyl ester 9b. Nevertheless, crystallization at a later stage ultimately
afforded the final product 1b in >99% e.e. from the benzyl ester, and the
methyl ester route was often accompanied by desuccinylation generating a
primary amino-containing impurity which would negatively affect the
ninhydrin assay, therefore the benzyl ester route was the superior route.
Furthermore, the benzyl ester route provides the TFA salt which was not
observed to be hygroscopic, in contrast to the hydrochloride salt from the
methyl ester route which is very hygroscopic and converts to a sticky and
un-weighable solid over time in storage.
Based on molecular modeling data performed by Dr. Cory Reidl and
Estefany Guzman, N6-methyl-L,L-SDAP #1b is predicted to retain an overall
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similar binding pose to L,L-SDAP #1a, making it a likely substrate analog
while N6-acetyl-L,L-SDAP #1c suffers significant binding alterations due to
the presence of the acetyl group, in addition to loss of the positive charge on
the nitrogen. Therefore, N2-succinyl-N6-methyl-L,L-DAP #1b was prepared
enantioselectively, as illustrated in Figure 26.

Note. The diaminopimelate moiety is depicted in yellow and the succinate in turquoise. A)
Native substrate L,L-SDAP, B) N6-methyl-L,L-SDAP, and C) N6-acetyl-L,L-SDAP. The
catalytic domain of Chain A is depicted in green, whereas the dimerization domain of Chain
B is shown in orange.

Figure 26. Minimized substrate/analogs docked and modeled in the HiDapE
active site
Section 5: Novel Preparation of N6,N6-Dimethyl-L,L-SDAP
Based on the developed route for asymmetric preparation of
monomethyl L,L-SDAP, the synthesis of N6,N6-dimethyl-L,L-SDAP was
executed starting with a protected DAP intermediate 9a as illustrated in
Scheme 22 below.
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Scheme 22. Preparation of N6,N6-dimethyl-L,L-SDAP

The synthesis of dimethyl L,L-SDAP begins with deprotection of the
Boc moiety from 9a using 4N HCl in dioxane which cleanly removes the Boc
group. After overnight reaction at room temperature and subsequent
concentration of the reaction mixture, the crude residue was dissolved in
DCM and the hydrochloride salt was precipitated by addition of diethyl ether
affording an 83% yield of 14. HPLC analysis of the resulting hydrochloride
salt 14 showed a 96% purity for the desired product plus 4% of a
component where both Boc and t-butyl groups were cleaved. Subjecting the
monomethyl hydrochloride 14 to reductive amination provided the dimethylDAP intermediate 15 in 96% yield after extractive workup which provided
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100% purity by HPLC, and MS analysis confirmed the correct molecular ion
for the desired dimethyl-DAP bis-ester 15. Subsequent hydrogenation of 15
(N6,N6-dimethyl-DAP bis-ester) provided the free amine 16 in quantitative
yield followed by succinylation which yielded the protected N6,N6-dimethylL,L-SDAP analog 17 in quantitative yield. Finally, hydrolysis of protected
dimethyl L,L-SDAP analog 17 in 6M HCl provided N6,N6-dimethyl-L,L-SDAP
HCl salt 18 in 90% yield. This chemistry was developed during process
development of monomethyl L,L-SDAP and it was also found that the
dimethyl L,L-SDAP HCl salt was hygroscopic as well. However, the benzyl
ester route was not applied in the synthesis of dimethyl L,L-SDAP TFA salt.
In the future, it is recommended that the synthesis be executed using the
route proposed illustrated below in Scheme 23.
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Scheme 23. Proposed Route to Improve the Synthesis for Dimethyl L,L-SDAP

Section 6: Conclusion
Overall, the described novel synthesis of the N6-monomethyl-L,L-SDAP
DapE substrate proved to be a scalable process, which will allow our group
and the scientific community at large to easily synthesize large quantities of
this new DapE substrate. Furthermore, this synthesis will enable other
research groups to use our newly-developed ninhydrin assay and easily
access the monomethyl substrate through synthesis or purchase from a
commercial supplier such as Regis Technologies. Process improvements
which have been achieved with this new synthesis of monomethyl L,L-SDAP
include higher atom economy due to the asymmetric hydrogenation, and
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that the process does not require the use of expensive and time-consuming
reverse-phase chromatographic separations or ion-exchange resin
purifications, and lastly this process employs very low loadings of normal
phase silica gel which increases throughput and reduces cost, and finally,
that organic solvents used in the purification can be easily removed in
contrast to aqueous media.
In summary, N6-methyl-L,L-SDAP 1b was predicted to be a potential
substrate for HiDapE whereas N6,N6-dimethyl-L,L-SDAP was predicted to
suffer significant binding alterations due to the presence of the second
methyl group based on molecular modeling. Two synthetic routes to DapE
substrate 1b were developed enabling the synthesis of 1b in nearly
quantitative yield on a multi-gram scale. Kinetic studies proved that
substrate 1b can be hydrolyzed by HiDapE at comparable rates to the
endogenous substrate, L,L-SDAP, establishing 1b as a viable substrate for
DapE enzymes and for our new ninhydrin-based assay. Since the aminecontaining product of the hydrolysis of 1b contains only one primary amine,
conditions that selectively modify the primary amine versus the secondary
amine with ninhydrin were developed, resulting in a new spectrophotometric
assay for DapE enzymes that is inexpensive, robust and reproducible. The
newly discovered DapE substrate,1b, coupled with ninhydrin development, is
superior to the standard UV-based (225 nm) assay which uses L,L-SDAP as
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the substrate, as it is alleviates interference from potential inhibitor
absorption at 225 nm, a common absorption region for aryl containing
compounds that are of interest to medicinal chemists. The feasibility of the
new 1b-ninhydrin-coupled DapE assay was established by accurately
determining IC50 values of known HiDapE inhibitors. In summary, this new
ninhydrin-based assay provides a method for the discovery of lead
compounds for DapE enzymes and for driving medicinal chemistry structureactivity relationships (SAR) and thus provide a critical tool for the discovery
of a new class of antibiotics that target DapE enzymes.
Section 7: Experimental
Materials and Methods
All solvents were distilled prior to use and all reagents were used
without further purification unless otherwise noted. All synthetic reactions
were conducted under a nitrogen or argon atmosphere. The term reactor
refers to a large round-bottom flask. Silica gel 60 Å, 40−75 μm (200 × 400
mesh) or 60-200 μm (Silicycle), was used for column chromatography.
Aluminum-backed silica gel 200 μm plates were used for TLC (thin-layer
chromatography). 1H NMR spectra were obtained using a 300, 400, or 500
MHz spectrometer with trimethylsilane (TMS) as the internal standard.

13

C

NMR spectra were obtained using a 75, 100, or 125 MHz spectrometer. The
purity of all compounds was determined to be ≥95%, unless otherwise
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noted, by high performance liquid chromatography (HPLC) employing a
mobile phase A = 0.1% TFA in water and a mobile phase B = 0.1% TFA in
acetonitrile with a gradient of 60% B increasing to 95% over 10 min, holding
at 95% B for 5 min, then returning to 60% B and holding for 5 min. Chiral
purities were determined using Chiral HPLC on various chiral HPLC columns
using varying chromatographic conditions, therefore for any procedure that
reports chiral purity will describe the chiral HPLC method used. HRMS
spectra were measured on a TOF instrument by electrospray ionization
(ESI). HRMS spectra were collected using a Waters Acquity I class UPLC and
Xevo G2-XS QTof mass spectrometer with Waters Acquity BEH C18 column
(1.7 µm, 2.1x50 mm). Mobile phase A was 0.05% formic acid in water and
mobile phase B was 0.05% formic acid in acetonitrile. A gradient of 5% to
90% B over 5 min was applied.
Organic Synthesis
(2S,6S)-2-(3-Carboxypropanamido)-6-(methylamino)heptanedioic
acid hydrochloride (1b.HCl)
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To a 100 mL reactor was added 10a (1.50 g, 3.16 mmol) and a freshly
prepared 6M HCl solution (30 mL). The reaction mixture was allowed to stir
at 25°C for 5 h and concentrated under reduced pressure (0.1-10 mbar) at
25°C on a rotary evaporator and triturated in acetonitrile overnight at room
temperature. The resulting slurry was filtered and dried under reduced
pressure overnight to provide 1b as the hydrochloride salt (1b.HCl, 1.04 g,
97%, deliquescent solid) as a white foam.1H NMR (400 MHz, D2O): δ 4.35
(q, 1 H, J = 9.0, 5.0 Hz), 3.95 (t, 1 H, J = 6.2 Hz), 2,73 (s, 3 H), 2.64 (m, 2
H), 2.58 (m, 2 H), 2.03-1.88 (m, 3 H), 1.81-1.72 (m, 1 H), 1.58-1.46 (m, 1
H), 1.43-1.36 (m, 1 H). HRMS (IT-Tof): m/z calcd for
C12H21N2O7+[M+H]+:305.1349, found 305.1309.
(2S,6S)-2-(3-Carboxylatopropanamido)-6(methylamino)heptanedioate, 2,2,2-trifluoroacetate salt (1b.TFA)

To a solution of succinyl t-butyl ester 10b (0.608 g, 1.32 mmol) in
DCM (5.75 mL) was added TFA/DCM solution (30/70, 15 mL) under argon.
The mixture was stirred at room temperature for 4 hours and concentrated
under reduced pressure. The resulting residue was dissolved in dry methanol
(1.0 mL) and slowly added to diethyl ether (50 mL) with vigorous stirring to
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precipitate TFA salt. The slurry was filtered and the wetcake was rinsed with
diethyl ether (2.0 mL), hexane (10 mL), and dried in vacuo at 35oC
overnight to provide the mono-methyl SDAP TFA salt (550 mg, 99.6% yield)
as a white solid. 1H NMR (400 MHz, D2O): δ 4.36 (dd, 1H, J = 9.2, 5.2 Hz),
3.76 (t, 1H, J = 6.4 Hz), 2.72 (s, 3H), 2.69-2.66 (m, 2H), 2.66-2.59 (m,
2H), 1.98-1.92 (m, 3H), 1.80-1.77 (m, 1H), 1.52-1.50 (m, 1H), 1.44-1.42
(m, 1H).

13

C NMR (100 MHz, D2O): δ 176.9, 175.6, 174.9, 172.3, 62.1,

52.3, 31.5, 30.0, 29.9, 29.0, 28.2, 20.5. HRMS (ESI-ToF): m/z calcd for
C12H21N2O7+[M+H]+: 305.1349, found: 305.1365. Achiral HPLC purity:
100%. Chiral HPLC purity: 100% (100% e.e.). Chiral HPLC was performed
using either two methods. Chiral HPLC method 1: a RegisPack column
(250x4.6 mm, 5 micron) eluting with an isocratic gradient of hexane/IPA
(90/10) + 0.1%TFA at 1.5 mL/min and monitoring at 210 nm. Chiral HPLC
method 2: Chirosil SCA(-) column (150 mm x 4.6 mm, 5 micron) with
isocratic elution employing 84% MeOH in water containing 5 mM HClO4 with
an elution time of 15 minutes with column temp at 25oC and a flow rate of
0.75 mL/min monitoring at a wavelength of 210 nm.
Scale-up of the TFA Salt:
To a solution of succinyl t-butyl ester 10b (6.08 g, 14.8 mmol) in DCM
(60 mL) was added a TFA/DCM solution (30/70, 135 mL) under nitrogen.
The mixture was stirred at room temperature for 6 h and concentrated on a
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rotary evaporator at 35-40oC. The resulting residue was dissolved in
anhydrous methanol (6.0 mL) and slowly added to anhydrous diethyl ether
(450 mL, HPLC grade, inhibitor-free) with vigorous stirring to precipitate the
TFA salt. The slurry was allowed to stir overnight at room temperature. The
slurry was filtered, and the wet cake was rinsed with anhydrous diethyl ether
(50 mL), n-hexane (100 mL), and dried in vacuo at room temperature
overnight to provide 1b as the mono-methyl L,L-SDAP TFA salt (L,L-succinyl
diaminopimelate trifluoroacetate; 6.06 g, 98% yield) as a white solid.
1-(tert-Butyl) 5-methyl (tert-butoxycarbonyl)-L-glutamate (5)

According to the general and herein improved method of Glinka,41 to a
2 L reactor was added Boc-L-Glu-OtBu (4) (95.65 g, 315.3 mmol), milled
K2CO3 (69.72 g, 504.5 mmol), and anhydrous DMAC (480 mL). To the
reaction mixture was added methyl iodide (49.3 g, 21.2 mL, 112 mmol). The
reaction was agitated with mechanical stirring (300 rpm) at 25oC for 18 h
which 1H NMR and TLC analysis confirmed that the reaction had gone to
completion. To the reaction mixture was added methyl iodide (228 g, 100
mL, 1.61 mol) followed by Ag2O (110.0 g, 474.7 mmol). The resulting
reaction mixture was stirred at 400 rpm with a water bath (15oC) in place to
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control the exotherm and allowed to further stir overnight (12 hours) and
gradually warm to room temperature.

1

H NMR analysis confirmed that the

reaction had gone to completion. The reaction mixture was then diluted with
EtOAc (750 mL) and treated with Celite (43 g), stirred for 15 min, filtered
over a fritted funnel (fine porosity) containing a pad of Celite. The filter was
washed with EtOAc (500 mL). The filtrate was concentrated under reduced
pressure at 40oC to remove EtOAc and DMAC to provide crude residue oil
(168.0 g). The crude oil was diluted with EtOAc (500 mL) and heptane (400
mL) and subsequently washed with 50 wt% sodium thiosulfate pentahydrate
solution (2 x 500 mL), USP purified water (3 x 500 mL), brine (500 mL),
dried with sodium sulfate (40 g)/silica gel (20 g), filtered, and concentrated
to provide title compound 5 (101.6 g, 97%) as a colorless oil. HPLC purity:
97.7%.1H NMR(400 MHz, CDCl3) δ 4.59 (m, amide rotamer, 0.50 H), 4.37
(m, amide rotamer, 0.50 H), 2.77 (d, mixture of amide rotamers, 3H), 2.382.20 (m, 3H), 2.00 (m, 1H), 1.45 (s, 18H).

13

C NMR (100 MHz, CDCl3): δ

173.4, 173.3, 170.4, 170.3, 156.3, 155.8, 81.6, 81.5, 80.3, 80.0, 59.5,
58.4, 51.7, 31.3, 31.2, 30.9, 30.5, 28.4, 28.1, 24.3, 24.1. HRMS (ESIToF): m/z calcd for C16H29NNaO6+ [M+Na]+: 354.1887, found: 354.1920.
HRMS also found [M+Li]+ : 338.2166 and [M+K]+: 370.1658.
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tert-Butyl-(S)-2-((tert-butoxycarbonyl)(methyl)amino)-5hydroxypentanoate (6)

To a 3 L 3-necked reactor was added methyl ester 5 (100.0 g, 301.7
mmol) and ethanol (HPLC grade, 1500 mL) and the mixture was cooled to <
5oC in an ice water bath. Sodium borohydride (57.6 g, 1520 mmol) was
added in 5 portions over 15 minutes. The reaction was allowed to stir at <
5oC and subsequently allowed to gradually warm to room temperature
overnight while the cooling bath remained in place. After 20 hours, TLC
analysis showed complete consumption of methyl ester starting material. To
a 12 L reactor containing a cold solution of 50% aqueous ammonium
chloride solution (3000 mL, < 5oC) was slowly added the reaction mixture
over a period of 15 min such that the temperature remained < 15oC. The
mixture was allowed to stir at 15-20oC for 30 min, then EtOAc (1000 mL)
was added. The organic layer was separated, and the aqueous layer was
further extracted with EtOAc (3 x 1000 mL). The combined organic layers
were washed with brine (300 mL), dried with sodium sulfate, filtered, and
concentrated to a colorless oil (90.77 g). The crude oil was dissolved in
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EtOAc/heptane (20/80, 100 mL), which was purified through a silica gel plug
(1000 g) and the plug was flushed with EtOAc/heptane (20/80, 2 L) and
EtOAc/heptane (40/60, 6 L) to afford the title alcohol 6 (88.60 g, 97%) as a
colorless oil. 1H NMR: (400 MHz, CDCl3): δ 4.65 (m, amide rotamer, 0.50
H), 4.35 (m, amide rotamer, 0.50 H), 3.68 (t, 2H, J = 6.4 Hz), 2.78 (m,
mixture of amide rotamers, 3H), 2.04-1.71 (m, 3H), 1.69-1.53 (m, 2H),
1.45 (s, 18H).

13

C NMR(100 MHz, CDCl3): δ 171.1, 171.0, 156.6, 155.9,

81.4, 81.4, 80.2, 80.0, 62.2, 62.1, 59.7, 58.4, 30.6, 29.4, 29.3, 28.5, 28.1,
25.5, 25.3. MS: M+1 (304 m/z), M+23 (326 m/z), M+39 (342 m/z), and
2M+23 (629 m/z). HRMS (ESI-ToF): m/z calcd for C15H29NNaO5+[M+Na]+:
326.1938, found: 326.1969.
tert-Butyl (S)-2-((tert-butoxycarbonyl)(methyl)amino)-5oxopentanoate (7)

To a 250 mL reactor containing alcohol 6 (6.09 g, 20.1 mmol) was
added DCM (90 mL) followed sequentially by PCC (pyridinium
chlorochromate, 6.50 g, 44.1 mmol) and silica gel (60-200 micron, 7.00 g)
with DCM (18 mL) as a rinse. The mixture was allowed to stir at room
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temperature for 1 hour after which time TLC showed complete consumption
of starting material. The reaction mixture was filtered through a plug of silica
gel (60-200 micron, 90.00 g) packed in heptane, and product was eluted
through plug with a gradient of DCM (350 mL), 20% EA/heptane (500 mL),
40% EA/heptane (500 mL), and 100% EA (250 mL) to afford aldehyde 7
(5.67 g, 94%) as a colorless oil.

1

H NMR (400 MHz, CDCl3): δ 9.78 (d, 1H,

amide rotamer), 4.59 (m, amide rotamer, 0.50 H), 4.34 (m, amide rotamer,
0.50 H), 2.77 (d, mixture of amide rotamers, 3H), 2.51-2.40 (m, 2H), 2.282.22 (m, 1H), 1.98 (m, 1H), 1.46 (s, 18H).

13

C NMR (100 MHz, CDCl3): δ

201.4, 201.1, 177.8, 170.3, 170.2, 156.5, 155.9, 81.8, 80.6, 80.3, 59.4,
59.4, 58.6, 58.4, 40.8, 40.4, 31.4, 31.3, 30.8, 30.4, 28.5, 28.1, 24.1, 24.0,
21.7, 21.5. HRMS (ESI-ToF): m/z calcd for C15H27NNaO5+ [M+Na]+:
324.1781, found: 324.1816. HRMS also detected [M+Li]+: 308.2084,
[M+K]+: 340.1542 and [M+Cr]+: 354.4117.
Scale-up using alternative oxidation conditions using Pyridinium
Dichromate (PDC)
To a 3-L 3-necked reactor containing alcohol 6 (62.5 g, 206.01 mmol)
was added DCM (1.6 L) and cooled to < 10oC. To the reaction mixture was
added PDC (116.2 g, 309.0 mmol) and silica gel (60-200 micron, 100 g).
The mixture was allowed to stir overnight (16 hr) and allowed to gradually
warm to room temperature while the cooling bath was in place. The reaction
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mixture was then partially concentrated to remove approximately 1 L of
DCM. The reaction mixture was loaded onto a silica plug (940 g, 60-200
micron) packed in EtOAc/heptane (10/90) followed by flushing the plug with
EtOAc/heptane (20/80, 2.5 L), EtOAc/heptane (30/70, 2.5 L), and
EtOAc/heptane (40/60, 2.5 L) to furnish aldehyde 7 (57.43 g, 92.5%) as a
colorless oil.
Scale-up using alternative Swern oxidation conditions
To a 1-L 3-necked reactor was equipped with a mechanical stirrer, JKem thermocouple, dropping funnel, nitrogen inlet, and a dry-ice Dewar
bath. The reactor was placed under a nitrogen atmosphere and was charged
with anhydrous DCM (170 mL) and anhydrous DMSO (13.2 mL, 14.5 g, 186
mmol). This mixture was cooled to -78 oC (dry ice/acetone). To the
cryogenic solution (stir rate: 200 rpm) was slowly added oxalyl chloride
(8.00 mL, 11.8 g, 93.3 mmol) using a syringe over a period of 6 minutes
such that the temperature was maintained < -65oC. The resulting mixture
was allowed to stir at -78oC for an additional 15 minutes, then a solution of
alcohol 6 (14.00 g, 46.15 mmol) in anhydrous DCM (100 mL) was added
over 15 minutes. An additional portion of anhydrous DCM (20 mL) was used
to quantitatively transfer all alcohol to the reactor. The reaction continued to
stir at -78 oC for an additional 45 minutes. The rate of stirring was increased
to 550 rpm, then triethylamine (57 mL, 41.61 g, 411.2 mmol) was slowly
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charged to the reactor over 15 minutes such that the temperature was
maintained < -65 oC. The reaction mixture was allowed to stir at -78 oC for
30 minutes, then allowed to warm to room temperature, stirred an
additional 30 minutes at ambient temperature, and quenched with 25 wt%
ammonium chloride solution in USP purified water (400 mL). The pH of the
mixture was adjusted to 7 using 2M HCl, then the organic layer was
separated. The aqueous stream was extracted with DCM (2 x 100 mL). The
combined organic layers were successfully washed with USP purified water
(300 mL), brine (300 mL), dried with sodium sulfate, and concentrated
under reduced pressure to provide crude aldehyde (14.93 g) as a golden
yellow oil. The crude aldehyde was purified using a glass gravity column
using silica gel (400 g, 60-200 micron) and the desired product was eluted
with an EtOAc/Heptane gradient (0/100 to 30/70) to furnish purified
aldehyde (10.8 g, 77.6% isolated yield, pale yellow oil).
(S,Z)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6-(tertbutoxycarbonyl(methyl)amino)hept-2-enedioate (8a)
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In a 250 mL round-bottom reactor was placed, under an argon
atmosphere, (±)-Cbz-α-phosphonoglycine trimethyl ester 11 (3.96 g, 11.92
mmol) and DCM (30 mL), then DBU (1.71 g, 11.21 mmol) was added
followed by a DCM rinse (7 mL). The mixture was allowed to stir at room
temperature for 45 min and subsequently added to a solution of aldehyde
(3.00 g, 9.93 mmol) in DCM (40 mL) over 2 minutes to give a pale-yellow
solution. The reaction was allowed to stir for 2 hours and then concentrated
under reduced pressure at 40-45 oC. The residue was dissolved into
isopropyl acetate (100 mL) and was washed with 6% citric acid (3 x 100
mL), USP purified water (75 mL), brine (75 mL), dried with sodium sulfate
for 30 min, filtered, and concentrated to give a crude oil. The crude oil
(dissolved in EtOAc/heptane, 20/80) was purified over a glass gravity
column (10 in x 2.75 in) packed with silica gel (Silicycle, 60-200 micron, 125
g) in heptane. The column was eluted with EtOAc/heptane gradient (10/90
to 40/60). Appropriate fractions containing pure product were combined and
concentrated to afford the enamide 8a (4.55 g, 90% yield, viscous colorless
oil). HPLC purity: 96.4%.

1

H NMR (400 MHz, CDCl3): δ 7.36-7.31 (m, 5

H), 6.76 (bs, amide rotamer, 0.70 H), 6.59 (m, 1 H), 6.28 (bs, 0.30 H), 5.12
(m, 2 H), 4.55 (m, 0.60 H), 4.30 (m, 0.40 H), 3.76 (bs, 3 H), 2.77-2.71 (s,
3 H, amide rotamers), 2.23 (m, 2 H), 2.01 (m, 1 H), 1.86 (m, 1 H), 1.45
(bs, 18 H).

13

C NMR (100 MHz, CDCl3): δ 170.4, 165.1, 164.9, 156.9,

120
155.8, 154.6, 154.0, 136.4, 136.2, 135.9, 128.7, 128.6, 128.5, 128.3,
128.2, 128.1, 81.6, 80.4, 80.3, 67.5, 67.2, 59.5, 58.0, 52.4, 52.3, 30.7,
30.6, 28.3, 28.0, 27.6, 26.6, 25.2, 24.8. HRMS (ESI-ToF): m/z calcd for
C26H38N2NaO8 [M+Na]+: 529.2520, found: 529.2553. HRMS also detected
[M+K]+: 545.2288.
1-Benzyl 7-(tert-butyl) (S,Z)-2-(((benzyloxy)carbonyl)amino)-6((tert-butoxycarbonyl)(methyl)amino)hept-2-enedioate (8b)

To a 500 mL reactor was added benzyl Z-phosphinoglycine dimethyl
ester 13 (22.00 g, 54.00 mmol) and DCM (100 mL). At ambient
temperature, DBU (7.88 g, 51.65 mmol) was added to the mixture under
argon. After 30 minutes, a solution of aldehyde 7 (14.15 g, 84% pure based
on 1H NMR, 39.44 mmol) in DCM (150 mL) was slowly added via dropping
funnel over 10 min. The reaction mixture was allowed to stir at room
temperature for 21 h and subsequently was concentrated, diluted with ethyl
acetate (350 mL), and washed with USP purified water (175 mL). The
aqueous stream was extracted with ethyl acetate (2 x 85 mL). The
combined organic streams were successively washed with 6% citric acid
(110 mL), saturated sodium bicarbonate (110 mL), brine (110 mL), dried
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with sodium sulfate and concentrated to provide the crude enamide product
(30.67 g) as a yellow oil. The crude product dissolved in diethyl ether (350
mL) and silica gel (48 g, 60-200 micron) were combined and concentrated to
dryness to afford a dry-loaded material that was placed in a 750 g cartridge
coupled to another cartridge containing silica gel (615 g, 60-200 micron)
equilibrated with heptane. Purification was performed on a Teledyne Isco Rf
Flash chromatography unit eluting with a step-gradient of 100% heptane (2
CV), 2% IPA in heptane (5 CV), and 5% IPA in heptane (4.5 CV) at 200
mL/min providing pure enamide Horner-Emmons product 8b (21.40 g, 93%)
as a colorless viscous oil. HPLC purity: 98.4%.

1

H NMR (400 MHz,

CDCl3): δ 7.34 (bm, 10H), 6.77 (bs, amide rotamer, 0.60H), 6.62 (m, 1H),
6.29 (bs, amide rotamer, 0.40H), 5.19 (s, 2H), 5.11 (d, amide rotamer, 2H),
4.55 (m, amide rotamer, 0.60 H), 4.29 (m, amide rotamer, 0.40 H), 2.73 (d,
mixture of amide rotamer, 3H), 2.24 (m, 2H), 2.02 (m, 1H), 1.98 (m, 1H),
1.85 (m, 1H), 1.43 (s, 18H).

13

C NMR (100 MHz, CDCl3): δ 170.5, 164.5,

164.4, 156.9, 155.8, 154.6, 154.1, 136.7, 136.2, 136.0, 135.7, 135.5,
128.6, 128.6, 128.5, 128.3, 128.2, 81.7, 80.4, 80.4, 67.5, 67.4, 67.3, 67.2,
59.6, 58.2, 30.7, 28.4, 28.1. HRMS (ESI-ToF): m/z calcd for
C32H42N2NaO8+[M+Na]+:605.2833, found: 605.2928. HRMS also detected
[M+K]+:621.2646.
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(2S,6S)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6-(tert
butoxycarbonyl(methyl)amino)heptanedioate (9a)

To a Mettler Toledo RC1e system equipped with a MP06-HC 1.2-liter
pressure glass reactor, mechanical stirrer, and an external temperature
control unit under nitrogen was added a solution of enamide 8a (4.00 g,
7.90 mmol) in HPLC-grade methanol (110 mL, degassed with argon). A
solution of Rh(I)(COD)(S,S)-Et-DuPHOS catalyst (86 mg, 0.12 mmol) in
degassed methanol (HPLC grade, 10 mL) was added and the reactor was
pressurized with nitrogen (3x) and hydrogen (3x), then placed under 50 psi
of hydrogen. The mixture was agitated with mechanical stirring (500 rpm) at
25°C for 25 h after which 1H NMR indicated complete consumption of the
alkene. The reaction mixture was purged with nitrogen three times and then
concentrated under reduced pressure. The crude residue (4.04 g) was
dissolved in ethyl acetate/heptane (50/50, 8 mL) and passed through a silica
gel plug (20.5 g) eluting with ethyl acetate/heptane (50/50, 200 mL) to
afford Cbz-protected amino acid derivative 9a (3.74g, 93% yield) as a
colorless viscous syrup. HPLC purity (achiral): 100% AUC (area under the
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curve). Chiral HPLC: e.e. = 97.4%. Chiral HPLC was performed using a
Chiralpak AD-H column (250x4.6 mm, 5 micron) eluting with a gradient of
hexane/EtOH (90/10 to 30/70) over 20 min at 1.0 mL/min and monitoring at
210 nm.

1

H NMR (400 MHz, CDCl3): δ 7.36-7.30 (m, 5 H), 5.30-5.10 (s, 3

H, amide rotamers), 4.60 (m, 0.55 H), 4.34 (m, 1.45 H, amide rotamer),
3.74-3.68 (s, 3 H, amide rotamers), 2,76-2.71 (s, 3 H, amide rotamers),
1.83 (m, 2 H), 1.74 (m, 2 H), 1.44-1.26 (m, 20 H).

13

C NMR (100 MHz,

CDCl3): δ 172.9, 172.8, 170.9, 170.7, 156.5, 156.0, 155.8, 136.2, 128.5,
128.1, 81.4, 81.3, 80.1, 79.9, 67.0, 59.4, 57.9, 53.7, 53.6, 52.4, 32.1,
31.9, 30.5, 28.4, 28.0, 21.8. HRMS (ESI-ToF): m/z calcd for
C26H40N2NaO8+ [M+Na]+: 531.2677, found: 531.2726.
1-Benzyl-7-(tert-butyl) (2S,6S)-2-(((benzyloxy)carbonyl)amino)-6((tert-butoxycarbonyl)(methyl)amino)heptanedioate (9b)

To a Mettler Toledo RC1e system equipped with a MP06-HC 1.2-liter
pressure glass reactor, mechanical stirrer, and an external temperature
control unit under nitrogen was added a solution of enamide 8b (19.9 g,
34.1mmol) in HPLC grade methanol (110 mL, degassed with argon). This
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mixture was sparged with argon for an additional 30 min. A solution of
Rh(I)(COD)(S,S)-Et-DuPHOS catalyst (378 mg, 0.52 mmol) in degassed
methanol (HPLC grade, 50 mL) was added and the reactor was pressurized
sequentially with nitrogen (3x), hydrogen (3x), and finally placed under 50
psi of hydrogen. The mixture was agitated with mechanical stirring (500
rpm) at room temperature for 21 hours after which 1H NMR indicated
complete consumption of the alkene. The reaction mixture purged with
nitrogen three times, then concentrated under reduced pressure. The crude
residue (19.7 g) was dissolved in ethyl acetate/heptane (50/50, 45 mL) and
passed through a silica gel plug (106 g) using ethyl acetate/heptane (50/50,
600 mL) to afford Cbz-protected amino acid derivative 9b (19.3 g, 97%
yield) as a colorless viscous oil. HPLC analysis (achiral): 95.1%. Chiral
HPLC: e.e. = 92%. Chiral HPLC was performed using a RegisPack column
(250x4.6 mm, 5 micron) eluting with an isocratic gradient for 15 minutes
consisting of hexane/IPA (70/30) + 0.1%DEA at 1.5 mL/min and monitoring
at 220 nm. 1H NMR(400 MHz, CDCl3): δ 7.35 (m, 10 H), 5.28 (t, 0.89 H, J =
8.0 Hz, amide rotamer), 5.17-5.10 (m, amide rotamer, 4.10 H), 4.56 (m,
0.53 H, amide rotamer), 4.41 (m, 0.90 H, amide rotamer), 4.23 (m, 0.58 H,
amide rotamer), 2.71 (d, mixture of amide rotamers, 3H), 1.89-1.59 (m, 4
H), 1.50-1.25 (m, 20 H).

13

C NMR (100 MHz, CDCl3): δ 172.4, 172.3,

170.9, 170.8, 156.6, 156.1, 156.0, 155.9, 136.3, 135.4, 135.3, 128.7,
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128.6, 128.5, 128.4, 128.3, 128.2, 81.5, 81.4, 80.2, 80.0, 67.3, 67.3, 67.1,
59.6, 58.1, 54.0, 53.8, 32.2, 32.0, 30.6, 28.6, 28.5, 28.1, 22.02. HRMS
(ESI-ToF): m/z calcd for C32H44N2NaO8+ [M+Na]+: 607.2990, found:
607.3088. HRMS also detected [M+K]+:623.2815.
4-((2S,6S)-7-tert-Butoxy-6-(tert-butoxycarbonyl(methyl)amino)-1methoxy-1,7-dioxoheptan-2-ylamino)-4-oxobutanoic acid (10a)

To a 250 mL reactor under argon was added a solution of 9a (3.15 g,
6.19 mmol) in HPLC grade methanol (85 mL). The mixture was sparged with
argon for 10 min followed by addition of 10% Pd/C (320 mg). The reactor
was flushed with argon for 5 min, hydrogen for 5 min, then placed under
balloon pressure of hydrogen and allowed to stir overnight (16 h) at room
temperature, when TLC analysis (EtOAc/DCM/MeOH, 20/75/5) indicated
complete consumption of starting material. The mixture was sparged with
argon, filtered over a pad of Celite®, rinsed with methanol (50 mL) and the
resulting filtrate was concentrated and chased with toluene to provide the
free deprotected amino methyl ester (2.34 g, 100%) as a colorless oil. 1H
NMR (400 MHz, CDCl3): δ 4.60 (m, 0.50 H, amide rotamer), 4.32 (m, 0.50
H, amide rotamer), 3.72 (s, 3H), 3.47 (m, 1H), 2.77 (s, 3H, amide rotamer),
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1.90-1.60 (m, 6H), 1.47 (m, 20H).

13

C NMR (100 MHz, CDCl3): δ 176.5,

171.2, 171.0, 156.5, 156.0, 81.4, 81.3, 80.2, 79.9, 59.6, 58.3, 54.4, 54.3,
52.1, 34.4, 34.4, 30.7, 28.8, 28.5, 28.1, 22.4. HRMS (ESI-ToF): m/z calcd
for [M+H]+ for C18H35N2O6+: 375.2490, found: 375.2514.
To a 250 mL reactor was added Cbz-deprotected amine (2.25 g, 6.01
mmol), succinic anhydride (0.66 g, 6.60 mmol), and DCM (50 mL). The
mixture was cooled to < 5oC and triethylamine (0.92 mL, 6.60 mmol) was
added dropwise over 2 min. The cooling bath was removed, and the reaction
was allowed to stir overnight at room temperature. After 24 hours, the
reaction mixture was diluted with DCM (50 mL), washed sequentially with
6% citric acid (2 x 50 mL), brine (25 mL), dried with sodium sulfate, filtered,
and concentrated under reduced pressure and chased with DCM and heptane
to furnish 10a (2.90 g, 99%) as a colorless viscous syrup, which was used
without further purification.1H NMR (400 MHz, CDCl3): δ 6.43 (d, 0.50H, J =
8.0 Hz, amide rotamer), 6.32 (d, 0.50H, J = 8.0 Hz, amide rotamer), 4.694.57 (m, 1.5H, amide rotamer), 4.36-4.32 (m, 0.50H, amide rotamer), 3.75
(d, 3H, mixture of amide rotamers), 2.83-2.72 (m, 4H), 2.65-2.42 (m, 3H),
1.88-1.70 (m, 5H), 1.46-1.44 (m, 19H). HRMS (ESI-ToF): m/z calcd for
C22H38N2NaO9+ [M+Na]+: 497.2470, found: 497.2493.

127
4-(((2S,6S)-1-(Benzyloxy)-7-(tert-butoxy)-6-((tertbutoxycarbonyl)(methyl)amino)-1,7-dioxoheptan-2-yl)amino)-4oxobutanoic acid (10b)

BnO 2C

O

1) H2 (1 atm)
Pd/C, MeOH

O

O

O
NHCbz

Me
9b

N

Boc

2) succinic anhydride
Et3N, DCM
(92-98%)

HO2C

O
NH

HO

Me

N

Boc

O
10b

To a 500 mL reactor was added Cbz-protected amino acid 9b (10.65
g, 18.2 mmol) and methanol (275 mL). The mixture was sparged with
nitrogen for 10 min followed by addition of 10% Pd/C (1.04 g). The reactor
was flushed with nitrogen for 5 min, hydrogen for 5 min, then placed under
balloon pressure of hydrogen for 6 h. The mixture was treated with Celite®
(5.0 grams) and sparged with nitrogen for 10 min, filtered over a pad of
Celite®, and rinsed with methanol (200 mL). The resulting filtrate was
concentrated to provide the free amino acid intermediate 10b (6.39 g,
97% yield) as an off-white solid. HPLC purity: 100%. UPLC/MS analysis of
the free amino acid: [M+H]+ = 361.3. HRMS (ESI-ToF): m/z calcd [M+H]+
for C17H33N2O6+: 361.2333, found: 361.2377. HRMS also detected [M+Na]+:
383.2194 and [M+K]+: 399.1936. The crude free amino acid
intermediate10b was carried forward without any further purification.
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To a 500 mL reactor was added the free amino acid intermediate
10b (6.02 g, 16.7 mmol), succinic anhydride (1.73 g, 17.3 mmol), and DCM
(175 mL). The mixture cooled to < 5°C and triethylamine (3.66 g, 36.17
mmol) was added dropwise over 3 min. The cooling bath was removed, and
the reaction was allowed to stir for 2 h at room temperature.
HPLC/UPLC/TLC analysis showed that the reaction was deemed complete.
The reaction mixture was concentrated, diluted with EtOAc (300 mL),
washed sequentially with 0.10 N HCl (390 mL), USP purified water, (250
mL), brine (200 mL), dried with sodium sulfate, filtered, and concentrated to
provide crude 10b (7.40 g). The crude product 10b was dissolved in EtOAc
(25 mL) and was purified by passing through a silica gel plug (52 g, 60-200
micron, equilibrated with EtOAc/THF then EtOAc). The silica plug was flushed
with EtOAc (100 mL) and EtOAc/THF (1:1, 250 mL). Appropriate fractions
were combined, concentrated, and chased with DCM followed by anhydrous
1,4-dioxane affording pure succinamide adduct 10b (7.10 g, 92% yield).
HPLC purity: 98.6% AUC. Chiral HPLC: e.e. = 100%. Chiral HPLC was
performed using a RegisPack column (250x4.6 mm, 5 micron) eluting with
an isocratic gradient for 15 minutes consisting of hexane/IPA (90/10) +
0.1%TFA at 1.5 mL/min and monitoring at 210 nm. 1H NMR (400 MHz,
CDCl3): δ 10.74 (bs, 2H), 7.10 (d, 1H, J = 8.0 Hz), 4.65-4.51 (m, amide
rotamer, 1.5H), 4.29-4.27 (m, amide rotamer, 0.5H), 2.78-2.49 (m, mixture
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of amide rotamers, 7H), 1.87-1.60 (m, 4H), 1.45 (d, 18H), 1.38-1.16 (m,
2H).

13

C NMR (100 MHz, CDCl3): δ 176.5, 176.5, 175.5, 175.4, 173.1,

172.9, 170.8, 157.1, 156.8, 81.7, 81.0, 80.8, 67.1, 59.9, 58.4, 53.5, 52.5,
52.1, 31.3, 30.7, 30.6, 30.4, 29.7, 28.5, 28.3, 28.1, 22.3, 21.7. HRMS
(ESI-ToF): m/z calcd for C21H36N2NaO9 [M+Na]+: 483.2313, found:
483.2368. HRMS also detected [M+K]+: 499.2093.
(±)-Cbz-α-phosphonoglycine dimethyl ester (12)

According to a reported patent procedure,42 to a 1 L 3-neck reactor
equipped with a mechanical stirrer, J-Kem thermocouple, nitrogen inlet, and
water bath (20-25oC), were added (±)-Cbz-α-phosphonoglycine trimethyl
ester 11 (33.13 g, 100.0 mmol), MeOH (180 mL), and USP purified water
(20 mL). To the slightly hazy mixture was added a solution of 1N aq NaOH
(102 mL, 102.0 mmol) via dropping funnel over a period of 1 hr to give a
homogeneous mixture. The resulting mixture was allowed to stir for an
additional 1 hr at room temperature and subsequently concentrated under
reduced pressure at 25-30oC to remove methanol. The aqueous residue was
polish filtered through filter paper and pH adjusted to pH 1.5 with 1N
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H2SO4solution (100 mL) to provide a white murky solution. The mixture was
extracted with EtOAc (4 x 150 mL) and the combined organic streams were
washed with brine (150 mL), dried with magnesium sulfate, and
concentrated under reduced pressure to afford (±)-Cbz-α-phosphonoglycine
dimethyl ester 12 (30.98 g, 98%) as a viscous oil that solidifies to a white
solid upon standing. HPLC purity: 97.4%. 1H NMR (400 MHz, CDCl3): δ
7.90 (bs, 2H), 7.36-7.29 (m, 5H), 5.96 (d, 1H, J = 12.0 Hz), 5.16 (d, 1H, J
= 12.0 Hz), 5.11 (d, 1H, J = 12.0 Hz), 5.00 (dd, 1H, J = 24.0, 8.0 Hz), 3.84
(d, 3H, J = 8.0 Hz), 3.79 (d, 3H, J = 8.0 Hz). HRMS (ESI-ToF): m/z calcd
for C12H17NO7P+ [M+H]+: 318.0737, found: 318.0782. HRMS also detected
[M+Na]+: 340.0599 and [M+K]+: 356.0319.
Benzyl 2-(benzyloxycarbonylamino)-2(dimethoxyphosphoryl)acetate (13)

According to the general and herein improved procedure of
Nakanishi,43 a 500 mL 3-neck reactor was charged with (±)-Cbz-αphosphonoglycine dimethyl ester 12 (30.77 g, 97.00 mmol), ACN (80 mL),
and DBU (15.2 g, 21.0 mL, 99.9 mmol) to provide a clear solution. To the

131
reaction mixture was added benzyl bromide (17.4 g, 102 mmol) dropwise
over 5 min which a cooling bath (ambient temperature) was used to control
the exotherm. After 2 hours at room temperature, the reaction mixture was
concentrated under reduced pressure and diluted with EtOAc (350 mL). The
organic mixture was washed with USP purified water (130 mL), 3% citric
acid solution (1 x 110 mL), saturated NaHCO3 solution (100 mL), brine (100
mL), dried with sodium sulfate, and concentrated under reduced pressure to
give crude product (43.5 g). The crude product was dissolved in
EtOAc/heptane (1:1, 90 mL) at 45oC, seeded, and diluted with heptane (350
mL) and the resulting slurry was allowed to stir an additional 1 hr at ambient
temperature, and filtered. The filter cake was washed with heptane (50 mL)
and pulled dry to give benzyl 2-(benzyloxycarbonylamino)-2(dimethoxyphosphoryl)acetate 13 (38.7 g, 98%) as a white solid. HPLC
purity: 95.9% AUC. 1H NMR: (400 MHz, CDCl3): δ 7.35 (m, 10H), 5.62 (d,
1H, J = 12.0 Hz), 5.29 (d, 1H, J =12.0 Hz), 5.22 (d, 1H, J = 12.0 Hz), 5.14
(dd, 2H, J = 12.0, 4.0 Hz), 4.96 (dd, 24.0, 12.0 Hz), 3.72 (d, 6H. J = 12.0
Hz). HRMS (ESI-ToF): m/z calcd for C19H23NO7P+ [M+H]+:408.1207,
found: 408.1255. HRMS also detected [M+Na]+: 430.1061 and [M+K]+:
446.0810.
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(2S,6S)-6-(Benzyloxycarbonylamino)-1-tert-butoxy-7-methoxy-Nmethyl-1,7-dioxoheptan-2-aminium chloride (14)

To a 20 mL scintillation vial was added Boc-protected monomethyl DAP
Bis-ester 9a (400 mg, 0.80 mmol), magnetic stirring bar, and anhydrous
1,4-dioxane (4 mL). The mixture was purged with argon and then cool to 05 oC, then a solution of 4N HCl in 1,4-dioxane (0.8 mL, 3.2 mmol) was
added. The thick slurry was allowed to stir at 0-5 oC for 20 minutes then
allowed to stir overnight at room temperature. After 26 hours at ambient
temperature, the reaction mixture was deemed complete by HPLC analysis.
The reaction mixture was concentrated under nitrogen, diluted with DCM (3
mL), and diethyl ether (4 mL) was added to precipitate the desired product.
The slurry was allowed to stir overnight at room temperature. The following
day, the slurry was filtered and the filter cake was washed with diethyl ether
(2 x 4 mL), pulled dry, and further dried in vacuo at room temperature to
provide the monomethyl hydrochloride product 14 (290 mg, 83% yield) as a
white solid and taken forward without further purification. HPLC purity:
96% AUC. MS (ESI): m/z calcd for C21H33N2O6+ [M+H]+: 409.5, found:
409.5.
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(2S,6S)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6(dimethylamino)heptanedioate (15)

To a 10 mL vial was added monomethyl HCl salt 14 (150 mg, 0.34
mmol), magnetic stirring bar, sodium acetate (29 mg, 0.35 mmol), and
methanol (HPLC grade, 1.0 mL). The mixture was allowed to stir for 5
minutes at room temperature, then a solution of 35% formaldehyde in water
(40 µL, 0.50 mmol, stabilized with methanol) was added. The mixture was
allowed to stir 15 minutes at room temperature, then sodium
triacetoxyborohydride (STAB, 143 mg, 0.67 mmol) was added in 5 portions.
The reaction mixture was allowed to stir overnight at room temperature.
After 17 hours, the reaction was sampled for HPLC analysis which indicated
that the reaction was complete. The reaction mixture was added to ethyl
acetate (10 mL) and to this mixture was added USP purified water (6 mL).
The mixture was allowed to stir for 5 minutes, then a saturated aqueous
sodium bicarbonate solution (2 mL) was added to adjust the pH of the
aqueous phase to pH 8-9. The organic layer was separated and the aqueous
phase was extracted with ethyl acetate (3 x 4 mL). The combined organic
layers were washed with brine, dried with sodium sulfate, and concentrated
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under reduced pressure to afford dimethyl DAP bis-ester product 15 (136
mg, 96% yield) as a colorless oil and taken forward without further
purification. HPLC purity: 100% AUC. MS (ESI): m/z calcd for C22H35N2O6+
[M+H]+: 423.5, found: 423.5.
(2S,6S)-7-tert-Butyl 1-methyl 2-amino-6
(dimethylamino)heptanedioate (16)

To a 10 mL vial were added dimethyl DAP bis-ester product 15 (117
mg, 0.26 mmol), a magnetic stirring bar, and ethyl acetate (3 mL). The
solution was sparged with argon for 5 minutes at room temperature then
10% Pd/C (20 mg) was added. The mixture was sparged for an additional 2
minutes with argon, then sparged with hydrogen for 5 minutes, and finally
placed the reaction mixture under hydrogen atmosphere (~1 atm, balloon
pressure). After 5 hours at room temperature, TLC analysis showed
complete consumption of Cbz-protected starting material (Rf = 0.35 in
EtOAc/DCM/MeOH, 20/75/5). The reaction mixture was filtered over a pad of
Celite®, the filter cake was washed with ethyl acetate (2 x 5 mL), and the
corresponding filtrate was concentrated under reduced pressure to provide
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the free amine 16 (76 mg, 100% yield) as a colorless viscous oil. The free
amine product was taken forward without any further purification.
4-((2S,6S)-7-tert-Butoxy-6-(dimethylamino)-1-methoxy-1,7dioxoheptan-2-ylamino)-4-oxobutanoic acid (17)

To a 10 mL vial containing free amine 16 (76 mg, 0.26 mmol) was
added DCM (2 mL) and a magnetic stirring bar. To the reaction mixture was
added succinic anhydride (26 mg, 0.26 mmol) and DCM (1 mL) as a rinse.
The resulting reaction mixture was allowed to stir overnight at ambient
temperature. After 16 hours, the reaction mixture was analyzed by TLC
analysis (EtOAc/CHCl3/MeOH/H2O/AcOH, 50/24/18/5.5/2.5, ninhydrin stain)
which revealed that the free amine (Rf = 0.07, red spot) was entirely
consumed and a new spot appeared (desired succinate amide, Rf = 0.28,
yellowish-peach spot). The reaction mixture was concentrated under reduced
pressure to provide protected dimethyl L,L-SDAP 17 (103 mg, 100% yield)
as a colorless glass film and was carried forward without any further
purification.
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(1S,5S)-1,5-Dicarboxy-5-(3-carboxypropanamido)-N,Ndimethylpentan-1-aminium chloride (18)

To a 10 mL vial containing protected dimethyl L,L-SDAP 17 (102 mg,
0.26 mmol) was added a magnetic stirring bar, and 6M HCl (2 mL). Purged
with nitrogen and the reaction mixture was allowed to stir at room
temperature. After 7 hours at room temperature, 1H NMR analysis revealed
that the reaction mixture contained 96% desired product and 4% unreacted
starting material. The reaction mixture was concentrated under reduced
pressure to provide dimethyl L,L-SDAP HCl salt 18 as a white foam (82 mg,
90% yield). 1H NMR: (400 MHz, CDCl3): δ 4.41 (dd, 1H, J = 8.0, 4.0 Hz),
3.87 (dd, 1H, J = 12.0, 8.0 Hz), 2.95 (bs, 3H), 2.92 (bs, 3H), 2.71-2.60 (m,
4H), 2.05-1.93 (m, 3H), 1.87-1.76 (m, 1H), 1.62-1.41 (m, 2H).

CHAPTER FOUR
PROCESS-SCALE ASYMMETRIC SYNTHESIS OF L,L-DAP, N6-MONOMETHYLL,L-SDAP, AND N6,N6-DIMETHYL-L,L-SDAP ENABLING A NEW DAPE
INHIBITION ASSAY
Carboranes are boron cage molecules that have found use in the
treatment of diseases including various cancers and rheumatoid arthritis,
most notably through boron neutron capture therapy (BNCT). Carboranes
are also distinguished with a rich and diverse synthetic chemistry.1 BNCT is
a useful binary cancer treatment, in which a drug containing
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B atoms is

selectively transported into tumor cells and then irradiated with thermal
neutrons. Thereupon, a

10

B nucleus absorbs a neutron to form an excited11B

nucleus that undergoes decay via fission, emitting an α-particle (4He2+) as
well as a 7Li3+ ion, both with high kinetic energy. These highly charged
particles damage the surrounding tissue, but they have a range of only
about one cell diameter (5-9 μm), which limits the radiation damage to the
cell in which they arise, thus avoiding damage to the surrounding tissue.2
As noted recently,3BNCT is a very promising treatment for cancers
given its exquisitely ability to target cancer cells, given that it relies on the
induced fission of boron within tumor cells. Ideally, a BNCT agent should
137
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concentrate in tumor cells while avoiding healthy cells. The U.S. FDAapproved BNCT drugs boronophenylalanine (BPA), sodium borocaptate and
sodium decahydrodecaborate and sodium decahydrodecaborate, which were
developed in the 1950’s and 1960’s are neither tumor-specific nor do they
accumulate with in tumor cells.3 Thus, there is an urgent need for boroncontaining therapeutics that both contain a higher density of boron atoms,
i.e. which have a high neutron-capture cross section, and which are selective
for tumor cells. Similarly, agents are needed for boron neutron capture
synovectomy for the treatment of severe cases of rheumatoid arthritis,
which works through the same principle and mechanism as BNCT for
cancer.1
Matrix metalloproteinases (MMPs) are a family of zinc-dependent
endopeptidases that are involved in the remodeling and degradation of all
components of the extracellular matrix (ECM).4 MMP enzymes play a key
role in normal development, morphogenesis, bone remodeling, wound
healing, and angiogenesis, yet inappropriately high MMP activity has been
implicated in a number of disease states including tumor growth and
metastasis and in the degradation of articular cartilage in arthritis.5 Thus,
MMP enzymes are over expressed in both tumors and in arthritic cartilage.
In order to halt disease progression resulting from exaggerated matrix
remodeling mediated by MMPs, MMP inhibitors (MMPi's) have been
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extensively explored with the goal of discovering and developing potent,
selective, and druggable MMP inhibitors.6-8
MMPs are known to be over expressed in tumors and also in articular
cartilage in patients suffering from rheumatoid and osteoarthritis.
Interestingly, MMP inhibitors have been used in the imaging of cancer cells
by binding tightly and specifically to MMP receptors.9 The goal of this
research is to discover orally bioavailable MMP inhibitors that bind with high
potency and selectivity to MMP enzymes, for it is these enzymes that are
over expressed in tumors and in arthritic tissues enabling the delivery of a
high density of boron atoms to tumor and/or arthritic tissue, thus with a
high neutron-capture cross section, to enable binary treatment of tumors
utilizing BNCT as well as the treatment of RA with neutron therapy. In
addition, it is appropriate to target potent inhibitors of a several MMP
enzymes specifically, including the collagenase MMP-13 and the gelatinases
MMP-2 and MMP-9, but with much lower potencies at MMP-1 and MMP-7
enzymes, enabling these inhibitors to inhibit angiogenesis, invasion, and
metastasis of tumors as well as inhibiting the MMP-induced destruction of
articular cartilage.
The presence of fluorine (19F) atoms in several derivatives among the
presently-described ligands enables the use of magnetic resonance
spectroscopy for the detection and localization of fluorinated drug in tumors,
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which will be very valuable in demonstrating the localization of tissues to be
irradiated with neutrons in therapy.10
Section 1: Synthesis of BNCT Analogs and Discussion
Carborane-containing MMP inhibitors to be applied in BNCT have been
designed and synthesized. A multitude of synthetic targets were explored
intellectually, and some were carried out experimentally. The synthesis of
carborane derived analogs were constructed by utilizing the alkyne moiety of
the THP-protected hydroxamate (Cmpd9). The nature and reactivity of
alkynes, both internal and terminal, enables the use of many different types
of chemistry to covalently bind carboranyl clusters. In this work, the
chemistry focuses on the use of ortho-closo-carboranes. The chemistries
that were evaluated focused around the reactivity of alkynes with specific
reactants carrying the carboranyl cluster. More specifically, the chemistries
evaluated include the reaction of alkynes with an activated decaborane
complex (B10H12*2MeCN) forming ortho-closo-carboranes, reaction of
alkynes and azides either via thermal Huisgen 1,3-dipolar cycloaddition or
copper-mediated azide-alkyne cycloaddition (CuAAC), or the rutheniumcatalyzed azide alkyne cycloaddition (RuAAC) affording triazole compounds,
as well as reaction of alkynes with thiols affording alkenyl sulfides.
The chemistry begins with the preparation of THP-MMP-18 (Cmpd 9).
The synthetic route was based on the literature preparation of THP-MMP-
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187,8 and the route was improved during process development. In order to
prepare carboranyl derivatives using the THP-MMP-18 scaffold, sufficient
quantities of the MMP-18 starting material was synthesized. The alkyne was
selected based on the fact that decaborane can react to produce carboranyl
derivatives, but the alkyne can also be used in Click chemistry to produce
triazolecarboranyl derivatives.
Section 2: Preparation and Process Development
of THP-MMP-18 (Cmpd 9)
Preparation of the THP-MMP-18 (Cmpd 9) was accomplished using a
modified procedure based on Becker et al.7,8 The improved preparation of
THP-MMP-18 is illustrated in Scheme 24.
Scheme 24. Improved Synthetic Route to THP-MMP-18 (Cmpd 9)
Step 1
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142
Step 2
CO 2Et
1) LDA then

1) UHP, Phthalic Anhydride
EtOAc, room temp

S

EtO

Compound 1

N
BOC

Step 3

O

F

N
BOC

2) Silica plug

2) Aq Sodium Sulfite
3) Adjust pH to 8

86% Yield
Compound 2
Ethyl N-Boc-piperidine-4-carboxylate
CAS# 142851-03-4
257.33 g/mol

O O

Step 4

O
S

EtO

HCl (g)
F

N
BOC

99% Yield

Compound 3
C19H26FNO4S
383.48 g/mol

O O

1) propargyl bromide

IPOAc

N
H

100% Yield

F
HCl

N

K2CO3, DMF, rt
2) water
94% Yield

Compound 5
C14H18FNO4S
351.82 g/mol

Compound 6
C17H20FNO4S
353.41 g/mol

Step 6

1)

HO

99% Yield

O
S

EtO

90°C, DMF
2) Aqueous workup

Step 7

O O

OCF 3

N

O
S

EtO

S

EtO

Compound 4
C19H26FNO6
415.48 g/mol

O O

Step 5

O

OCF 3
O
Compound 7
C24H24F3NO6S
511.51 g/mol

1) NaOH, 60 oC
2) 2M HCl
98% Yield

F

143
Step 8
O O

O
OCF 3

S

HO
N

O

1) THPONH

O O

THPO
2

EDC, HOBT, DMF
2) Chromatography

O
S

N
H
N

OCF 3
O

90% Yield
Compound 8
C22H21ClF3NO6S
519.92 g/mol

THP-MMP-18
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Step 1 involved the formation of the disulfide (Cmpd 1) and the
isolation procedure was improved such that the yield increased dramatically
if the product slurry was chilled prior to isolation. Step 2 required the
formation of the enolate anion 2 which was subsequently reacted with the
disulfide 1 to produce the corresponding sulfide adduct (Cmpd 3). Step 3
involved oxidation of the sulfide 3 to the sulfone (Cmpd 4) using recentlydeveloped novel oxidative conditions.11 During the development of Step 2, it
was determined that the sulfone (Cmpd 4) can accessed directly by reaction
of enolate 2 with 4-fluorophenyl sulfonyl chloride as shown below (Scheme
25). The reaction proved to be successful in cleanly producing the desired
product in 80% yield. For future preparation, this route can be used as an
alternative route to access the sulfone directly from 2 either in batch or
potentially in continuous flow mode.
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Scheme 25. Enolate and Sulfonyl chloride to produce Sulfone Adduct 4
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Compound 4
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Step 4 entailed removal of the BOC moiety using hydrogen chloride
gas in isopropyl acetate to access the ammonium hydrochloride salt (5).
Step 5 involved installation of the propargyl group via N-alkylation using
propargyl bromide and potassium carbonate to give exclusively the tertiary
amine product (6). Step 6 involved the preparation of the diaryl ether (7)
using SNAr conditions. Step 7 involved alkaline hydrolysis of the ethyl ester
to the carboxylic acid (8) which required overnight heating to achieve >90%
conversion by HPLC. This ester is highly hindered, and it was surprising that
this reaction did not go to completion. This type of reaction would be highly
amendable for flow chemistry at high temperatures. The final step, Step 8 is
a peptide coupling reaction to form the protected hydroxamate material (9)
which also required 2-3 days to fully consume the starting material.
As shown in Scheme 24, the synthesis commences with the reaction of
inexpensive and commercially available ethyl N-Boc-piperidine-4-carboxylate
(2) with Lithium Diisopropylamide (LDA) under cryogenic conditions to
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produce the enolate anion that subsequently reacts with disulfide (1) to
produce the sulfide adduct (3). The preparation of disulfide (1) was easily
achieved by the reaction of 4-fluorothiophenol in DMSO. It is noteworthy
that the process and yield of the disulfide (1) was drastically improved by
isolating the disuflide at 0-5 oC providing crystalline material as a low
melting solid. The corresponding sulfide adduct (2) was originally oxidized to
the sulfone (3) using MCPBA and required chromatographic purification.7,8
However, the process for oxidation of the sulfide to the sulfone was
significantly improved with the use of the newly-developed, safe and
efficient, scalable, and cost-efficient urea hydrogen peroxide (UHP)/phthalic
anhydride system11 in ethyl acetate, which allowed this oxidation to be easily
carried out on 180 g scale and enabled facile isolation of highly pure sulfone
via an extractive workup eliminating the need for chromatography. The
corresponding N-Boc sulfone (4) was reacted with hydrogen chloride gas in
isopropryl acetate to cleave the Boc protecting group producing the
piperidine as the hydrochloride salt (5), which is then alkylated with
propargyl bromide and potassium carbonate in DMF to cleanly produce the
propargylamine adduct (6) in high yield. SNAr reaction of propargylamine
(6) with 4-(trifluoromethoxy)phenol and potassium carbonate in DMF cleanly
produced the diphenyl ether adduct (7) in high yield. Alkaline hydrolysis of
diphenyl ether (7) in ethanol required an excess (10 equiv. of NaOH) of
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hydroxide and overnight heating to achieve at least 90% conversion of ester
to carboxylic acid (8). Lastly, the reaction of carboxylic acid (8) with O(tetrahydro-2H-pyran-2-yl)hydroxylamine using EDC, HOBt and DIPEA in
DMF afforded pure protected hydroxamate (9) after purification via normal
phase chromatography.
Section 3: Borane-Alkyne Reactions and Synthesis
of the 1,2-C2B10Carborane Cluster
The reaction involving alkynes and decaborane have been a useful
method of covalently attaching boron clusters to carrier molecules12 for a
wide range of chemical fields including electronics, nanomaterials, and
medicine. There are a variety of methods of carrying out reactions of alkynes
and decaborane to prepare ortho-closo-carboranes. The classical method
requires the formation of an activated decaborane complex, B10H12(MeCN)2,
which can be prepared in situ or isolated and can be stored at ambient
temperature for some time, however the isolated yield of activated
decaborane complex is undesirably low with yields of only 20-40% isolated
yield. B10H12(MeCN)2 is typically prepared in toluene and acetonitrile
(typically in excess) and the generated B10H12(MeCN)2 complex can be
isolated as a solid with a moderate shelf-life when stored under an inert
atmosphere, or the B10H12(MeCN)2 complex can be prepared in situ for direct
carborane synthesis. Preparation of the B10H12(MeCN)2 complex is usually
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performed at 80-120oC for at least 1 hour. Over the course of the reaction
hydrogen gas is generated as a byproduct and 2 molar equivalents of
acetonitrile as a Lewis base replaces the liberated hydrogen. Subsequent
reaction of B10H12(MeCN)2 and an alkyne at 80-120 oC affords the closocarboranyl derivative, usually requiring overnight heating to fully consume
the alkyne starting material. However, the reaction can be accelerated when
a catalytic amount of silver nitrate is added reducing the reaction, reducing
the reaction time to 1-4 hours.13 In addition, direct reaction of alkynes with
decaborane can be carried out efficiently using ionic liquids as the
solvent/activator, and this process does not require the use of a Lewis base
to form a B10H12(Lewis base)2 complex. The use of an ionic liquid allows
complete conversion in much shorter timeframe at 100-120oC, which makes
this process amendable for flow chemistry since it is a fast reaction, and the
toxic decaborane can be more safely handled.
It was projected that the reaction of THP-MMP-18 and B10H12(MeCN)2
would serve as a convenient pathway to prepare and isolate carboranyl
targets for BNCT. However, we eventually realized that the reaction was not
as straightforward as one might perceive. A significant amount of time was
spent on scoping process conditions in attempt to form the desired
carboranyl product (Cmpd 24) as illustrated in Scheme 26. Conditions that
were evaluated included temperature, solvent, prior preparation of the B-
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10H12(MeCN)2

complex, in situ generation of the B10H12(MeCN)2 complex,

stoichiometry of B10H12(MeCN)2, and catalytic addition of silver nitrate. Table
4 summarizes the results from the reaction of THP-MMP-18 with decaborane
in attempt to form the closo-carborane. Pilot reactions performed were
monitored by HPLC and TLC analysis.
The results summarized in Table 5 showed that the reactions
performed generated a multitude of products which were not identified or
characterized. It was postulated that the hydroxamate moiety was
undergoing chelation with decaborane or the corresponding decaborane
activated complex.
Scheme 26. Reaction of THP-MMP 18 with decaborane activated complex to
form Compound 24
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Table 5. Reaction Conditions for the coupling of Decaborane with THP-MMP18 (Cmpd 9)
Pilot

Reactions Conditions

Temp

Time

HPLC/TLC Result

Pilot 1
PR075113

B10H14 (1.2 equiv)
ACN (100 equiv)
Toluene
THP-MMP-18 (1 equiv)

110oC

21 h

Highly complex mixture

Pilot 2
PR075133

B10H14 (1.2 equiv)
ACN (100 equiv)
Toluene
THP-MMP-18 (1 equiv)

50oC

13 h

Highly complex mixture

40oC

21 h
37 h
11 days

Highly complex mixture
Highly complex mixture
Highly complex mixture

110oC

7h
22 h
2.5 days

Highly complex mixture
Highly complex mixture
Highly complex mixture

40oC

21 h
37 h
11 days

Highly complex mixture
Highly complex mixture
Highly complex mixture

110oC

7h
22 h
2.5 days

Highly complex mixture
Highly complex mixture
Highly complex mixture

Pilot 3
PR075148

B10H14 (2 equiv)
ACN (100 equiv)
Toluene
THP-MMP-18 (1 equiv)

Pilot 4
PR075149

B10H14 (3 equiv)
Toluene
ACN (100 equiv)
THP-MMP-18 (1 equiv)

Pilot 5
PR075150

B10H14 (3 equiv)
Toluene
ACN (100 equiv)
THP-MMP-18 (1 equiv)
AgNO3 (0.10 equiv)

25oC

21 h
32 h
11 days

Highly complex mixture
Highly complex mixture
Highly complex mixture

110oC

2h

Highly complex mixture

Pilot 6
PR075156

B10H14 (0.5 equiv)
ACN (100 equiv)
THP-MMP-18 (1 equiv)

40oC

15 h

Highly complex mixture

110oC

7h
2.5 days

Highly complex mixture

Pilot 7
PR075157

B10H14 (0.5 equiv)
Toluene
ACN (100 equiv)
THP-MMP-18 (1 equiv)
AgNO3 (0.10 equiv)

40oC

15 h

Highly complex mixture

110oC

2h

Highly complex mixture
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Pilot

Reactions Conditions

Temp

Time

HPLC/TLC Result

Pilot 8
PR075164

B10H12(MeCN)2 (0.5 equiv)
Toluene
THP-MMP-18 (1 equiv)

110oC

2h
16 h
2 days

Highly complex mixture

Pilot 9
PR075165

B10H12(MeCN)2 (1.2 equiv)
Toluene
THP-MMP-18 (1 equiv)

110oC

2h
16 h
2 days

Highly complex mixture

Pilot 10
PR075166

B10H12(MeCN)2 (1.2 equiv)
Toluene
THP-MMP-18 (1 equiv)

110oC

2h
16 h
2 days

Highly complex mixture

According to Kliegel et al,14 reaction of 9-BBN with a THP protected
hydroxymate can generate boron chelates14 (illustrated in Scheme 27) and
based on this precedent, it was suspected that this chelation behavior was a
contributing factor to the complex reaction of THP-MMP-18 with decaborane
or B10H12(MeCN)2. Kliegel et al14 showed that hydroxamic acids chelate 9BBN, but he also demonstrated that O-THP protected hydroxamates can
chelate to Lewis acidic boron compounds such as 9-BBN, BF3, and
diphenylborinic anhydride. Based on the work by Kliegel et al14 showing that
O-THP protected hydroxamates chelate to boron containing compounds, it
was hypothesized that the reaction of THP-MMP-18 with decaborane or the
decarborane activated complex resulted in cleavage of the THP group as
illustrated in Scheme 28. Further evidence for the deprotection of THP ethers
were reported by Yung15 who employed the use of catalytic amounts of
decaborane in various solvents (MeOH, EtOH, MeOH/THF) to cleave THP
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ethers. Gigg et al. also reported that boric acid at 90oC cleaves THP ethers.16
Furthermore, the use of borane in THF cleaves tetrahydropyranyl ethers at
room temperature according to Cossy et al.17
Scheme 27. 9-BBN Reaction with Free Hydroxamic Acid (based on
ChemischeBerichte, 116(7), pg 2616, 1983)

Scheme 28. Proposed undesired reaction of THP-MMP-18 (Cmpd 9) with
decaborane/decaborane activated complex
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Given that hydroboration of decaborane and THP-MMP-18 (Cmpd 9)
proved undesirable, an alternative approach was considered. The alternative
approach, illustrated in Scheme 29, involved hydroboration of ethyl ester (7)
with B10H12(MeCN)2 which proved successful in generating the ortho-closocarborane ethyl ester adduct 20. In addition to the carboranyl ethyl ester
(20), a side-product was formed and identified to be the nido ethyl ester
form (23). Nido formation is typically a result of deboronation of the
carborane cluster under alkaline conditions (> pH 9) either with alkali
hydroxide or organic amines. Given that ethyl ester carborane (22) does
contain an organic amine moiety from the piperidine scaffold, the formation
of the nido complex is likely due to the presence of the piperidine scaffold. It
has been shown that treatment of boron clusters in toluene and
triethylamine at reflux generate the nido form.18 Additionally, Viñas et al.
showed that using piperidine in ethanol generated nido carboranes.19
Since electron donors (such as MeCN, SEt2, or Et3N) coordinate to
decaborane to form decaborane activated complexes, it is quite possible that
B10H12(MeCN)2 underwent an exchange with the piperidine nitrogen to eject
one equivalent of acetonitrile. This swapping reaction could also explain why
the HPLC/TLC analysis resulted in a significantly complex mixture of
byproducts or why lower isolated yields for ethyl ester carboranyl adduct
were achieved.
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Scheme 29. MMP-18 Ethyl Ester (Cmpd 7) Reaction with Activated
Decaborane

The reaction of MMP-18 ethyl ester (Cmpd 7) with activated
decaborane was monitored by HPLC analysis. After 19 h at 80-85 oC, the
reaction completely consumed starting material and resulted in a 70%
conversion to the desired carborane (Cmpd 20) along with 16% of a major
impurity which was identified and assigned as the nido ethyl ester species
(Cmpd 21) based on HRMS analysis. Purification by flash chromatography
afforded the desired MMP-18 carboranyl ethyl ester (Cmpd 20) in 35% yield
and >98% purity. It is still undetermined why the isolated yield is lower than
expected since the conversion was 70% by HPLC. Based on the observation
that ethyl ester 7 coupled effectively to decaborane, the interaction of the
alkyne moiety of Cmpd 9 with decaborane should proceed as expected, and
shows that Lewis acidic decaborane was probably chelating to the
hydroxamate moiety.
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With experiment PR074-052 (see Scheme 30 below), direct access to
MMP-18 carboranyl acid (Cmpd 22) was explored by using an MMP-18
carboxylic acid (Cmpd 8) and activated decaborane which led to essentially
complete consumption of MMP-18 carboxylic acid (Cmpd 8) after 17 h at
80oC. The resultant reaction mixture contained only 18% of the desired
carboranyl acid 22. The HPLC chromatogram for this reaction of MMP-18
carboxylic acid and activated decaborane is shown in Figure 27.
Scheme 30. Reaction of MMP-Carboxylic Acid (Cmpd 8) with activated
decaborane
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Figure 27. Reaction of MMP-18 carboxylic acid and activated decaborane
The next step was to determine if the ethyl ester carborane (Cmpd 20)
can be hydrolyzed to its corresponding carboxylic acid derivative (Cmpd 22).
The first attempt to hydrolyze the ethyl ester using sodium hydroxide in
aqueous ethanol at room temperature proved unsuccessful since
deboronation occurred much faster than hydrolysis of the hindered ester
group leading to the nido form as the major component. See below in Figure
28, Figure 29, and Table 6 that show two HPLC chromatograms and
tabulated data which illustrate that deboronation occurred faster than ester
hydrolysis and that a significant amount of ethyl ester starting material
remained unreacted even after 210 h at room temperature. Heating this
alkaline mixture was not explored since deboronation is likely to be
enhanced leading to an even higher population of nido ester or nido acid.
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Note that the nido form is of interest in the future for preparing water
soluble MMP carboranyl inhibitors, however the initial goal of this project is
to prepare the analogs that encompass the closo-carborane cage.

Figure 28. Alkaline Hydrolysis of Ethyl Ester Carborane at 44 hrs at RT

Figure 29. Alkaline Hydrolysis of Ethyl Ester Carborane at 210 hrs at RT
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Table 6. Alkaline Hydrolysis and Deboronation of Ethyl Ester Carborane over
210 hours at RT
Time
at RT
44 h
84 h
108 h
162 h
210 h

HPLC
Carboranyl
Ester Cmpd 20
(%AUC)
85
82
73
64
58

HPLC
Desired Carboranyl
Acid
Cmpd 22
(%AUC)
4
5
7
9
11

HPLC
Nido Ester
Cmpd 21
(26.4 mins)
(%AUC)
10
12
18
22
29

The steric hindrance of MMP-18 Ethyl Ester contributed to the very
slow hydrolysis using sodium hydroxide in aqueous ethanol at 60oC
overnight. This demonstrates that the ester would prove to be very difficult
to completely convert to the carboxylic acid.
As it appeared that alkaline hydrolysis of carboranyl ester (Cmpd 20)
is not a viable pathway to access the carboxylic acid carborane, since
deboronation and nido formation would predominate, conditions employing
acidic hydrolysis were pursued. Below in Table 7 is summarized the process
development toward hydrolysis of the hindered ethyl ester using acidic
mixtures employing conventional thermal heating in batch mode.

158
Table 7. Screening Results for Hydrolysis Hindered MMP-18 Carboranyl Ethyl
Ester
Reaction Conditions

Experiment

Solvent
Medium

Pilot 1
PR075147-A

33%
HBr in
aq
AcOH
sealed
vial

Pilot 2
PR075147-B

6M HCl
(aq) in
AcOH
sealed
vial

Pilot 3
PR075153

6M HCl
(aq) in
AcOH
sealed
vial

Temp

100
o
C

100
o
C

100
o
C

HPLC (%AUC)

Time

Ester
Cmpd
20

Acid
Cmpd
22

Nido
Ester
Cmpd
21

Nido
Ester
Isomer

Nido
Acid

Arachno
Acid

27 h

61

30

2

2

0

0

48 h

56

33

3

2

0

0

80 h

42

37

3

2

1

0

15 h
49 h

76
76

15
16

2
1

0
0

3
3

0
0

71 h

66

21

2

0

3

0

52

15

13

0

0.6

0

38

13

21

0

8

0

20

22

4

0

15

16

92

8

0

0

0

0

69

31

0

0

0

0

44

56

0

0

0

0

31

68

0

0

0

0

21

79

0

0

0

0

96

4

0

0

0

0

85

15

0

0

0

0

61

39

0

0

0

0

51

48

0

0

0

0

45

55

0

0

0

0

50

18

10

11

0

1

18

47

9

12

0

1

4

61

10

12

0

2

2
days
3
days
7
days
6h

Pilot 4
PR075168

Pilot 5
PR075169

Pilot 6
PR075170

70%
H2SO4
in
AcOH
sealed
vial

50%
MsOH
in
AcOH
sealed
vial

33%
HBr in
aq
AcOH

100
o
C

100
o
C

100
o
C

1
day
3
days
4
days
5
days
6h
1
day
3
days
4
days
5
days
6h
1
day
2
days

Comments

recharged with
additional water
and 33% HBr

recharged with
additional water
and 33% HBr
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Reaction Conditions

Experiment

Solvent
Medium

sealed
vial

Temp

HPLC (%AUC)

Time

Ester
Cmpd
20

Acid
Cmpd
22

Nido
Ester
Cmpd
21

Nido
Ester
Isomer

Nido
Acid

Arachno
Acid

3
days

0

43

18

15

0

2

Comments

As seen in Table 7, acids that were screened included hydrochloric
acid, hydrobromic acid, sulfuric acid, and methanesulfonic acid. Screening
was limited to 100 oC, limited by the boiling point of water and given the
azeotropic nature of aqueous acetic acid mixtures. The addition of acetic acid
was necessary to ensure that the mixtures remained homogeneous. During
screening of these acids in batch mode at 100 oC (standard thermal
heating), the acids screened generated the desired carboxylic acid as well as
the nido carborane ethyl ester and carboxylic acid forms. However, the
formation of the nido ethyl ester and carboxylic acid forms depended on the
acid used. For instance, hydrochloric acid generated larger amounts of nido
carboxylic acid form, whereas sulfuric acid generated lower levels of nido
carboxylic acid. Interestingly, methanesulfonic acid also generated larger
amounts of nido carboxylic acid form compared to sulfuric acid. Solubility of
the carborane ethyl ester in mineral acids and methanesulfonic acid was
relatively poor and required the addition of acetic acid to ensure complete
dissolution. Given that the batch reaction was excessively slow, the use of
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microwave heating at elevated temperature was evaluated. During the
evaluation using microwave heating, only sulfuric acid/acetic acid conditions
were employed since these conditions appeared to form less of the nido
ethyl ester or carboxylic acid form(s). Note that the nido carboxylic acid
form is a degradation product from deboronation of the desired carboranyl
carboxylic acid. Table 8 summarizes the HPLC results of the hydrolysis of
carboranyl ethyl ester (Cmpd 20) under microwave irradiation.
Table 8. Microwave Irradiation of Carboranyl Ethyl Ester 20 using sulfuric
acid/acetic acid
H2SO4
Carboranyl
Ethyl Ester
Sample

%wt

volumes

AcOH
(volumes)

Temp
(oC)

τ
(mins)

(Cmpd 20)
32.3 min
(%AUC)

29.3
min
Impurity
A
(%AUC)

DESIRED
Carboranyl
Acid
Product
(Cmpd 22)
28.8 min

26.3
min
Impurity
B
(nido)
Ester

25.7
min
Impurity
C
(nido)
Acid

(%AUC)

(%AUC)

(%AUC)

16.1 min
Impurity
D
(arachno)
Ester
(%AUC)

9.7-9.9
min
Impurity
E
(arachno)
Acid
(%AUC)

PR075173

70

325

650

200

5

0

2

28

8

1

0

0

PR075174

70

325

650

175

10

0

17

50

6

20

0

1

PR075175

70

325

650

135

10

91

0

9

0

0

0

0

160

+20

28

3

66

0

1

0

1

10

50

1

46

0

2

0

0

20

28

2

65

0

3

0

1

30

13

3

75

0

6

0

1

PR075176

70

325

650

150

PR074069-A

70

77

154

150

30

46

0

51

0

1

0

0

PR074069-B

50

250

500

150

30

69

0

29

0

0

0

0

PR074069-C

70

250

500

150

30

48

0

49

0

1

0

0

PR074069-D

70

250

500

150

45

39

0

58

0

1

0

0

PR074069-E

70

250

500

150

60

33

0

63

0

1

0

0
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PR074069-L

70

125

250

150

60

33

0

64

0

1

0

0

PR074069-F

90

250

500

150

60

6

4

83

0

4

0

0

PR074069-G

90

125

500

150

60

33

1

63

0

1

0

0

PR074069-H

90

125

375

150

60

21

1

75

0

1

0

0

PR074069-I

90

125

250

150

60

1

9

78

0

8

0

0

PR074069-K

90

125

250

150

50

5

5

82

0

5

0

0

PR074069-J

90

125

250

140

60

28

1

68

0

1

0

0

140145

10

27

0

0

70

0

3

0

150170

10

0

0

0

67

0

23

0

PR074069-M

0

0

PR074069-N

0

0

250
(AcOH)
125
(H2O)
375
(AcOH)
250
(H2O)

Section 4: Discussion about Results
Initial screening under microwave irradiation at 200oC resulted in rapid
consumption of the carboranyl ethyl ester, however severe degradation
occurred resulting in only 28% desired product with many unknown
byproducts accompanying an undesirable stench. Decreasing the
temperature to 175oC resulted in consumption of starting material and
produced 50% desired product along with associated nido byproducts.
Operating at 135oC for 10 minutes resulted in 91% unreacted starting
material and 9% desired product, and subjecting the same reaction mixture
to 160oC for an additional 20 minutes generated 66% desired carboxylic acid
product, 28% unreacted starting material, and trace amounts of nido
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species. Based on those observations, a convenient procedure is warranted
for scaling the hydrolysis of carboranyl ethyl ester using continuous flow, the
maximum operating temperature is restricted to 150 oC with the current flow
chemistry configuration due to that sulfuric acid is employed and the thermal
limitation of the PFA plug flow reactor is typically restricted to 150 oC for
safety and durability considerations. The next phase was to evaluate
microwave irradiation at 150 oC and to optimize the residence time (Tau or
τ), minimize the formation of nido species, and evaluate the solvent volumes
and concentration of sulfuric acid. It was found that performing the
hydrolysis for 60 minutes using 90% sulfuric acid (125 volumes) and acetic
acid (250 volumes) gave the best conversion to the desired carboranyl acid
product (~80%), with near consumption of starting material, and <10% of
nido impurities. Interestingly, when carrying out microwave heating using
solely aqueous acetic acid (experiment PR074-069-M and -N), hydrolysis of
the ethyl ester was not affected, however the only products formed were
mono and di-deboronated compounds that were identified by HRMS to be
nido-ester and arachno-ester adducts.
To confirm that the desired carboranyl acid was forming, one of the
pilot reactions (PR074-069-C) was analyzed by HPLC followed by UPLC/MS.
Before analysis, the pilot reaction (PR074-069) was concentrated to remove
acetic acid under reduced pressure followed by adjusting the pH of the
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sulfuric acid residue to pH 5-6 (by litmus paper) using saturated aqueous
sodium bicarbonate solution and subsequently extracting the organic
material with dichloromethane. Analysis of the organic layer by HPLC
showed that the ratio of starting material carboranyl ester and desired
carboranyl acid remained the same (see below). Furthermore, UPLC/MS of
this mixture showed the correct molecular ion [M+H]+ = 602 m/z for the
carboranyl acid, and this result confirmed that the carboranyl acid is forming
under acid hydrolysis. The [M+H]+ = 631 m/z is unreacted carboranyl ethyl
ester starting material. The UPLC/MS data is depicted in Figure 30 below.

Figure 30. UPLC/MS - Carboranyl MMP-18 Carboxylic Acid (Compound 22)
Based on the microwave irradiation experiments, the next step was to
evaluate the hydrolysis of carboranyl ethyl ester under continuous flow mode
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using conditions developed with microwave batch irradiation. Under
continuous flow mode at 150 oC for 60 minutes residence time, the
formation of nido ester was significantly lower than microwave heating,
however hydrolysis of the ethyl ester was slightly slower than expected. It
was postulated that the heat transfer property under microwave heating is
significantly higher than flow mode since glass has better heat transfer
properties than PFA (Perfluoroalkoxy) tubing which is widely used in
continuous mode application especially with corrosive or oxidizing agents.
Furthermore, the higher levels of formation of the nido form under
microwave heating is likely due to that the concentration of water (within
the reaction medium) decreased since some of the water within the reaction
was in the headspace of the microwave vessel as the vapor state. The HPLC
chromatogram for a residence time of 60 minutes is depicted in Figure 31.
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Figure 31. Hydrolysis of Ethyl Ester Carborane under Continuous Flow at 150
o
C with τ = 60 mins
Given that the conversion was ~10-15% lower than conditions
developed using microwave heating, the residence time was increased to 75
minutes at 150 oC which provided the same conversion observed with
microwave irradiation. The HPLC chromatogram for the hydrolysis at 150 oC
for 75 minutes under continuous flow mode is illustrated in Figure 32.
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Figure 32. Hydrolysis of Ethyl Ester Carborane under Continuous Flow at
150 oC with τ = 75 mins
The use of continuous flow with a residence time of 75 minutes
achieved 78-80% conversion to product that was substantially cleaner and
contained 18-20% unreacted starting materiel ethyl ester which can be
easily recovered by normal-phase chromatography and subsequently
recycled for continuous flow processing.
With the desired carboranyl acid (Cmpd 22) in hand, the rest of the
synthesis focused on preparation of the acid chloride, subsequently forming
the protected hydroxamate using THPONH2 and lastly cleaving the THP
group with acidic reagent to isolate the carboranyl MMP-18 salt. The scheme
for this synthetic pathway is illustrated in Scheme 31.
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Formation of acid chloride and subsequent hydroxamate formation has
not been pursued. Current efforts on this front will be addressed in due time.
Scheme 31. Synthetic Pathway to access Carboranyl MMP-18 salt

Section 5: Utilizing Click Chemistry to Attach Boron
Cluster to THP-MMP-18
The scope of the next phase of this project revolved around the use of
Click chemistry to attach boron clusters to the alkyne moiety of THP-MMP-18
(Cmpd 9). There are a number of methods of employing Click chemistry to
couple azides to alkynes either thermally or via copper or ruthenium
catalysis (CuAAC or RuAAC, respectively). Since we are targeting matrix
metalloproteinases (MMPs), the use of copper has the potential to cause
issues downstream since MMPs have a natural affinity to divalent metals
(zinc, cobalt, copper). Based on this, the thermal Click reaction (without
metal catalysis) was used to prepare both the 1,4-disubstituted and 1,5disubstituted Click products.
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Synthesis of both the 1,4-disubstituted and 1,5-disubstituted Click
products was accomplished by preparation of protected carboranyl propyl
azide and subsequent Click reaction with THP-MMP-18 in toluene at elevated
temperatures (120-140oC). The synthetic scheme for preparation of
carboranyl propyl azide is shown in Scheme 32.
Scheme 32. Preparation of TBDMS Propyl Azido Carborane (13)

Formation of 1-azido-iodopropane was accomplished based on
literature precedent (reference: ACIEE, 56(26), 7420-7424; 2017) which
entailed SN2 reaction of sodium azide and 1-bromo-3-chloropropane in DMF
affording a 95% yield of 1-azido-3-chloropropane that contained ~15% of 1azido-3-bromopropane and was taken forward without further purification.
The crude 1-azido-3-halopropane was subjected to Finkelstein conditions
using sodium iodide in warm acetone that generated pure 1-azido-3iodopropane in 81% isolated yield after silica plug purification. The next
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reaction involved preparation of the TBDMS-protected carborane derivative
(13) which involved deprotonation of the o-carborane with n-butyllithium (nBuLi) generating the carborane anion which subsequently attacks TBDMSCl
affording highly pure TBDMS carborane (10) in 94% isolated yield post silica
plug purification. The last step to prepare the TBDMS propyl azido carborane
(13) uses novel anion generating conditions not reported in literature for
this particular reaction. The deprotonation was accomplished using lithium
hexamethyldisilazide (LiHMDS) to generate the carboranyl anion that
sequentially attacks 1-azido-3-iodo-propane to furnish pure TBDMS propyl
azido carborane in 98% isolated yield post silica plug purification.
The thermal heating of an azide and an alkyne without copper or
ruthenium agents generates a mixture of 1,4-disubstituted and 1,5disubstituted triazole products. Executing the Click chemistry on TBDMS
propyl azido carborane (13) and THP-MMP-18 did confirm that a mixture of
two products were formed as determined by TLC and HPLC analysis. In order
to determine which Click product by TLC and HPLC correlated to the 1,4disubstituted triazole and 1,5-disubstituted triazole products, two separate
reactions were carried out using copper to facilitate the selective formation
of the 1,4-disubstiuted Click product and ruthenium catalysis to promote
selective formation of the 1,5-disubstituted Click product. Scheme 33 depicts
the thermal click reaction and Figure 35 also shows the HPLC profile of a

170
thermal Click reaction. Furthermore, Figures 33 and 34 provide the
mechanism of how each regioisomer is formed.
Scheme 33. Thermal click reaction between alkyne (9) and azide (13)

Figure 33. Mechanism for 1,4-Click Product
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Figure 34. Mechanism for 1,5-Click Product

Figure 35. HPLC chromatogram of the thermal click reaction between Alkyne
(9) and Azide (13)
Using stoichiometric copper sulfate and excess sodium ascorbate in
aqueous THF at room temperature, the CuAAC reaction (Scheme 34)
produced solely the 26.5 min component by HPLC (Figure 36) and confirmed
that this component was the 1,4-disubstituted triazole. Figure 37 depicts the

172
mechanism for the formation of the 1,4-regioisomer under CuAAC
conditions.
Scheme 34. CuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide

Figure 36. CuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide
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Figure 37. CuAAC mechanism for the formation of the 1,4-disubstituted
triazole
The RuAAC reaction (Scheme 35) generated the 27.5 minute
component by HPLC (Figure 38) and verified that this component was the
1,5-disubstituted triazole. The RuAAC affords predominately the 1,5-click
product, but trace amounts (<2% AUC) of the 1,4-click product are
produced when performing the reaction at ambient temperature. The
mechanism for the formation of the 1,5-disubstituted triazole click product is
shown in Figure 39.
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Scheme 35:RuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide

Figure 38.RuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide
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Figure 39.RuAAC mechanism for the formation of the 1,5-disubstituted
triazole
To evaluate the RuAAC chemistry, two ruthenium catalysts were
screened in toluene or tetrahydrofuran to determine which catalyst/solvent
system was most effective in generating the 1,5-disubstituted triazole. The
results of this screening are summarized in Table 9. It is apparent that the
chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II)
(Cp*Ru(COD)Cl) catalyst was superior compared to
pentamethylcyclopentadienylbis-(triphenylphosphine)ruthenium(II) chloride
(Cp*Ru(PPh3)2Cl) catalyst, and performing the reaction in a polar solvent
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(THF) generated higher conversion to the 1,5-click product compared to
running the reaction in non-polar media such as toluene. Granted that the
reaction could have been pushed to completion by adding in more catalyst,
but this was not explored. It is expected that ruthenium catalysis may serve
useful for future selective preparation of carboranyl Click products and even
trace levels of ruthenium should not interfere with binding to MMPs or
coordinate with the hydroxamate ligand of the MMP-18 scaffold.
Table 9. RuAAC Reaction screening catalyst type and solvent
Pilot
Rxn
Pilot 1
PR074035-A1
Pilot 2
PR074035-A2
Pilot 3
PR074035-B1
Pilot 4
PR074035-B2

Alkyne
SM
%AUC

1,5-Click
Product
%AUC

Catalyst‡

Solvent

Time
(Temp)

Cp*Ru(COD)Cl

THF

40 h (RT)
48
o
65 h (50 C) 34

49
54

Cp*Ru(PPh3)2Cl

Toluene

40 h (RT)
88
65 h (50oC) 73

7
20

Cp*Ru(COD)Cl

THF

40 h (RT)
76
65 h (50oC) 69

22
27

Cp*Ru(PPh3)2Cl

Toluene

40 h (RT)
86
o
65 h (50 C) -----

7
-----

‡Catalyst loading was 0.025 equivalents.

The next phase was to optimize the thermal click reaction in toluene as
the solvent. The goal of this phase was to determine the optimum
temperature that provided good conversion to Click products and to
minimize the formation of impurities such as nido species. Formation of nido
species was expected since the starting material alkyne (Cmpd 9) does
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contain an internal tertiary organic piperidine base and the resulting Click
products are alkaline as well, although not as basic as the piperidine
nitrogen, and with the combination of heat and basicity leads to formation of
nido complexes. The temperatures screened for the thermal click reaction
were 100 oC, 120 oC, and 140 oC and the HPLC results from the evaluated
temperatures are illustrated in Table 9. It is evident that the Click reaction at
100 oC is significantly slower compared to the reactions at 120 oC and 140
o

C. The reaction at 120 oC progressed to 62% conversion (sum of both Click

regioisomers) after 42 h whereas the reaction at 140 oC for 19 h performed
slightly better with a total conversion of 69% (sum of both Click
regioisomers) and contained less starting material alkyne (22%). The
formation of impurities (nido) was lower at 120 oC even after 42 h and
slightly elevated at 140 oC after 19 h, however heating the mixture for
longer periods of time at 140 oC does consume more starting material
alkyne, but at the expense of forming significantly higher amount of nidolike impurities which makes purification difficult downstream.
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Table 10. Temperature Evaluation for the Thermal Click Reaction

Pilot Rxn

Pilot 1
PR074-023

Temp

Time

Alkyne
SM
%AUC

100 oC

2.5
days
5 days
12
days
15
days

79
70
29
24

Pilot 2
120
19 h
56
PR074-036- o ▲
C
42 h
34
A
Pilot 3
140
19 h
22
PR074-036- o ▲
C
42 h
9
B
▲ - Reaction was performed in a pressure vial.

1,4-Click
Product
%AUC

1,5-Click
Product
%AUC

Impurities
%AUC

12
18
29
29

7
10
19
20

2
2
23
27

26
38

16
24

2
4

42
32

27
23

9
36

Based on the development of the thermal click chemistry work, scaling
this procedure was attempted in a microwave vessel, however the poor
microwave absorption of toluene prohibited the reaction from proceeding
smoothly. A safer and more efficient method that would allow the
preparation of Click products would be to perform the Click reaction in
continuous flow which will allow the reaction to be rapidly heated to target
temperature, and also to safely handle organo-azides especially at elevated
temperatures. Continuous flow was not evaluated at this time, therefore the
Click regioisomers was executed on a gram scale using batch-type pressure
vessels at 120oC for 58 h. HPLC analysis of the reaction after 58 h showed
~65% conversion (sum of Click regioisomers) and indicated that there was
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~20% unreacted alkyne. The reaction was deemed complete at this point to
avoid degradation of product and introduction of nido-based impurities that
are difficult to remove. Furthermore, HPLC analysis confirmed that the
thermal Huisgen 1,3-dipolar cycloaddition reaction gives 1,4-Click and 1,5Click products with a ratio of 1.6 to 1, respectively, which agrees with
Sharpless' study20 the component ratio of the click regioisiomers.
To access the final targets intended for assaying MMP inhibition and
subsequent biodistribution studies, the protected carboranyl Click products
(1,4- and 1,5-disubstituted) require deprotection of both the TBDMS and
THP groups. Cleavage of the TBDMS group was executed using 1M
tetrabutylammonium fluoride (TBAF) in THF which is shown in Scheme 36
for the 1,4-Click regioisomer and in Scheme 37 for the 1,5-Click
regioisomer. The reaction conditions require cooling the mixture to cryogenic
conditions prior to charging 1M TBAF to control the exotherm and also to
prevent deboronation. Once the TBAF was added, the reaction was allowed
to warm temperature and the reaction was complete within 30 minutes at
ambient temperature.
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Scheme 36. Cleaving the TBDMS group of the 1,4-Click regioisomer

Scheme 37. Cleaving the TBDMS group of the 1,5-Click regioisomer

The final stage of chemistry required the deprotection of the THP
protecting group which was executed using 4N HCl in 1,4-dioxane as
depicted in Schemes 38 and 39. The reaction was performed at room
temperature and monitored by HPLC to ensure complete deprotection of THP
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group, since TLC would lead to false interpretations of reaction completion
since the starting material would simply form a hydrochloride salt and
remain at the baseline along with desired product. Once the reaction was
complete, the reaction mixture was concentrated, redissolved in
dichloromethane, and subsequently precipitated using diethyl ether.
Scheme 38. Cleaving the THP group of the 1,4-Click regioisomer

182
Scheme 39. Cleaving the THP group of the 1,5-Click regioisomer

Section 6: Conclusion and MMP Inhibition Data of the Click Products

The two Click products (1,4-Click and 1,5-Click) that were synthesized
as hydrochloride salts were tested against three MMP enzymes (MMP-1,
MMP-2, and MMP-9). In parallel to testing the Click products, Compound 9
was deprotected to produce the free hydroxamate as the hydrochloride salt
and this sample was designed to be a control since it does not have a
carborane cluster attached to it. The inhibition results shown in Table 10
illustrate that the 1,4-Click product and 1,5-Click product remained highly
potent against MMP-2 and MMP-9. It is worth noting that these Click
products showed insignificant binding to MMP-1 which is a positive result
since reduced binding of MMP-1 will avoid the musculoskeletal syndrome
(MSS) side effects if administered to humans. The control sample

183
(Compound 9 deprotected) showed sub-nanomolar potency for MMP-2 and
MMP-9 (0.24 and 0.3 nM) as well but did not spare MMP-1 (860 nM). It is
interesting that the 1,5-Click product was more potent for MMP-2 and MMP-9
compared to 1,4-Click product. A possible explaination of why the 1,5-Click
product was more potent is that while being bound inside MMP-2 or MMP-9,
the functionality extending from the piperidine nitrogen is essentially sticking
out in solvent more than the 1,4-Click product. Furthermore, the
regiochemistry is different between the 1,4 and 1,5-Click product and it
could be that the carboranyl moiety of the 1,4-Click product is
intramolecularly interacting with the hydroxamic acid through desirable lewis
acid and lewis base chemistry since carboranes are lewis acidic and
hydroxamic acids are lewis basic/chelators.
The results for the Click products positively indicate that the
installation of the carborane moiety does not affect the host-guest
interaction of MMP-2 and MMP-9 with 1,4 and 1,5-Click carboranyl
substrates. In fact, it is likely that the carborane moiety is outside in solvent
whereas the remaining of the substrate is acting as the pharmacophore and
is bound tightly inside the active site of either MMP-2 and MMP-9.
In conclusion, this research has demonstrated that the two Click
derived analogs can target MMP enzymes at nanomolar potency making
BNCT a more viable route fighting and killing cancer cells.
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Table 11.MMP Inhibition of Click Products vs. MMP-1, MMP-2, and MMP-9
IC50 (µM) or % Inhibition

Compounds

MMP-1

MMP-2

MMP-9

PRO74-092-1
Compound 9
deprotected

0.86

0.00024

0.0003

PRO74-062-5
1,4-Click Product

>10µM,
*NI at 10µM

0.037
>270x sel

0.046
>217x sel

PRO74-088-2
1,5-Click Product

>10µM,
20% at 10µM

0.0098
1020x sel

0.013
769x sel

NNGH1

0.12

0.0027

0.0051

2, 3

1

NNGH (BML-205) is N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid
standard MMP inhibitor.
2
PRO74-092-1 is compound 9 deprotected.
3
Literature MMPi for 9 deprotected [Becker, J. Med. Chem. 2010, 53, 6653-6680]: MMP-1
IC50 = 2.6 μM, MMP-2 IC50 = <0.0001 μM, MMP-9 IC50 = 0.0001 μM.

Section 7: Experimental
Preparation of Bis(4-Florophenyl) disulfide (Compound 1)
F
SH

Step 0

S
S

o

1) DMSO, 65 C
F

2) Ice-water, -5 to 0 oC

4-Fluorothiophenol
C6H5FS
128.17 g/mol

3) Filtration

F
Compound 1
Bis(4-Fluorophenyl) Disulfide
C12H8F2S2
254.32 g/mol

Procedure
The reaction consisted of heating a mixture of 4-fluorothiophenol
(215.25 g, 1.68 moles) and DMSO (1.4 liters) at 65 oC for 8 hours. The

185
mixture was cooled to 15 oC and this mixture was added (via vacuum
transfer using a PTFE transfer line) to a second reactor equipped with an
overhead mechanical stirrer containing a mixture of ice/USP purified water
(5 Kg) to afford a white slurry which was stirred overnight at 0-5 oC. The
slurry was filtered, and the wetcake was washed with cold USP water (1.5
L). Cmpd 1 was pulled dry overnight under a stream of nitrogen to provide
white crystalline solids (Lot PR075-028-2, 207.4 g, low melting solid, 97.1%
yield, HPLC purity: 100% AUC, 1H NMR and

13

C NMR analysis: conforms to

structure). Stored in the fridge under nitrogen.
1

H NMR (CDCl3, 400 MHz): δ = 7.44 (m, 4H), 7.00 (m, 4H).

13

C NMR (CDCl3, 100 MHz): δ = 163.96, 161.49, 132.32, 132.29, 131.43,

131.34, 116.51, 116.29, 77.47, 77.16, 76.84.
Preparation of 1-tert-butyl 4-ethyl 4-(4-fluorophenylthio)piperidine1,4-dicarboxylate (Compound 3)
F

Step 1
F
CO 2Et

2) Cool to 0 oC

S

CO 2Et

o

3) then add Disulfide at -40 C
F

4) Stir overnight at RT
N

BOC
Compound 2
Ethyl N-Boc-piperidine-4-carboxylate
C13H23NO4
257.33 g/mol

S

S

+
N

1) LDA, - 78 to -50 oC, THF

Compound 1
Bis(4-Fluorophenyl) Disulfide
C12H8F2S2
254.32 g/mol

BOC
Compound 3
Sulfide Adduct
C19H26FNO4S
383.48 g/mol
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Procedure
A solution of Compound 2 (150.00 g, 0.58 moles) in anhydrous THF
(1.8 liters) was cooled to -78 oC (dry ice/acetone). To this mixture was
slowly added a solution of LDA (2.0 M in THF/Ethylbenzene, 350 mL, 0.70
moles) over 22 minutes maintaining the temperature < -70 oC. The resulting
mixture was allowed to warm to 0 oC, then cooled to -40 oC, and
subsequently added a solution of Compound 1 (148.75 g, 0.583 mole) in
anhydrous THF (600 mL) via addition funnel over 30 minutes. The mixture
was allowed to warm to ambient temperature overnight. The following day,
the reaction was deemed completed by HPLC analysis. The reaction mixture
was quenched with a solution of acetic acid (7.7 g) in USP water (200 mL),
concentrated under reduced pressure at 35-40 oC. The aqueous residue was
extracted with ethyl acetate (3 x 450 mL) and the combined organic layers
were successively washed with USP water (300 mL), and brine (500 mL).
After drying with sodium sulfate, the solution was concentrated under
reduced pressure to provide crude sulfide adduct (232.4 g). A silica plug (1.2
Kg, 60-200 micron, 5:1 ratio) purification of crude sulfide using ethyl
acetate/heptane provided Compound 3 as a light yellow oil (Lot PR075-0364, 192.26 g, 86.0% yield, HPLC purity: 99% AUC, 1H NMR and
analysis: conforms to structure).

13

C NMR
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1

H NMR (CDCl3, 400 MHz): δ =7.41 (m, 2H), 7.02 (m, 2H), 4.13 (q, 2H, J =

14.4 Hz), 3.80 (bd, 2H), 3.09 (m, 2H), 2.09 (m, 2H), 1.76 (m, 2H), 2.122.06 (m, 2H), 1.75 (m, 2H), 1.45 (s, 9H), 1.22 (t, 3H, J = 7.2 Hz).
13

C NMR (CDCl3, 100 MHz): δ = 171.72, 165.16, 162.67, 154.71, 139.17,

139.08, 125.16, 125.13, 116.12, 115.90, 79.81, 77.48, 77.16, 76.84,
61.33, 53.79, 33.17, 28.48, 14.16.
Preparation of 1-tert-butyl 4-ethyl 4-(4fluorophenylsulfonyl)piperidine-1,4-dicarboxylate (Compound 4) Alternative Route
F

CO 2Et

O

O

O
S
Cl

+
N

S
LDA, - 78 oC
THF

F

N

BOC
Compound 2
Ethyl N-Boc-piperidine-4-carboxylate
C13H23NO4
257.33 g/mol

CO 2Et

O

BOC
4-Fluorobenzenesulfonyl chloride
C6H4ClFO2S
194.61 g/mol

Compound 4
Sulfone Adduct
C19H26FNO6S
415.48 g/mol

Procedure
A pilot reaction was performed to determine if the sulfone adduct
(Compound 4) can be easily accessible through anion generation of
piperidine scaffold via LDA followed by addition of aryl sulfonyl chloride. The
reaction proved to be successful cleanly producing 80% conversion to
desired product. No workup was performed on this reaction as it was solely
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for information only. For future preparation, this route can be used to
directly access sulfone.
Preparation of 1-tert-butyl 4-ethyl 4-(4fluorophenylsulfonyl)piperidine-1,4-dicarboxylate (Compound 4)
F
F

Step 2
1) UHP, Phthalic Anhydride
EtOAc, room temp

S

CO 2Et

2) Water, aq Sodium Sulfite

O
S

CO 2Et

O

3) Adjust pH to 8
N

N

BOC

BOC

Compound 3
Sulfide Adduct
C19H26FNO4S
383.48 g/mol

Compound 4
Sulfone Adduct
C19H26FNO6S
415.48 g/mol

Procedure
To a 5 L glass reactor (3-necked), equipped with an overhead
mechanical stirrer, J-Kem thermocouple, cooling bath (water bath at 15-20
o

C) , nitrogen inlet, and an additional funnel, was charged with ethyl acetate

(1.5 L), urea hydrogen peroxide (UHP, 132.61 g, 1.41 moles), and
Compound 3 (180.00 g, 0.469 moles). Solid phthalic anhydride (209.16 g,
1.41 moles) was added over 5 minutes and ethyl acetate (700 mL) was used
as a rinse. The resulting mixture was allowed to stir overnight while the
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cooling bath (15-20 oC) remained in place. After 18 hours, HPLC analysis
showed complete conversion to sulfone. The reaction slurry was filtered (to
remove urea and phthalic acid) and the filtrate was washed with a solution
of aqueous 10% sodium sulfite (1.27 liters). The organic layer was digested
with aqueous 10% sodium carbonate (800 mL), washed with brine, dried
with sodium sulfate, concentrated and finally chased with heptane to provide
Compound 4 (Lot PR075-042-2, off-white solid, 193.61 g, 99.3% yield, HPLC
purity: 100% AUC, 1H NMR and
1

13

C NMR analysis: conforms to structure).

H NMR (CDCl3, 400 MHz): δ =7.81 (m, 2H), 7.25 (m, 2H), 4.20 (m, 4H),

2.63 (vbs, 2H), 2.30 (bs, 2H), 2.04 (td, 2H, J = 12.0, 4.0 Hz), 1.45 (s, 9H),
1.25 (t, 3H, J = 8.0 Hz)
13

C NMR (CDCl3, 100 MHz): δ = 167.66, 166.7, 165.10, 154.40, 133.26,

133.16, 131.11, 131.08, 116.41, 116.18, 80.26, 77.48, 77.16, 76.84,
72.58, 62.77, 28.41, 27.80, 13.99, 0.05
HRMS (ESI-ToF): m/z calcd for C19H26FNNaO6S+ [M+Na]+: 438.1363,
found 438.1361.
m.p. 89-97 oC.
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Preparation of ethyl 4-(4-fluorophenylsulfonyl)piperidine-4carboxylate hydrochloride (Compound 5)

F

F

Step 3
O

O

HCl (g)

S

CO 2Et

O

IPAc

N

S

CO 2Et

O

N
H

HCl

BOC
Compound 4
Sulfone Adduct
C19H26FNO6S
415.48 g/mol

Compound 5
C14H19ClFNO4S
351.82 g/mol

Procedure
The reaction consisted of sparging HCl gas (10.00 g) into a solution of
Compound 4 (10.25 g, 24.7 mmoles) in isopropylacetate (IPAc, 120 mL) and
the resultant mixture was allowed to stir overnight at room temperature.
HPLC analysis confirmed that the reaction was complete and then the
mixture was concentrated under reduced pressure to afford Compound 5 as
a white solid (8.72 g, 100% yield, HPLC purity: 100% AUC, 1H NMR and
NMR analysis: conforms to structure.

13

C
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1

H NMR (DMSO-d6, 400 MHz): δ =9.65 (bs, 1H), 9.42 (bs, 1H), 7.89 (m,

2H), 7.58 (t, 2H, J = 8.8 Hz), 4.13 (q, 2H, J = 14.4 Hz), 3.41 (d, 2H J =
13.2 Hz), 2.76 (bs, 2H), 2.32 (m, 4H), 1.10 (t, 3H, J = 7.2 Hz)
13

C NMR (CDCl3, 100 MHz): δ = 170.74, 167.94, 165.97, 165.36, 133.46,

133.36, 130.33, 130.30, 116.79, 116.56, 77.47, 77.15, 76.84, 70.05,
67.69, 63.58, 41.32, 25.12, 21.88, 21.50, 13.92, 0.05
HRMS (ESI-ToF): m/z calcd for C14H19FNO4S+ [M+H]+: 316.1019, found
316.1018.
Preparation of ethyl 4-(4-fluorophenylsulfonyl)-1-(prop-2ynyl)piperidine-4-carboxylate (Compound 6)
F
F

Step 4
O

Propargylamine

S

CO 2Et

O

O
S

CO 2Et

O

K2CO3, DMF, rt
N

N
H

HCl

Compound 5
Sulfone Adduct HCl Salt
C14H19ClFNO4S
351.82 g/mol

Compound 6
Propargylamine Adduct
C17H20FNO4S
353.41 g/mol

Procedure
The reaction was carried out in a 2-liter reactor which involved
charging Compound 5 (30.00 g, 85.27 mmoles), anhydrous DMF (600 mL),
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and potassium carbonate (23.8 g, 172.20 mmoles) and the resulting mixture
was allowed to stir (mechanical stirring) for 10 minutes. Propargylamine
(97% purity, 10.35 g, 87.00 mmoles) was added and the reaction was
allowed to stir for 23 hours at room temperature in which HPLC analysis
revealed 11.75% AUC of unreacted Compound 5 and 87.3%AUC of
Compound 6. The reaction was charged with an additional portion of
propargylamine (1.58 g, 1.00 mL, 8.41 mmoles) and the reaction was
allowed to stir for an additional 1 hour at room temperature in which HPLC
showed that the reaction was deemed complete (2.3% AUC of unreacted
Compound 5 was noted and 96.3% AUC of Compound 6).
The reaction mixture was transferred to a 5-liter reactor and diluted
with ice-cold USP purified water (2.5 liters) to initiate crystallization. The
resulting slurry was stirred overnight at 0-5 oC via mechanical stirring,
filtered, washed with USP water (150 mL), and pulled dry under a stream of
nitrogen to provide Compound 6 (28.44 g, 94.4% yield, Lot PR075-053-3,
light beige solids, HPLC analysis: 99.81% AUC, 1H NMR and

13

C NMR

analysis: conforms to desired product).
1

H NMR (CDCl3, 400 MHz): δ = 7.82 (m, 2H), 7.23 (m, 2H), 4.21 (q, 2H, J

= 12.0 Hz), 3.26 (d, 2H, J = 4.0 Hz), 2.90 (m, 2H), 2.39 (m, 2H), 2.20 (m,
5H), 1.25 (t, 3H, J = 12.0 Hz)
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13

C NMR (CDCl3, 100 MHz): δ = 167.5, 166.8, 165.0, 133.2, 133.1, 131.4,

116.3, 116.1, 78.2, 77.4, 77.1, 76.8, 73.5, 71.9, 62.5, 49.1, 46.6, 49.1,
46.6, 28.1, 14.0
HRMS (ESI-ToF): m/z calcd for C17H21FNO4S+ [M+H]+: 354.1175, found
354.1176.
Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate
(Compound 7)
O

F

OCF 3
O

O
S

CO 2Et

O

+
N

S

Step 5

HO

CO2Et

O
Milled K2CO3
OCF 3

DMF, 90 oC

N

4-(trifluoromethoxy)phenol
C7H5F3O2
178.11 g/mol
Compound 6
Propargylamine Adduct
C17H20FNO4S
353.41 g/mol

Compound 7
Diaryl Ether Adduct
C24H24F3NO6S
511.51 g/mol

Procedure
To a 500-mL reactor equipped with an overhead mechanical stirrer, JKem thermocouple, heating mantle, nitrogen inlet, and an additional funnel,
was charged with Compound 6 (24.86 g, 70.34 mmoles), anhydrous DMF
(125 mL), milled potassium carbonate (19.54 g, 141.38 mmoles), and 4(trifluoromethoxy)phenol (25.10 g, 140.69 mmoles). The reaction was
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heated at 90 oC for 19 hours which HPLC analysis showed that the reaction
was deemed complete. The reaction mixture was cooled to room
temperature and DMF was removed on a rotary evaporator under reduced
pressure at 40-60 oC. The residue was diluted with MTBE/Toluene (1:1, 300
mL) and washed with 1M NaOH (2 x 250 mL), USP purified water (250 mL),
brine (250 mL), dried with sodium sulfate, filtered, and concentrated to
furnish Compound 7 (36.06 g, 100% yield, Lot PR075-058-4, yellow oil,
HPLC analysis: 98.03% AUC, 1H NMR and

13

C NMR analysis: conforms to

desired product).
1

H NMR (CDCl3, 400 MHz): δ = 7.76 (m, 2H), 7.27 (m, 2H), 7.10 (m, 2H),

7.06 (m, 2H), 4.23 (m, 2H), 3.25 (s, 2H), 2.90 (bs, 2H), 2.40 (bd, 2H), 2.19
(m, 5H), 1.27 (m, 3H)
13

C NMR (CDCl3, 100 MHz): δ = 167.0, 162.5, 153.3, 146.1, 132.8, 129.6,

123.0, 121.6, 117.3, 78.3, 77.4, 77.1, 76.7, 73.4, 72.0, 62.4, 49.3, 46.7,
28.3, 14.0
HRMS (ESI-ToF): m/z calcd for C24H25F3NO6S+ [M+H]+: 512.1355, found
512.1353.
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Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate
(Compound 8)
O

O
OCF 3

O

OCF 3
O

S

CO 2Et

O

Step 6

S

CO 2H

O
1) NaOH, H2O

N

EtOH, THF, 65 oC

N

2) 2M HCl

Compound 7
Diaryl Ether Adduct
C24H24F3NO6S
511.51 g/mol

Compound 8
Diaryl Ether Free Acid
C22H20F3NO6S
483.46 g/mol

Procedure
To a 2-Liter reactor equipped with an overhead mechanical stirrer, JKem thermocouple, heating mantle, reflux condenser with nitrogen inlet, and
an additional funnel, was charged with a solution of Compound 7 (28.50 g,
55.72 mmoles) in EtOH/THF (1:1, 850 mL) and a solution of NaOH (22.30 g,
557.17 mmoles) in USP water (425 mL). The reaction mixture was heated to
65 oC and allowed to stir for 18 hours which HPLC analysis showed complete
consumption of Compound 7. The mixture was allowed to cool to ambient
temperature, diluted with USP water (300 mL), and concentrated at 45-50
o

C on a rotary evaporator to remove EtOH and THF. The aqueous residue
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was diluted with USP water (600 mL) and the pH was adjusted to pH 2.25
using 2M HCl (282 mL) providing a thick white slurry. The slurry was
filtered, washed with USP water (750 mL), pulled dry, and dried further in a
vacuum oven at 40 oC to provide Compound 8 (26.30 g, 97.6% yield, Lot
PR075-063-2, white solid, HPLC analysis: 94.4% AUC, 1H NMR and

13

C NMR

analysis: conforms to desired product).
1

H NMR (CDCl3, 400 MHz): δ = 7.78 (m, 2H), 7.49 (d, 2H, J = 8.0 Hz), 7.31

(m, 2H), 7.19 (m, 2H), 3.31 (s, 2H), 3.17 (s, 1H), 2.85 (d, 2H, J = 12.0 Hz),
2.19 (d, 2H, J = 12.0 Hz), 2.11 (t, 2H, J = 12.0 Hz), 1.92 (td, 2H, J = 12.0,
4.0 Hz)
13

C NMR (CDCl3, 100 MHz): δ = 167.5, 161.7, 153.3, 145.03, 145.01,

132.8, 129.2, 123.32, 122.0, 117.4, 78.5, 76.3, 71.0, 48.4, 45.7, 27.5
HRMS (ESI-ToF): m/z calcd for C22H21F3NO6S+ [M+H]+: 484.1042, found
484.1042.
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Preparation of 1-(prop-2-ynyl)-N-(tetrahydro-2H-pyran-2-yloxy)-4(4-(4-(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4carboxamide (Compound 9)
O
O

OCF 3
OCF 3

O
S

CO2H

O

Step 7

O
O

S

OTHP

O
N
H

EDCI-HCl, THP-ONH2
N

Compound 8
Diaryl Ether Free Acid
C22H20F3NO6S
483.46 g/mol

DMAP, DMF

N

Compound 9
MMP-18 THP Free Base
C27H29F3N2O7S
582.59 g/mol

Procedure
To a 500-mL reactor, equipped with a large magnetic stirring bar, JKem thermocouple, cooling dewer, and nitrogen inlet, was charged with
Compound 8 (20.00 g, 41.37 mmoles) and anhydrous DMF (180 mL). The
mixture was allowed to stir for 10 minutes at ambient temperature then
cooled the mixture to < 5 oC. To the cooled mixture was sequentially added
O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (7.50 g, 64.02 mmoles), EDCIHCl (10.00 g, 81.85 mmoles), and DMAP (8.00 g, 65.36 mmoles). The
mixture was allowed to stir overnight and gradually warmed to room
temperature while the reactor remained in the cooling bath. After 17 hours,
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HPLC analysis revealed 16.1% of unreacted Compound 8 free acid. The
cooling bath was removed and the reaction mixture was allowed to stir an
additional 33 hours at room temperature whereby HPLC analysis confirmed
that the reaction was deemed complete. The reaction was quenched with
USP water (5 mL) and concentrated at 30 oC on a rotovap evaporator to
remove DMF. The residue was diluted with ethyl acetate (350 mL) and
subsequently washed with saturated aqueous sodium bicarbonate solution
(200 mL), brine (200 mL), dried with magnesium sulfate, filtered, and
concentrated under reduced pressure to provide crude Compound 9
(34.31 g).
Crude Compound 9 (34.31 g) was purified by silica gel
chromatography using a glass gravity column (24 in x 3 in) and silica gel
(680 g, 60-200 micron, Silicycle, equilibrated with 30% EtOAc in heptane).
Crude Compound 9 was dissolved in ethyl acetate (20 mL) then diluted with
heptane (20 mL) and subsequently loaded onto the silica bed. The column
was eluted with an EtOAc/Heptane gradient (30% to 70%). Appropriate
fractions were combined and concentrated to provide Compound 9 (21.78 g,
90.4% yield, Lot PR075-070-9, white solid, HPLC analysis: 97% AUC, 1H
NMR and

13

C NMR analysis: conforms to desired product, Mass Spec

analysis: [M+H]+ = 583.46 m/z, FTIR: conforms to desired product).
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1

H NMR (CDCl3, 400 MHz): δ = 9.40 (s, 1H), 7.80 (dd, 2H, J = 6.9, 2.0 Hz),

7.27 (m, 2H), 7.12 (dd, 2H, J = 6.8, 2.3 Hz), 7.05 (dd, 2H, J = 6.9, 2.0 Hz),
5.00 (t, 1H, J = 2.8 Hz), 4.00 (td, 1H, J = 11.2, 2.4 Hz), 3.69 (m, 1H), 3.23
(d, 2H, J = 2.4 Hz), 2.92 (m, 2H), 2.35-2.30 (m, 3H), 2.25-2.20 (m, 4H),
1.88-1.76 (m, 3H), 1.68-1.58 (m, 3H).
13

C NMR (CDCl3, 100 MHz): δ = 164.0, 162.8, 153.0, 146.1, 146.0, 132.6,

128.0, 123.0, 121.8, 121.7, 119.2, 117.4, 102.0, 78.6, 73.4, 70.3, 62.3,
49.0, 48.9, 46.6, 28.6, 28.4, 27.8, 25.0, 18.3.
HRMS (ESI-ToF): m/z calcd for C27H30F3N2O7S+ [M+H]+: 583.1726, found
583.1723.
Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate
(Compound 8)
O

O
OCF 3

O

OCF 3
O

S

CO 2Et

O

Step 6

S

CO 2H

O
1) NaOH, H2O

N

EtOH, THF, 65 oC

N

2) 2M HCl

Compound 7
Diaryl Ether Adduct
C24H24F3NO6S
511.51 g/mol

Compound 8
Diaryl Ether Free Acid
C22H20F3NO6S
483.46 g/mol
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Procedure
To a 2-Liter reactor equipped with an overhead mechanical stirrer, JKem thermocouple, heating mantle, reflux condenser with nitrogen inlet, and
an additional funnel, was charged with a solution of Compound 7 (28.50 g,
55.72 mmoles) in EtOH/THF (1:1, 850 mL) and a solution of NaOH (22.30 g,
557.17 mmoles) in USP water (425 mL). The reaction mixture was heated to
65 oC and allowed to stir for 18 hours which HPLC analysis showed complete
consumption of Compound 7. The mixture was allowed to cool to ambient
temperature, diluted with USP water (300 mL), and concentrated at 45-50
o

C on a rotary evaporator to remove EtOH and THF. The aqueous residue

was diluted with USP water (600 mL) and the pH was adjusted to pH 2.25
using 2M HCl (282 mL) providing a thick white slurry. The slurry was
filtered, washed with USP water (750 mL), pulled dry, and dried further in a
vacuum oven at 40 oC to provide Compound 8 (26.30 g, 97.6% yield, Lot
PR075-063-2, white solid, HPLC analysis: 94.4% AUC, 1H NMR and

13

C NMR

analysis: conforms to desired product).
1

H NMR (CDCl3, 400 MHz): δ = 7.78 (m, 2H), 7.49 (d, 2H, J = 8.0 Hz), 7.31

(m, 2H), 7.19 (m, 2H), 3.31 (s, 2H), 3.17 (s, 1H), 2.85 (d, 2H, J = 12.0 Hz),
2.19 (d, 2H, J = 12.0 Hz), 2.11 (t, 2H, J = 12.0 Hz), 1.92 (td, 2H, J = 12.0,
4.0 Hz)
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13

C NMR (CDCl3, 100 MHz): δ = 167.5, 161.7, 153.3, 145.03, 145.01,

132.8, 129.2, 123.32, 122.0, 117.4, 78.5, 76.3, 71.0, 48.4, 45.7, 27.5
HRMS (ESI-ToF): m/z calcd for C22H21F3NO6S+ [M+H]+: 484.1042, found
484.1042.
Preparation of 1-(prop-2-ynyl)-N-(tetrahydro-2H-pyran-2-yloxy)-4(4-(4-(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4carboxamide (Compound 9)
O
O

OCF 3
OCF 3

O
S

CO2H

O

Step 7

O
O

S

OTHP

O
N
H

EDCI-HCl, THP-ONH2
N

Compound 8
Diaryl Ether Free Acid
C22H20F3NO6S
483.46 g/mol

DMAP, DMF

N

Compound 9
MMP-18 THP Free Base
C27H29F3N2O7S
582.59 g/mol

Procedure
To a 500-mL reactor, equipped with a large magnetic stirring bar, JKem thermocouple, cooling dewer, and nitrogen inlet, was charged with
Compound 8 (20.00 g, 41.37 mmoles) and anhydrous DMF (180 mL). The
mixture was allowed to stir for 10 minutes at ambient temperature then
cooled the mixture to < 5 oC. To the cooled mixture was sequentially added
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O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (7.50 g, 64.02 mmoles), EDCIHCl (10.00 g, 81.85 mmoles), and DMAP (8.00 g, 65.36 mmoles). The
mixture was allowed to stir overnight and gradually warmed to room
temperature while the reactor remained in the cooling bath. After 17 hours,
HPLC analysis revealed 16.1% of unreacted Compound 8 free acid. The
cooling bath was removed and the reaction mixture was allowed to stir an
additional 33 hours at room temperature whereby HPLC analysis confirmed
that the reaction was deemed complete. The reaction was quenched with
USP water (5 mL) and concentrated at 30 oC on a rotovap evaporator to
remove DMF. The residue was diluted with ethyl acetate (350 mL) and
subsequently washed with saturated aqueous sodium bicarbonate solution
(200 mL), brine (200 mL), dried with magnesium sulfate, filtered, and
concentrated under reduced pressure to provide crude Compound 9
(34.31 g).
Crude Compound 9 (34.31 g) was purified by silica gel
chromatography using a glass gravity column (24 in x 3 in) and silica gel
(680 g, 60-200 micron, Silicycle, equilibrated with 30% EtOAc in heptane).
Crude Compound 9 was dissolved in ethyl acetate (20 mL) then diluted with
heptane (20 mL) and subsequently loaded onto the silica bed. The column
was eluted with an EtOAc/Heptane gradient (30% to 70%). Appropriate
fractions were combined and concentrated to provide Compound 9 (21.78 g,
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90.4% yield, Lot PR075-070-9, white solid, HPLC analysis: 97% AUC, 1H
NMR and

13

C NMR analysis: conforms to desired product, Mass Spec

analysis: [M+H]+ = 583.46 m/z, FTIR: conforms to desired product).
1

H NMR (CDCl3, 400 MHz): δ = 9.40 (s, 1H), 7.80 (dd, 2H, J = 6.9, 2.0 Hz),

7.27 (m, 2H), 7.12 (dd, 2H, J = 6.8, 2.3 Hz), 7.05 (dd, 2H, J = 6.9, 2.0 Hz),
5.00 (t, 1H, J = 2.8 Hz), 4.00 (td, 1H, J = 11.2, 2.4 Hz), 3.69 (m, 1H), 3.23
(d, 2H, J = 2.4 Hz), 2.92 (m, 2H), 2.35-2.30 (m, 3H), 2.25-2.20 (m, 4H),
1.88-1.76 (m, 3H), 1.68-1.58 (m, 3H).
13

C NMR (CDCl3, 100 MHz): δ = 164.0, 162.8, 153.0, 146.1, 146.0, 132.6,

128.0, 123.0, 121.8, 121.7, 119.2, 117.4, 102.0, 78.6, 73.4, 70.3, 62.3,
49.0, 48.9, 46.6, 28.6, 28.4, 27.8, 25.0, 18.3.
HRMS (ESI-ToF): m/z calcd for C27H30F3N2O7S+ [M+H]+: 583.1726, found
583.1723.
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Preparation of TBDMS Carborane (Compound 10)

EXPECTED CHARGES
Reagent
o-Carborane
Toluene (anhydrous)
Diethyl Ether
(anhydrous with BHT)
nBuLi (1.66 M in hexanes)
TBDMSCl
USP Water
Diethyl Ether
(3 extractions each)
Theoretical Yield of Product
(in grams)

MW

Loading
eq

amount
g

amount
mL

mmole

144.23

1.00

3.00

---------

20.80

------------------------150.72
-----------------

------------------1.05
1.10
-------------------

5.38

------------------------3.45
-----------------

12.00
6.00

-----------------

13.16

21.84

---------

22.88

45.00
30.00

-----------------
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Procedure
To a 100 mL RBF was added 3.00 g of o-carborane, 12 mL anhydrous
Toluene, and 6 mL anhydrous Et2O. Stirred at room temperature until
completely dissolved then cooled to < 5oC. Added nBuLi solution (1.66M,
13.2 mL) over about 5 minutes to give a murky turbid white mixture.
Removed cooling bath after 5 minutes and allowed to store at room
temperature. After 2.5 hours, solid TBDMSCl (3.47 g) was added at room
temperature as one portion which addition was endothermic. Reaction is a
murky while solution. After 22.5 hours, the reaction slurry was analyzed by
TLC (80% Hexane and 20% Et2O) and showed a trace amount of starting
material and the reaction was deemed complete. The reaction mixture was
quenched reaction with 30 mL of USP purified H2O, then extracted with Et2O
(3x30 mL). The combined organic layers were dried with MgSO4, filtered and
concentrated to give crude product 7.07g (pale yellow oil, lot PR075-190-2).
The crude oil was purified over silica gel as follows. To a glass gravity fitted
column (12x2in) was added sand, n-hexane, a slurry of 140 g of silica gel
(60-200 micron) in n-hexane, further packed under a positive pressure of
nitrogen, and lastly placed a layer of sand on top of the silica bed. Loaded
neat crude product (7.07 g) onto glass gravity column and used n-hexane as
a rinse. The column was eluted with n-hexane (250 mL) and 10%
Et2O/hexane (825 mL). Collected 10 fractions (each approximately 75 mL).

206
Analyzed fractions using TLC. Appropriate fractions were combined and
concentrated on rotovap at 25-30oC to give 5.05 g of Compound 10 as white
crystalline solids (Lot PR075-190-3, 93.9% yield). Literature reference that
this procedure was followed: J. Med. Chem. 2011, 54, pg 2368.
1

H NMR (CDCl3, 400 MHz): δ = 3.44 (bs,1H), 2.87-1.54 (m, 10H), 1.02 (s,

9H), 0.23 (s, 6H).
11

B NMR (Decoupled, 100 MHz): δ = 0.34, -1.76, -7.02, -10.73, -12.31, -

13.26
11

B NMR (Coupled, 100 MHz): δ = 1.01, -0.94, -2.57, -6.29, -7.87, -9.99, -

11.62, -12.41, -13.2, -14.26
Preparation of 1-azido-3-chloropropane (Compound 11)
Safety Note on Handling Azido Compounds (refer to references 1, 2, 3
below)
Handling Sodium Azide
Sodium azide is extremely toxic (LC50 Inhalation = 37 mg/m3 for rats, LD50
Dermal = 20mg/kg for
rabbits) and very soluble in water (>30 g/100 mL at 0 °C). Sodium azide
can be easily absorbed
dermally and consequently must be handled with appropriate personal
protection equipment (PPE).
Sodium azide decomposes above 275 °C, generating highly reactive sodium
metal. Sodium
azide is not compatible with any acid as it spontaneously forms highly
explosive hydrazoic acid on contact, even in dilute solution.
Low Molecular Weight Organic Azides
Low molecular weight organic azides are potentially explosive substances
that can decompose with a slight input of external energy (heat, friction,
pressure etc). Although there has not been any documented explosions on
this end of work, any organic azides where the weight attributed to the azido
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group exceeds 25% of the molecular weight should be handled with
significant caution. It is recommended that a blast shield be used during
synthesis and avoid of very large-scale reactions when dealing with these
substances.
1. Sigma-Aldrich, Sodium Azide; MSDS No. 13412 [Online]; Auckland, NZ,
Nov 05, 2012
http://www.sigmaaldrich.com/catalog/product/sial/13412 (accessed March
29, 2017).
2. T. Archibald in Managing Hazardous Reactions and Compounds in Process
Chemistry, Vol. 1181
(Eds.: J. A. Pesti, A. F. Abdel-Magid), American Chemical Society:
Washington, DC, 2014; pp. 87109.
3. T. Keicher, S. Löbbecke in Organic Azides: Syntheses and Applications;
(Eds.: S. Bräse, K. Banert),Wiley: Chichester, U.K., 2010; pp 3.

Procedure
To a 250 mL round bottomed flask was added 100 mL of anhydrous
DMF and 10.02 g of 1-bromo-3-chloropropane and then 4.2 g of sodium
azide. The reaction was placed in an ambient water bath and stirred
overnight (16 hrs) at room temperature. The reaction mixture was diluted
with 50 mL of Et2O and 50 mL USP purified water. Stirred 2-3 minutes then
separated the organic layer (top). Extracted the bottom aqueous layer with
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Et2O (2x 60 mL). The combined organic layers were washed with USP
purified water (3x 50 mL), dried with Na2SO4, filtered and concentrated at
25-30oC under reduced pressure to give Compound 11 as a colorless oil, lot
PR075-191-1 (7.21g), 95% crude yield which was taken forward without any
further purification. This gives a mixture of 1-azido-3-chloropropane as the
major product (81%) and does contain ~19% of 1-azido-3-bromopropane.
The next step involves iodide formation which under Finkelstein conditions
will convert chloro/bromo to iodo as the sole product. Precedent:
Angewandte Chemie International Edition, 56(26), 7420-7424; 2017
1

H NMR (CDCl3, 400 MHz): δ = 3.64 (t, 2H, J = 8.0 Hz), 3.51 (t, 3H, J =

8.0 Hz), 2.02 (p, 2H, J = 12.0, 4.0 Hz)
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Procedure for 1-azido-3-iodopropane (Compound 12)

EXPECTED
CHARGES
Reagent

MW

Crude 1-azido-3chloropropane

119.55

Acetone

---------

Sodium Iodide

149.89

Silica Gel
(60-200 micron)

---------

Theoretical Yield of Product
12
(in grams)

Density
---------------------------------

Loading
eq

amount
g

amount
mL

mmole

1.00

7.50

---------

62.74

---------

----------

187.50

---------

2.00

18.81

---------

125.47

---------

----------

75.00

---------

13.24

Procedure for 1-azido-3-iodopropane (Compound 12)
To a 1000 mL round bottomed flask (3-necked) was added 19.35 g of
NaI, 7.5 g of crude 1-azido-3-chloropropane, and 190 mL of acetone. Purged
with N2 and heated to 52⁰C. Covered with foil. After 40 hours, the reaction
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was allowed reaction to cool to room temperature. The reaction mixture
(yellow slurry) was filtered over a pad of Celite, washed funnel and flask
with acetone (~100mL), then concentrated the yellow filtrate on a rotavap
at 25-30⁰C to remove acetone. After concentration, an orange-yellow
residue was obtained (oily solids, 26.2 g). Added 50 mL hexane to oil/solid
residue (yellowish-orange) which changed the color to a greenish solid.
Stirred the slurry overnight at room temperature then passed over a short
silica plug(65g) packed in hexane. Flushed with n-Hexane to collect fractions
(each 50-70 mL). Appropriate fractions were combined and concentrated at
25⁰C to give 10.77 g of Compound 12 as a colorless oil (81.3% yield, Lot
PR074-018-3). Precedent: Angewandte Chemie International Edition,
56(26), 7420-7424; 2017
1

H NMR (CDCl3, 400 MHz): δ= 3.44 (t, 2H), 3.25 (t, 2H), 2.04 (p, 2H)
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Preparation of TBDMS Propyl Azido Carborane (Compound 13)

EXPECTED CHARGES
Reagent

MW

TBDMS Carborane

258.49

THF (anhydrous) for
Carborane

-------------------------

LiHMDS (1M in THF)
THF (anhydrous)
for LiHMDS
1-azido-3iodopropane
THF (anhydrous)

211.00
---------

Theoretical Yield of Product 13
(in grams)

Density
------------------------------------------------2.64

Loading
eq

amount
g

amount
mL

mmole

1.00

2.00

---------

7.74

---------

10.00

---------

9.67

9.67

---------

-------------------------

20.00

---------

1.30

2.12

---------

10.06

---------

---------

12.00

---------

1.25
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Procedure
To a dry 100 mL round bottomed flask under a nitrogen atmosphere
was added anhydrous THF (18 mL) and 1M LiHMDS (9.7 mL). The mixture
was cooled to -78 oC. A solution of TBDMS Carborane (2.00 g) in anhydrous
THF (10 mL) was added to the cryogenic mixture via syringe over 5 mins
such that the temperature was maintained < -65 oC. The reaction mixture
was allowed to stir an additional 5 minutes at -78 oC then allowed to warm
to 0⁰C, stirred an additional 1.25 hrs at 0 oC, and cooled to -78 oC. A solution
of 1-azido-3-iodopropane (2.15 g) in anhydrous THF (12 mL) was added
over 3 minutes at -78 oC. The reaction was allowed reaction to stir at -78 oC
for 10 minutes then allowed to warm to room temperature and stirred an
additional 1.25 hours at ambient temperature. The reaction was cooled to
0⁰C, quenched with USP purified water (5 mL), concentrated under reduced
pressure, extracted with diethyl ether (2x 20mL). The combined organic
layers were dried with sodium sulfate, filtered and concentrated under
reduce pressure to give a crude yellow oil (3.13 g). The crude oil (3.13 g)
was dissolved in DCM/n-hexane (3.5 mL, 25/75, v/v) and passed through a
large silica plug (40g) packed in DCM/n-hexane (25/75, v/v). The silica plug
was flushed with DCM/n-hexane (200 mL, 25/75, v/v) to collect 8 fractions
(each about 10-15 mL). Fractions 2-6 were combined and concentrated to
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give 2.58 g of Compound 13 (97.7% yield, white solid). Stored in fridge (510⁰C). This is a novel compound.
1

H NMR (CDCl3, 400 MHz): δ = 3.32 (t, 2H), 3.15-1.5 (m, 14H), 1.07 (s,

9H), 0.34 (s, 6H)
11

B NMR (Decoupled, 100 MHz): δ = 0.29, -3.76, -7.29, -10.18

11

B NMR (Coupled, 100 MHz): δ = 0.99, -0.56, -3.13, -4.62, -6.57, -8.16, -

9.48, -11.24
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Preparation of 1,4 and 1,5-Disubstituted Click Products via Thermal
Click Reaction(Compound 14 and Compound 17)

EXPECTED CHARGES
Reagent
TBDMS Propyl Azido
Carborane
THP-MMP-18
Toluene (anhydrous)

MW

Loading
eq

amount
g

amount
mL

mmole

341.58

1.00

1.000

----------

2.928

585.59
----------

0.90
----------

1.543
----------

---------50.00

2.635
----------

Theoretical Yield of TBDMS Product
Corrected Theo based on recovered
SM, see below in procedure

2.44 g
1.87 g
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Procedure for the Thermal Click Products (Compounds 14 and 17):
To a 100 mL round bottomed flask was added carboranyl azide (1.00
g), THP-MMP-18 alkyne (1.54 g) and anhydrous toluene (50 mL). The
mixture was stirred for 10 minutes at ambient temperature and the mixture
was equally portioned into 6 different pressure vials (ChemGlass, 40 mL)
where each vial contained 8.3-8.5 mL of mixture. Each mixture was purged
with argon, placed on a heating block at 120 oC, and allowed to stir at 120
o

C for 58 hours. HPLC analysis of each reaction vial indicated that there was

~20% unreacted alkyne and the reaction was deemed complete at this point
to avoid degradation of product and introduction of impurities that are
difficult to remove downstream. Furthermore, HPLC analysis confirmed that
the thermal Huisgen 1,3-Dipolar Cycloaddition reaction gives 1,4-Click and
1,5-Click products with a ratio of 1.6 to 1, respectively, which agrees with
Sharpless' study (Sharpless, Angew. Chem. Int. Ed., 2002, 41, 2596-2599)
of determining the component ratio of the regioisiomers.
All six reactions (at room temperature) were combined and
concentrated under reduced pressure to provide a crude oil (2.76 g). The
crude oil was dissolved in DCM (30 mL), treated with silica gel (6.9 g, 60200 micron, Silicylcle), and concentrated to dryness to give dry-loaded
material on silica which was placed and packed in a 65 g solid loading
cartridge. An 80 g RediSep Rf Gold silica gel column cartridge was
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equilibrated with ethyl acetate/n-hexane (40/60, 2CV), 100% ethyl acetate
(1CV), and ethyl acetate/n-hexane (40/60, 2CV). The purification was
accomplished using a ethyl acetate/n-hexane step-gradient from ethyl
acetate/n-hexane (40/60) to 100% ethyl acetate. The elution of components
were in the following order: starting material, 1,5-Click product (Compound
17), and lastly 1,4-click product (Compound 14). Appropriate fractions were
combined and concentrated to isolate recovered starting material (THP-MMP18/Compound 9, 0.36 g, colorless oil, TLC Rf = 0.51 using 100% EtOAc),
1,5-click product (Compound 17, colorless glass solid, 0.60 g, 32.1% yield,
corrected yield for recovered SM, TLC Rf = 0.35 using 100% EtOAc), and
1,4-click product (Compound 14, white solid, 0.90 g, 48.1% yield, corrected
yield for recovered SM, TLC Rf = 0.15 using 100% EtOAc).
Analytical data for 1,4-Click (Compound 14) and 1,5-Click (Compound 17)
Products:


(1,4-Click) - Compound 14

HPLC purity: 96% AUC (retention time: 26.5 mins).
1

H NMR (CDCl3, 400 MHz): δ = 9.38 (s, 1H), 7.80 (m ,2H), 7.41 (s, 1H),

7.28 (d, 2H), 7.11 (d, 2H), 7.04 (d, 2H), 4.99 (s, 1H), 4.33 (t, 2H, J = 6.4
Hz), 3.99 (bt, 1H, J = 10.3 Hz), 3.68 (bd, 1H), 3.59 (s, 2H), 2.93 (bs, 2H),
2.40-1.20 (m, 26H), 0.98 (s, 9H), 0.23 (s, 6H).
13

C NMR (CDCl3, 100 MHz): δ =164.1, 162.9, 152.9, 146.1, 145.3, 132.5,
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128.5, 123.0, 122.3, 121.8, 117.4, 102.1, 79.8, 77.4, 77.2, 77.0, 76.7,
76.2, 70.5, 62.4, 52.9, 49.8, 49.8, 49.2, 34.9, 30.7, 28.5, 28.3, 27.8, 27.4,
24.9, 20.3, 18.24, -2.60.
11

B NMR (Decoupled, 100 MHz): δ = 0.27, -3.86, -7.47, -10.51

11

B NMR (Coupled, 100 MHz): δ = 1.09, -0.59, -3.17, -4.34, -6.64, -8.41, -

9.41, -10.81
HRMS (ESI-ToF): m/z calcd for C38H61B10F3N5O7SSi+ [M+H]+: 926.4944,
found 926.5007.
FTIR: 2941.1, 2863.3, 2575.8, 1686.5, 1587, 1501.4, 1488.6, 1316.7,
1244.2, 1220.2, 1185.8, 1149.4, 1133.2, 1086.5, 1038.0, 944.4, 896.8,
858.2, 838.3, 752.8, 731.2, 677.0 cm-1.


(1,5-Click) - Compound 17

HPLC purity: 95% AUC (retention time: 27.4 mins)
1

H NMR (CDCl3, 400 MHz): δ = 9.43 (s, 1H), 7.8 (d, 2H), 7.49 (s, 1H), ? (?,

3H), 7.1 (d,2H), 7.05 (d,2H), 5.01 (bs,1H), 4.39 (t, 2H), 3.99 (bt,1H), 3.7
(d, 1H), 3.49 (s, 2H), 2.8 (?, 2H), 1.58-2.30 (c, 24H), 1.25 (s, 1H), 1.00 (s,
9H)
13

C NMR (CDCl3, 100 MHz): δ = 164.16, 162.91, 152.91, 1461, 134.74,

132.63, 132.42, 127.82, 123.03, 121.80, 121.71, 117.50, 101.87, 80.13,
77.35, 77.23, 77.03, 76.71, 76.35, 70.15, 62.30, 50.20, 49.93, 49.74,
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47.42, 35.04, 30.11, 28.30, 28.10, 27.77, 27.43, 24.92, 20.32, 18.12, 2.59.
11

B NMR (Decoupled, 100 MHz): δ = 0.37, -3.85, -7.43, -10.47

11

B NMR (Coupled, 100 MHz): δ = 0.94, -0.47, -4.55, -6.70, -8.43, -10.83

HRMS (ESI-ToF): m/z calcd for C38H61B10F3N5O7SSi+ [M+H]+: 926.4944,
found 926.4999.
FTIR: 2939.8, 2869.6, 2579.3, 1685.9, 1586.8, 15014, 1488.7, 1319.0,
1295.5, 1220.0, 1243.6, 1185.7, 1149.9, 1134.3, 1086.8, 1037.2, 957.7,
944.6, 896.9, 873.3, 858.7, 838.3, 818.4, 732.1, 677.3 cm-1
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Preparation of the THP MMP-18 1,4-Click Product (Compound 15)

EXPECTED CHARGES
MW

Loading
eq

amount
g

amount
mL

1,4-Click Product TBDMSTHP Protected

924.17

1.00

0.128

---------- 0.139

1M TBAF in THF
Anhydrous THF

---------- 1.20
---------- ----------

Reagent

Theoretical Yield of Product 15 (in g)

---------- 0.17
---------- 1.28

mmole

0.166
----------

0.112

Procedure
To 1,4-click TBDMS protected product (Compound 14, 128 mg) was
added anhydrous THF (1.25 mL) and the resulting mixture was cooled
solution to –78⁰C. To the cryogenic mixture was added a solution of 1M

220
TBAF in THF (0.17 mL) over approximately 30 seconds. After 5 minutes, the
cooling bath was removed and then the reaction was permitted to warm to
room temperature. After 30 minutes at room temperature, TLC analysis
(100% EtOAc) showed complete consumption of starting material. The
reaction mixture was concentrated to a crude oil residue which was dissolved
in ethyl acetate (2 mL) and washed with water (1 mL, pH 7-7.5). The
aqueous phase was extracted ethyl acetate (1 mL). The combined organic
layers were washed with water (pH 7-7.5, 1 mL), dried with sodium sulfate,
filtered, and concentrated under reduced pressure to give crude product
(108 mg , lot PR074-055-2). The crude oil (108 mg) was dissolved in ethyl
acetate (0.5 mL) and passed through a silica plug (0.27 g) in ethyl acetate.
The plug was flushed with ethyl acetate. Appropriate fractions were
combined and concentrated to afford desired 1,4-click THP protected product
(Compound 15, 88 mg, 78.6% yield, colorless oil that solidifies upon
standing) which was taken forward without any further purification since it
contains residual tert-butyldimethylsilyl fluoride (which will be removed
downstream).
HPLC purity: 92.3% AUC (retention time: 24.1 mins)
HRMS (ESI-ToF): m/z calcd for C32H47B10F3N5O7S+ [M+H]+: 812.4079,
found 812.4131.
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FTIR: 2946.6, 2850.4, 2586.7, 1682.0, 1587.0, 1501.5, 1488.4, 1461.3,
1293.7, 1219.9, 1244.5, 1185.9, 1132.6, 1149.0, 1086.1, 1037.5, 1021.5,
956.2, 944.2, 896.0, 873.1, 835.1, 816.0, 754.5,
722.7, 678.9, 645.0 cm-1
Preparation of 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16)

EXPECTED
CHARGES
Reagent
THP Protected
1,4-Click Product
Dioxane
(anhydrous)
4N HCl in Dioxane

MW

Loading
eq

amount
g

amount
mL

mmole

809.91

1.00

0.088

----------

0.109

----------

----------

----------

0.88

----------

----------

5.00

----------

0.14

0.543

Theoretical Yield of Product 16 (in
g)

0.083
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Procedure
To a 10 mL vial containing THP protected 1,4-Click product (Compound
15, 88 mg) under nitrogen atmosphere was added anhydrous dioxane (0.9
mL) and allowed mixture to stir until complete dissolution was achieved. To
the solution was added 4N HCl in dioxane (0.14 mL) and the reaction was
allowed to stir for 2 hours at room temperature where HPLC analysis
revealed that the reaction was deemed complete. The reaction mixture was
concentrated under reduced pressure at 30 + 5 oC to give a crude oil. The
crude oil was dissolved in dichloromethane (1 mL) and diethyl ether (3 mL)
was added to generate a white slurry. The slurry was allowed to stir at
ambient temperature for 1.5 hours, filtered, and the filter cake was washed
with diethyl ether (2 mL) and n-heptane (5 mL), pulled dry under nitrogen,
and further dried in vacuo at room temperature to provide the title 1,4-Click
Carboanyl MMP-18 HCl salt (Compound 16, 60 mg, white solids, 72.2%
yield, Lot PR074-062-5).
HPLC purity: 95.1% AUC (retention time: 22.7 mins)
11

B NMR (Decoupled, 100 MHz): δ = 18.56, -2.94, -6.09, -9.67, -12.20,

-13.17
11

B NMR (Coupled, 100 MHz): δ = 18.56, -2.15, -3.64, -5.21, -6.32, -8.91,

-11.08, -12.95, -13.86
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HRMS (ESI-ToF): m/z calcd for C27H39B10F3N5O6S+ [M+H]+: 728.3504,
found 728.3540.
X-Ray crystallography: PENDING

Preparation of the THP MMP-18 1,5-Click Product (Compound 18)

EXPECTED CHARGES
Reagent
1,5-Click Product
TBDMS-THP Protected
1M TBAF in THF
Anhydrous THF

MW

Loading
eq

amount
g

amount
mL

924.17

1.00

0.071

---------- 0.077

----------

0.092

0.092

----------

0.71

----------

---------- 1.20
------------------

Theoretical Yield of Product 18 (in g)

0.062

mmole
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Procedure
To 1,5-click TBDMS protected product (Compound 17, 71 mg) was
added anhydrous THF (0.9 mL) and the resulting mixture was cooled
solution to –78⁰C. To the cryogenic mixture was added a solution of 1M
TBAF in THF (90 µL). After 5 minutes, the cooling bath was removed and
then the reaction was allowed to warm to room temperature. After 75
minutes at room temperature, TLC analysis (100% EtOAc) showed complete
consumption of starting material. The reaction mixture was concentrated to
a crude oil residue which was dissolved in ethyl acetate (2 mL) and washed
with water (1 mL, pH 7-7.5). The aqueous phase was extracted ethyl acetate
(2 mL). The combined organic layers were washed with water (pH 7-7.5, 1
mL), dried with sodium sulfate, filtered, and concentrated under reduced
pressure to give crude desired product Compound 18 (82 mg , lot PR074080-2, theoretically 62 mg present) which was taken forward without any
further purification since it contains residual tert-butyldimethylsilyl fluoride
(which will be removed downstream).
HPLC purity: 95.2% AUC (retention time: 26.4 mins)
HRMS (ESI-ToF): m/z calcd for C32H47B10F3N5O7S+ [M+H]+: 812.4079,
found 812.4139.
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Preparation of 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19)

EXPECTED CHARGES
Reagent
THP Protected 1,5-Click
Product
(crude, contains residual
TBDMS Fluoride)
Dioxane (anhydrous)
4N HCl in Dioxane

MW

Loading
eq

amount
g

amount
mL

mmole

809.91

1.00

0.082

---------

0.101

-----------------

---------

-----------------

0.82

---------

0.13

0.506

5.00

Theoretical Yield of Product 19 (in g)

0.077

Corrected Theo yield based on 62 mg
SM since TBDMSF is present (in g)

0.0584
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Procedure
To a 10 mL vial containing crude THP protected 1,5-Click product
(Compound 18, 82 mg) under nitrogen atmosphere was added anhydrous
dioxane (0.9 mL) and allowed mixture to stir until complete dissolution was
achieved. To the solution was added 4N HCl in dioxane (0.14 mL) and the
reaction was allowed to stir for 2.5 hours at room temperature where HPLC
analysis revealed that the reaction was deemed complete. The reaction
mixture was concentrated under reduced pressure at 30 + 5 oC to give a
crude oil. The crude oil was dissolved in dichloromethane (0.5 mL) and
diethyl ether (3 mL) was slowly added to generate a white slurry. The slurry
was allowed to stir at ambient temperature for 20 mins, filtered, and the
filter cake was washed with diethyl ether (2.5 mL) and n-hexane (5 mL),
pulled dry under nitrogen, and further dried in vacuo at room temperature to
provide the title 1,5-Click Carboanyl MMP-18 HCl salt (Compound 19, 58 mg,
white solids, 99% yield, Lot PR074-088-2).
HPLC purity: 92.2% AUC (retention time: 23.2 mins)
11

B NMR (Decoupled, 100 MHz): δ = 18.55, -2.90, -6.26, -9.74, -12.24, -

13.14
11

B NMR (Coupled, 100 MHz): δ = 18.58, -2.13, -3.71, -8.99, -11.11, -

12.88
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HRMS (ESI-ToF): m/z calcd for C27H39B10F3N5O6S+ [M+H]+: 728.3504,
found 728.3538.
X-Ray crystallography: PENDING
Preparation of MMP-18 Carboranyl Ethyl Ester (Compound 20)

EXPECTED CHARGES
Reagent
Decaborane,

11

B10H14

Acetonitrile (anhydrous)
Toluene (anhydrous) for
11
B10H14
Toluene (anhydrous) for MMP18 Ester

MW

Loading
eq

amount
g

amount
mL

mmole

122.22

1.20

0.860

NA

7.04

41.05

100.00

24.08

30.63

586.50

--------

--------

--------

45.00

--------

--------

--------

--------

15.00

--------

228
MMP-18 Ethyl Ester
(Cmpd 7)
Theoretical Yield of Product 20
(in grams)

511.51

1.00

3.00

NA

5.86

3.69

Procedure
A 250 mL round bottomed flask (1-necked) was equipped with a
Claisen adapter, reflux condenser with nitrogen inlet, magnetic stirring bar,
and a J-Kem thermocouple. To the reactor under nitrogen was added white
decaborane (0.90 g), anhydrous toluene (45 mL), and anhydrous ACN (31
mL). The mixture was purged with nitrogen and the reaction flask was
covered with foil. Heated the mixture to reflux (temp 82⁰C) for 80 minutes
followed by cooling the mixture to room temperature. To the reaction
mixture (light yellow solution) at ambient temperature was added a solution
of MMP-18 Ethyl Ester (Compound 7, 3.13 g) in anhydrous toluene (10 mL)
and additional anhydrous toluene (5 mL) was used to quantitatively transfer
all ester to the reactor. The reactor was purged with nitrogen and heated to
reflux. After 19 hours, the reaction was a dark yellowish-orange solution and
the reaction was sampled for HPLC analysis (8 drops of reaction mixture was
concentrated and dissolved in 4 mL of ACN). HPLC analysis indicated that
the starting material alkynyl ester (18.4 mins) was completely consumed.
The reaction mixture was cooled to room temperature and was concentrated
under reduced pressure at 40-50⁰C to give crude Compound 20 as an orange

229
foam (4.29 g, Lot PR074-057-2). Crude product (lot PR074-057-2) was
analyzed by HPLC and TLC*.
TLC Analysis of PR074-057-2 (crude, EtOAc/hept 40/60). TLC analysis was
done using a glass backed TLC plate visualizing with UV and 0.4% PdCl2 in
3M HCl:

Purification of PR074-057-2 via flash chromatography:
Crude product (PR074-057-2, 4.29 g) was dissolved in DCM and
transferred to a 250 mL round bottomed flask. To the flask was added silica
gel (10.0 g, 60-200 micron, Silicycle) and this mixture was concentrated to
dryness on rotovap at 25-30⁰C to provide dry-loaded crude product. The
dry-loaded crude product was loaded into a 65 g solid loading cartridge. An
80 g Redisep Rf Gold silica gel cartridge column was equilibrated with n-
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hexane (165 mL), ethyl acetate/n-hexane (50/50, 195 mL), and n-hexane
(275 mL). Purification on an Isco Rf unit was accomplished using an ethyl
acetate/n-hexane gradient (0/100 to 100/0) over 16.5 column volumes.
Collected fractions were analyzed by HPLC (refer to the table below for
information regarding purity of the fraction analyzed.
Table: HPLC Analysis of Fractions from Flash Chrom. Purification
Fraction
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29

% AUC
Product
(32.4 min)
0
100
(97 mAu)
100
(237 mAu)
100
(180 mAu)
97.4
(111 mAu)
100
(72 mAu)
100
(47 mAu)
90.6
(32 mAu)
78.9
(25 mAu)
75.5
(23 mAu)
38.1
(12 mAu)
30.7
(9 mAu)
10.9
(7 mAu)
8.8
(8 mAu)
0

% AUC
26.4 min
Impurity
0

Comments
Toluene (100% AUC, 17.4 mins)

0

N/A

0

N/A

0

N/A

0

2.6% (28.7 mins)

0

N/A

0

N/A

0

9.4% (30.3 mins)

0

9.4% (30.3 mins), 14.1% (30.9 mins)

0

24.5% (22.5 mins)

0

61.9% (25.2 mins)

0

47.8% (25.2 mins), 21.5% (28.2 mins)

0
0
90.4
(816

13.5%
61.5%
17.5%
33.5%

(24.6
(28.2
(24.6
(26.9

mins), 14.0% (25.2 mins),
mins)
mins), 15.5% (25.2 mins),
mins), 24.6% (28.2 mins)

Many small impurities present
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Fraction

% AUC
Product
(32.4 min)

31

0

33

0

35

0

37
40

0
0

% AUC
26.4 min
Impurity
mAu)
73.6
(212
mAu)
28.5
(23 mAu)
29.5
(6 mAu)
trace
trace

Comments

Other small impurities present
Many small impurities present
70.5% (27.5 mins)
N/A
N/A

Fractions 3-14 were combined and concentrated under reduced
pressure to give desired carboranyl ethyl ester product (Compound 20, 1.30
g, 33.8% yield, white foam solid, Lot PR074-057-3).
HPLC purity: 98.9% AUC (retention time: 32.4 mins)
1

H NMR (CDCl3

-7.04 (m,

4H), 4.18 (q, 2H, J = 8.0 Hz), 3.91 (s, 1H), 3.10-1.50 (complex, 20H), 1.24
(t, 3H, J = 8.0 Hz)
13

C NMR (CDCl3

166.87, 162.67, 153.06, 146.07, 146.06,

132.62, 128.77, 123.05, 121.71, 121.66, 119.15, 117.17, 77.34, 77.02,
76.71, 74.45, 71.41, 62.62, 58.16, 51.96, 13.95
DEPT135: 132.62, 123.06, 121.67, 117.18, 62.63, 58.17, 51.95, 13.96
C13APT: 166.87, 162.67, 153.06, 146.06, 132.62, 128.78, 123.06, 121.67,
117.18, 77.35, 77.03, 76.71, 74.45, 71.41, 62.62, 58.17, 51.96, 13.96
11

B NMR (Decoupled, 100 MHz): δ = -2.82, -5.21, -8.98, -11.69, -12.89
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11

B NMR (Coupled, 100 MHz): δ = -2.10, -3.73, -5.97, -8.20, -9.83, -12.35

HRMS (ESI-ToF): m/z calcd for C24H35B10F3NO6S+ [M+H]+: 632.3068,
found 632.3112.
Fractions 28-32 were pooled and concentrated to give 0.80 g of
Compound 21 as a yellow foam solid (Lot PR074-057-5) which is assigned to
be the nido-form of carboranyl ethyl ester product.
HPLC purity: 68.7% AUC (retention time: 26.4 mins)
HRMS (ESI-ToF): m/z calcd for C24H34B9F3NO6S + [M+H]+: 620.2896,
found 620.3022.
Hydrolysis of MMP-18 Carboranyl Ethyl Ester via Continuous Flow
Mode (Compound 22)
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EXPECTED CHARGES
MW

Loading
eq

amount
g

amount
mL

mmole

MMP-18 Carboranyl Ethyl
Ester, Cmpd 20

629.70

1.00

0.600

NA

0.96

Acetic Acid

41.05

100.00

157.50

150.00

--------

87.4 wt% H2SO4

--------

--------

--------

75.00

--------

Reagent

Theoretical Yield of Product 21
(in grams)

0.575

Procedure
MMP-18 Carboranyl Ethyl Ester (Compound 20, 0.60 g) was dissolved
in acetic acid (150 mL) and allowed to stir at room temperature until
complete dissolution was achieved. The solution of ester was diluted with
87% sulfuric acid (75 mL), stirred for 10 minutes at room temperature, then
processed through a Vapourtec plug flow reactor (10 mL) at 150 oC with a
flow rate of 0.133 mL/min providing a residence time of 75 minutes. Once all
the starting material feed was processed, the flow reactor was flushed with
glacial acetic acid at 150 oC at 2 mL/min for 30 minutes. The collected crude
product was concentrated at 60 oC under reduced pressure to remove acetic
acid. The resulting sulfuric acid residue was diluted with DCM (300 mL) and
then placed in a cooling bath (10 oC). The mixture was carefully diluted with
saturated sodium bicarbonate solution (300 mL) followed by slow addition of
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solid sodium bicarbonate (210 g) to achieved a pH of 3.5. The mixture was
further diluted with 300 mL of USP purified water and then extracted with
DCM (2 x 200 mL). The combined organic layers were dried with sodium
sulfate, filtered, and concentrated to give 0.52 g of crude Compound 22.
Formation of THP protected Hydroxamate hydrochloride salt:
HCl salt formation of THP-protected MMP-18 (Compound 9) via
addition of 4N HCl in Dioxane into a solution THP-protected MMP-18 in
isopropyl acetate was unsuccessful and only generated free MMP-18
hydroxamic acid and some minor impurities (refer to PR075-074).
However, treating a solution of THP-protected MMP-18 (Compound 9, 150
mg) in isopropyl acetate (1.5 mL) and 3,4-Dihydro-2H-pyran (1.0 mL) with
4N HCl in dioxane (0.25 mL) provided THP-protected MMP-18 HCl salt (159
mg, 97.5% yield, HPLC purity: 95% THP HCl salt, and 3% Free Hydroxamic
acid). Refer to PR075-075 for this interesting work where THP group
remained stable!
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Salt formation of THP-MMP-18 (Compound 9) was also successful by
treating a solution of THP-MMP-18 in ethyl acetate with a solution of oxalic
acid dihydrate (1.1 eq) in EtOH/EtOAc. Refer to PR075-075 for this work
regarding oxalate salt formation!
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B NMR analyses on carborane

APPENDIX A
SUPPLEMENTAL DATA FOR CHAPTER TWO
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237
HPLC for Racemic CTV-Lactam (19)

238
1

H NMR Spectra for Racemic CTV-Lactam (19)

239

240

241

242
Achiral HPLC of Recrystallized CTV-Menthyloxyacetic acid Imide (23)

243
IR of CTV lactam menthyloxyacetic acid imide (23)

244
1

H NMR Spectra for Different Lots of CTV lactam menthyloxyacetic
acid imide (23)

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259
Overlap of 1H NMR spectra of hydrolyzed 23 to 19 and analyzing the
same NMR sample over 20 min shown below.

When the chiral auxiliary group was cleaved, concentrated, dissolved in
CDCl3 and added Chirabite (0.30 eq), the sample was analyzed by 1H NMR
analysis over time to determine if there was any change. The figure above
clearly shows that there wasn't any change and this result further proves
that racemization occurs fast.

APPENDIX B
SUPPLEMENTAL DATA FOR CHAPTER THREE

260

261
1

H NMR - Compound 5

262

263

264

265

266
13

C NMR - Compound 5

267
Achiral HPLC - Compound 5

268
HRMS - Compound 5

269
1

H NMR - Compound 6

270

271
MS - Compound 6

272
HRMS - Compound 6

273
1

H NMR - Compound 7

274

275

276

277
13

C NMR - Compound 7

278

279

280

281
HRMS - Compound 7

282
Achiral HPLC - Compound 8a

283
1

H NMR - Compound 8a

284

285

286

287
13

C NMR - Compound 8a

288

289

290
HRMS - Compound 8a

291
Achiral HPLC - Compound 9a

292
Chiral HPLC - Compound 9a

293
1

H NMR - Compound 9a

294

295

296
13

C NMR - Compound 9a

297

298

299
HRMS - Compound 9a

300
1

H NMR - Amino Methyl Ester

301

302

303
13

C NMR - Amino Methyl Ester

304

305

306
HRMS - Amino Methyl Ester

307
1

H NMR - Compound 10a

308

309

310

311
HRMS - Compound 10a

312
1

H NMR - Compound 1a.HCl

313

314
HRMS - Compound 1a.HCl

315
Achiral HPLC - Compound 8b

316
1

H NMR - Compound 8b

317

318

319

320
13

C NMR - Compound 8b

321
HRMS - Compound 8b

322
Achiral HPLC - Compound 9b

323
Chiral HPLC - Compound 9b

324
1

H NMR - Compound 9b

325

326

327
13

C NMR - Compound 9b

328

329

330

H

331
MS - Compound 9b

332
UPLC/MS - Amino Acid Intermediate 10b

333
HRMS - Amino Acid Intermediate 10b

334
Chiral HPLC - Compound 10b

335
1

H NMR - Compound 10b

336

337
13

C NMR - Compound 10b

338

339

340
HRMS - Compound 10b

341
Chiral HPLC - Compound 1b.TFA on a Chirosil SCA(-) column (150
mm x 4.6 mm, 5 micron)

342
Chiral HPLC - Compound 1b.TFA on a RegisPack column (250x4.6
mm, 5 micron)

343
1

H NMR - Compound 1b.TFA

344

345
13

C NMR - Compound 1b.TFA

346

347

348
HRMS - Compound 1b.TFA

349
HPLC (achiral) - Compound 12

350
1

H NMR - Compound 12

351

352
HRMS - Compound 12

353
1

H NMR - Compound 13

354

355

356
HRMS - Compound 13

357
1

H NMR - Compound 18

358

359

360

APPENDIX C
SUPPLEMENTAL DATA FOR CHAPTER FOUR

361

362
H NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1)

363
1

H NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1)

364
13

C NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1)

365
13

C NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1)

366
HPLC - Isolated Sulfide Adduct (Compound 3)

367
1

H NMR - Isolated Sulfide Adduct (Compound 3)

368
1

H NMR - Isolated Sulfide Adduct (Compound 3)

369
1

H NMR - Isolated Sulfide Adduct (Compound 3)

370
1

H NMR - Isolated Sulfide Adduct (Compound 3)

371
13

C NMR - Isolated Sulfide Adduct (Compound 3)

372
HPLC - Sulfone Adduct (Compound 4)

373
1

H NMR - Sulfone Adduct (Compound 4)

374
1

H NMR - Sulfone Adduct (Compound 4)

375
1

H NMR - Sulfone Adduct (Compound 4)

376
13

C NMR - Sulfone Adduct (Compound 4)

377
HRMS - Sulfone Adduct (Compound 4)

378
HPLC - Sulfone Adduct HCl Salt (Compound 5)

379
1

H NMR - Sulfone Adduct HCl Salt (Compound 5)

380
1

H NMR - Sulfone Adduct HCl Salt (Compound 5)

381
13

C NMR - Sulfone Adduct HCl Salt (Compound 5)

382
13

C NMR - Sulfone Adduct HCl Salt (Compound 5)

383
HRMS - Sulfone Adduct HCl Salt (Compound 5)

384
HPLC - Propargylamine Adduct (Compound 6)

385
1

H NMR - Propargylamine Adduct (Compound 6)

386
1

H NMR - Propargylamine Adduct (Compound 6)

387
1

H NMR - Propargylamine Adduct (Compound 6)

388
13

C NMR - Propargylamine Adduct (Compound 6)

389
HRMS - Propargylamine Adduct (Compound 6)

390
HPLC - Diaryl Ether Adduct (Compound 7)

391
1

H NMR - Diaryl Ether Adduct (Compound 7)

392
1

H NMR - Diaryl Ether Adduct (Compound 7)

393
1

H NMR - Diaryl Ether Adduct (Compound 7)

394
13

C NMR - Diaryl Ether Adduct (Compound 7)

395
HRMS - Diaryl Ether Adduct (Compound 7)

396
HPLC - MMP-18 Carboxylic Acid (Compound 8)

397
1

H NMR - MMP-18 Carboxylic Acid (Compound 8)

398
1

H NMR - MMP-18 Carboxylic Acid (Compound 8)

399
1

H NMR - MMP-18 Carboxylic Acid (Compound 8)

400
13

C NMR - MMP-18 Carboxylic Acid (Compound 8)

401
HRMS - MMP-18 Carboxylic Acid (Compound 8)

402
HPLC - THP-MMP-18 (Compound 9)

403
1

H NMR - THP-MMP-18 (Compound 9)

404
1

H NMR - THP-MMP-18 (Compound 9)

405
1

H NMR - THP-MMP-18 (Compound 9)

406
13

C NMR - THP-MMP-18 (Compound 9)

407
HRMS - THP-MMP-18 (Compound 9)

408
1

H NMR - TBDMS Carborane (Compound 10)

409
1

H NMR - TBDMS Carborane (Compound 10)

410
11

B NMR (Coupled) - TBDMS Carborane (Compound 10)

411
11

B NMR (Decoupled) - TBDMS Carborane (Compound 10)

412
1

H NMR - Crude Chloro Propyl Azide (Compound 11)

413
1

H NMR - Crude Chloro Propyl Azide (Compound 11)

414
1

H NMR - Crude Chloro Propyl Azide (Compound 11)

415
1

H NMR - Iodo Propyl Azide (Compound 12)

416
1

H NMR - Carboranyl Propyl Azide (Compound 13)

417
1

H NMR - Carboranyl Propyl Azide (Compound 13)

418
11

B NMR (Coupled) - Carboranyl Propyl Azide (Compound 13)

419
11

B NMR (Decoupled) - Carboranyl Propyl Azide (Compound 13)

420
HPLC - 1,4-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 14)

421
FTIR - 1,4-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 14)

422
1

H NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

423
1

H NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

424
1

H NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

425
13

C NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

426
13

C NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

427
13

C NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

428
13

C NMR - 1,4-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 14)

429
HRMS - 1,4-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 14)

430
HRMS - 1,4-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 14)

431
11

B NMR (Coupled) - 1,4-Disubstituted Click Product (TBDMS/THP
Protected) (Cmpd 14)

432
11

B NMR (Decoupled) - 1,4-Disubstituted Click Product (TBDMS/THP
Protected) (Cmpd 14)

433
HPLC - THP MMP-18 1,4-Click Product (Compound 15)

434
FTIR - THP MMP-18 1,4-Click Product (Compound 15)

435
HRMS - THP MMP-18 1,4-Click Product (Compound 15)

436
HRMS - THP MMP-18 1,4-Click Product (Compound 15)

437
HPLC - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16)

438
HRMS - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16)

439
HRMS - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16)

440
11

B NMR (Coupled) - 1,4-Click Carboranyl MMP-18 HCl Salt
(Compound 16)

441
11

B NMR (Decoupled) - 1,4-Click Carboranyl MMP-18 HCl Salt
(Compound 16)

442
HPLC - 1,5-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 17)

443
FTIR - 1,5-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 17)

444
1

H NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

445
1

H NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

446
1

H NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

447
1

H NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

448
13

C NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

449
13

C NMR - 1,5-Disubstituted Click Product (TBDMS and THP

Protected) (Compound 17)

450
13

C NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

451
13

C NMR - 1,5-Disubstituted Click Product (TBDMS and THP
Protected) (Compound 17)

452
HRMS - 1,5-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 17)

453
HRMS - 1,5-Disubstituted Click Product (TBDMS and THP Protected)
(Compound 17)

454
11

B NMR (Coupled) - 1,5-Disubstituted Click Product (TBDMS/THP
Protected) (Compound 17)

455
11

B NMR (Decoupled) - 1,5-Disubstituted Click Product (TBDMS/THP
Protected) (Cmpd 17)

456
HPLC - THP MMP-18 1,5-Click Product (Compound 18)

457
HRMS - THP MMP-18 1,5-Click Product (Compound 18)

458
HPLC - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19)

459
HRMS - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19)

460
HRMS - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19)

461
11

B NMR (Coupled) - 1,5-Click Carboranyl MMP-18 HCl Salt
(Compound 19)

462
11

B NMR (Decoupled) - 1,5-Click Carboranyl MMP-18 HCl Salt
(Compound 19)

463
HPLC - Carboranyl MMP-18 Ethyl Ester (Compound 20)

464
1

H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

465
1

H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

466
1

H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

467
13

C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

468
13

C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

469
13

C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

470
13

C APT NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

471
13

C DEPT135 NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20)

472
HRMS - Carboranyl MMP-18 Ethyl Ester (Compound 20)

473
HRMS - Carboranyl MMP-18 Ethyl Ester (Compound 20)

474
11

B NMR (Coupled) - Carboranyl MMP-18 Ethyl Ester (Compound 20)

475
11

B NMR (Decoupled) - Carboranyl MMP-18 Ethyl Ester (Compound
20)

476
HPLC - Nido Carboranyl MMP-18 Ethyl Ester from B10H14 Reaction
(Compound 21)

477
HRMS (Positive Mode) - Nido Carboranyl MMP-18 Ethyl Ester from
B10H14 Reaction (Compound 21)

478
HPLC - Nido Carboranyl MMP-18 Ethyl Ester from microwave heating
(Compound 21)

479
HRMS (Negative Mode) - Nido Carboranyl MMP-18 Ethyl Ester from
microwave heating (Compound 21)

480
HPLC - Carboranyl MMP-18 Carboxylic Acid (Compound 22)

UPLC/MS - Carboranyl MMP-18 Carboxylic Acid (Compound 22)

481
HRMS - Carboranyl MMP-18 Carboxylic Acid (Compound 22)

482
HRMS (Negative Mode) - Nido Carboranyl MMP-18 Ethyl Ester
(Compound 21)

483
HRMS - Arachno Carboranyl MMP-18 Ethyl Ester (Compound 24)
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